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Migraines are a painful and life-interrupting disease which strikes around 23 million Americans every year (Goadsby et al ., 2017) . 
Not enough studies have been done to help the public fully understand migraines . Details regarding the causes and pathophysiol-
ogy of migraines continue to be analyzed by physicians and scientists, as no theory has been fully confirmed regarding a migraine’s 
concrete path. The goal of this scientific review is to provide an overview for the main triggers of migraines, in reference to recent 
clinical investigations, and to understand why they might cause patients to be more prone to having a migraine attack upon 
encountering these triggers . Additionally, topics including the uncertainty whether migraineurs should avoid their triggers or learn 
to live with them, and the pathophysiology behind the triggers will be explored in this review . Some physicians suggest staying 
away from known triggers, while others say to allow one’s self to be exposed, as a means of getting the sensitized central nervous 
system (CNS) used to the triggers and to make the CNS aware that these stimuli are, in essence, not harmful . 
Migraines have been affecting people’s lives for over two thousand years and are said to be the 6th leading cause of disability, ac-
cording to the World Health Organization (WHO) (Goadsby et al ., 2017) . Of the 23 million Americans that suffer from migraines, 
women are predominantly affected (Silberstein et al ., 1999) . The ratio of 3:1 women versus men getting migraines is most likely 
due to hormonal changes and leads to an understanding of the reason migraines usually begin in females at puberty and can last 
until the age of 35-45, according to the WHO . Migraineurs claim that their daily lives are impacted by their frequent migraines, 
with 50% of them having 1 or more migraines per month (Silberstein et al ., 1999) . 
Migraine Triggers
Adina Jeidel
Adina Jeidel graduated in January 2021 with a Bachelor of Science degree in Biology.
Methods
Through the usage of databases such as Google Scholar, 
Touro Library, and the National Center for Biotechnology 
Information (NCBI), scholarly articles and peer-reviewed 
journals were obtained and reviewed for inclusion pur-
poses. Each article was analyzed and verified, before 
assuming validity. Some key phrase searches included 
“migraine triggers,” “hormonal migraine triggers,” and 
“caffeine as a migraine trigger.”
Introduction
Migraine is a neurological disease that is not under-
stood very well. It is more than just a headache and can 
be debilitating and life-altering at times. According to the 
International Classification of Headache Disorders, a head-
ache is only classified as a migraine if it fits the description 
of a “recurrent headache manifesting in attacks lasting 4-72 
hours. Typical characteristics of the headache are unilateral 
location, pulsating quality, moderate or severe intensity, ag-
gravation by routine physical activity and association with 
nausea and/or photophobia and phonophobia.” 
Many scientists have tried taking a deeper look into 
what exactly causes a migraine, what transpires in the 
brain while a migraine is occurring, why some people are 
more prone than others, and how to successfully treat 
migraine patients. From the studies that have been done 
to relate what can trigger a migraine, very few have been 
successful and completed in their entirety. However, sci-
entists have gained some knowledge over the past cen-
tury based on diary studies, clinical questionnaires, and 
patient surveys. The most common triggers are known 
to be caffeine, stress, sleep deprivation, a woman’s men-
strual cycle which involves hormonal changes, and some 
foods (Marmura, 2018). This review will give an overview 
of those triggers and explain some possible reasons why 
these triggers will cause a migraine headache.
What is a Migraine?
Migraines can be broken down into 4 phases. A migraine 
begins with the premonitory phase, followed by aura (if 
present). It then proceeds into a migraine headache, and 
finally, the postdrome phase. Although there is a listed se-
quence of events, most migraineurs say that many of the 
phases overlap each other. For example, although exhaus-
tion is associated with the premonitory phase, a migraine 
patient typically feels tired throughout the duration of the 
migraine (Goadsby et al., 2017). 
The first phase is named the premonitory phase, and 
this occurs around 24-48 hours prior to the headache. 
Many people, including some doctors, believe that the mi-
graine begins with a headache. However, contrary to the 
public’s belief, some scientists admit that the headache 
phase of a migraine is already well into it. The premonito-
ry phase notifies the patient of an upcoming headache. It 
can be observed as tiredness and having a hard time con-
centrating, as well as a feeling of irritability. The hypothala-
mus, which controls homeostasis, is said to be involved in 
this phase, due to altered homeostatic functions such as 
thirst, nausea, and frequent urination, which are observed 
during this phase. Studies done using positron emission 
tomography (PET) have shown increased blood flow to 
the hypothalamus during the premonitory phase, indicat-
ing a connection between the two. Seventy two percent 
of migraineurs can recognize when a migraine is coming, 
according to these premonitory symptoms (Goadsby et 
al., 2017).
Aura, which is found in one of three migraineurs, can 
present itself in numerous ways- mainly sensory and visu-
al. Although symptoms play out differently in each patient, 
a sensory aura usually involves a patient feeling numb in 
one body part or limb. A visual aura can be character-
ized as visual hallucinations with flashing lights. Aura is 
correlated with cortical spreading depression (CSD), as 
6
Adina Jeidel
a result of experimental discussion. CSD is defined as a 
depolarization of glial cells across the visual cortex, fol-
lowed by an electrical or chemical wave spreading across 
the brain (Goadsby et al., 2017). Animal studies have 
shown that CSD causes changes in blood flow as well as 
a release of neuropeptides involved in vasodilation and 
inflammation which is linked to migraine pain. CSD is also 
known to activate the trigeminal nociceptive pathways 
(Cui, Kataoka, & Watanabe, 2014).
The migraine phase is characterized, as stated above 
by the World Health Organization, as unilateral pulsating 
pain accompanied by photophobia or phonophobia, and 
very often nausea. Migraineurs report this pain as mod-
erate to severe and tend to crawl into bed at this point.
The postdrome phase is very similar to the premoni-
tory phase. It involves neck stiffness, drowsiness, and diffi-
culty concentrating. In fact, scientists are unsure whether 
these symptoms persist throughout the entire migraine 
malady, or if they reappear after the headache phase. 
Interestingly, many migraineurs attribute these symptoms 
to the medication they took to relieve their headache 
(Goadsby et al., 2017).
Trigeminal Path
The trigeminal nerve is one of twelve cranial nerves. Its 
function is to supply sensation to parts of the head in-
cluding the face and mucous membranes. This nerve is 
connected to many blood vessels throughout the brain, 
and it originates in the brainstem. Upon receiving signals 
from the meninges, which in turn releases neuroinflamma-
tory mediators, the trigeminovascular system is activated 
and can cause a migraine headache (Goadsby et al., 2017). 
Scientists do not know why this signal occurs, and they 
continue to investigate its source. The release of inflam-
matory substances such as prostaglandins or serotonin, 
can cause the blood vessels near the end of the nerve to 
swell, which causes head pain (Professional, 2018). These 
inflammatory substances cause the surrounding tissue to 
be sensitive to otherwise normal activities, and therefore 
pulsations, which under normal circumstances are not 
felt, are perceived as throbbing pain in a migraine. In turn, 
anything that would cause one’s heart rate to climb, and 
increase the rate of blood flow, will be perceived as pain 
during a migraine. Examples include exercise and phys-
ical activity (Amin et al., 2018). This may be the reason 
why migraineurs avoid daily physical activities during their 
attacks.
Symptoms
One of the countless symptoms related to migraine 
headaches, is known as allodynia. This refers to having 
pain from regular daily activities, such as brushing their 
hair, laying their head down on a pillow, scratching their 
scalp, or wearing contact lenses. This pain is perceived as 
a result of these small stimuli, through sensitization of 
migraine pain pathways (Moy & Gupta, 2020). Two thirds 
of migraine patients experience this symptom together 
with migraine attacks. This aspect of migraine pain is usu-
ally attributed to the more severe headaches and can be 
a pointer leading to the diagnosis of chronic migraines. 
Proven by studies that measure the brain signals during a 
migraine, sensitized thalamic neurons are said to be the 
cause of this overreaction towards normally harmless 
stimuli (Goadsby et al., 2017).
Photophobia
Photophobia is described by patients when light becomes 
bothersome and too bright. When most people are not 
bothered by this light, migraineurs can become aggravat-
ed by it. For example, in a study done, non-migraineurs 
were able to endure light until it reached the intensity 
of a sunny day, yet the migraineurs already reported pain 
and discomfort at the level of an overcast, rainy day (Rossi 
& Recober, 2015). Studies show that light can activate 
nociceptive thalamic neurons and worsen migraine pain. 
This is true even if the patient is blind yet has an intact 
optic nerve (Goadsby et al., 2017).
Triggers
Many ideas and hypotheses have been reported regard-
ing the connection between migraine pain and triggers. A 
trigger is anything that causes a migraine to be more like-
ly to occur. Migraines can be brought about by anything 
that directly or indirectly initiates vasodilation, activation 
of the trigeminal pathway or the brainstem, and corti-
cal spreading depression. Dietary triggers can cause mi-
graines by releasing norepinephrine and serotonin, which 
can act as vasodilators. Additionally, migraine attacks are 
more likely to occur when the migraine threshold is di-
minished by a trigger, which makes it easier to initiate an 
attack (Nowaczewska et al., 2020). 
Many migraineurs cannot point to one specific thing 
that most likely causes their migraines, but rather a com-
bination of a few factors (Nowaczewska et al., 2020). In 
fact, when asked what a possible cause of their migraine 
is, migraineurs most often cannot answer that question 
point blank, and are only able to identify some triggers 
when given a list of options. Confirming migraine triggers 
is almost impossible with the methods used most often 
such as diary studies, surveys, and questionnaires. This 
demands participants to think retrospectively and they 
very often confuse their thoughts with common migraine 
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misbeliefs, as opposed to actual symptoms that they’ve 
had. Electronic diaries seem to be the best method of re-
cording data, as contributors can mark down their symp-
toms as they are experiencing them, and it is less likely for 
them to get confused (Nowaczewska et al., 2020).
Although some scientists believe that there are actual 
triggers that can bring on a migraine, others say that this 
is only a confusion of premonitory symptoms. They claim 
that a migraine has already begun 24-48 hours before the 
onset of pain (during the premonitory phase), and factors 
that others believe to be triggering the migraine, are only 
a consequence of premonitory symptoms. Some of these 
symptoms include food cravings, inability to stay focused 
and to concentrate, and fatigue. So, for example, when 
one feels tired as a result of this premonitory symptom in 
his already existing migraine, he is inclined to drink coffee 
or another caffeinated drink, and later feels the pain that 
is characterized as a migraine headache. This causes the 
patient to believe that coffee, or any other caffeinated 
food item, generates migraine headaches for him, when, 
in reality, it was only a cause and effect of his premonito-
ry symptom. In the face of this confusion and difference 
of opinion amongst the scientists, the general public still 
believes that some factors, whether endogenous or ex-
ogenous, can cause one to be more prone to migraines 
(Goadsby et al., 2017).
A study was done in the Headache Outpatient 
Department of the University Medical Center at 
Hamburg-Eppendorf that proves this point, in which 
around 1000 participants were asked to highlight their 
so-called triggers and to relate the time interval in which 
it took to perceive head pain. While analyzing the results, 
38.5% of the migraine patients claimed to have symptoms 
starting at the earliest 6 hours before the headache, and 
many of the presumed triggers were very closely related 
to leading premonitory symptoms. For instance, those 
who claimed flickering or bright light was a trigger for 
their migraine, also mentioned having photophobia during 
their premonitory phase. It is very likely that the flicker-
ing and bright lights were confused as a trigger and were 
in fact only early signs of a looming migraine. Researchers 
say that some ‘migraine triggers’ do have the ability to 
prompt a migraine, depending on which phase it is per-
ceived (Schulte, Jürgens, & May, 2015).
If a migraine is said to be due to sensory neurons mal-
functioning, then each individual’s trigger threshold can 
be different, and even within one individual there can be 
different threshold levels during independent migraine 
attacks. It would therefore be clear, that triggers will only 
cause a migraine to materialize if the trigger reaches 
the sensory threshold. So, an external stimulus like an 
environmental factor or stress will only induce a migraine 
if it is above the threshold level during that specific time 
(Schulte, Jürgens, & May, 2015).
Caffeine 
Caffeine has a dual job in migraine headaches. On one 
hand, caffeine is said to be beneficial to many migraineurs 
as it can lessen their symptoms or the length of their 
migraine headache. In fact, many migraineurs will choose 
their medication based on whether or not caffeine is in-
cluded in its makeup. Yet, on the other hand, caffeine is 
said to be a migraine trigger, as well as being reported 
to cause headaches upon withdrawal. Coffee, tea, and 
other soft drinks all contain caffeine and have been list-
ed as migraine triggers in around 10% of the population 
(Nowaczewska et al., 2020).
According to the Association of Migraine Disorders, 
when people enjoy consuming this substance to boost 
their energy, they tend to overdose. Their bodies then 
become dependent on having their daily coffee and no 
longer produce the same results as they have gotten ac-
customed to. They then try to consume more caffeine, 
hoping that a larger dose will increase the benefits, and 
run into a nasty cycle. If one day, they miss a coffee, they 
will most likely experience a caffeine withdrawal head-
ache. This can occur after drinking coffee for as little as 
seven days. Caffeine withdrawal must be done gradually 
to avoid a migraine headache. Therefore, migraine patients 
are advised to be consistent with their amount of caffeine 
intake, and not to drink beyond 200 mg a day, about two 
servings of a coffee (this amount varies depending on 
how one makes their coffee) (Nowaczewska et al., 2020).
In a recent caffeine withdrawal study done in Norway, 
80 participants were told to terminate their daily caffeine 
intake and replace it with either a capsule filled with 
caffeine or a placebo, identical looking. This study was 
randomized, and participants did not know which cap-
sule they received. They divided the capsules of caffeine/
placebo into smaller doses, to enable the participants to 
continue their way of life (i.e. having a few cups of coffee 
scattered throughout the day). Many of the participants 
dropped out before the end of the study due to with-
drawal headaches. The study ended with nine participants, 
of which seven had intense migraines upon withdrawal 
from their usual intake of caffeine. When these partici-
pants continued with this daily dose for some time, they 
ceased to have migraines. However, one participant chose 
to reintroduce caffeine into his diet and consequently suf-
fered from a migraine attack (Alstadhaug, Ofte, Müller, & 
Andreou, 2020).
Caffeine reduces the amount of urinary magnesium 
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by acting as a reabsorption minimizer. Magnesium is im-
portant in managing chronic pain as well as migraines. 
Therefore, if someone has a reduction of magnesium 
in their urine due to excess intake of caffeine, they will 
be more prone to having a migraine attack. Additionally, 
caffeinated drinks such as coffee can cause a person to 
need to urinate which can lead to dehydration, another 
well-known migraine trigger (Nowaczewska et al., 2020).
Sleep deprivation and Malnourishment 
When looking at nuclei in the hypothalamus before and 
during a migraine attack, scientists noticed that they 
were more active than usual. These nuclei are involved 
in activating the trigeminovascular system and are rec-
ognized as migraine triggers. The hypothalamus regulates 
homeostasis regarding food and energy systems, circadian 
rhythm, and salt balance. Therefore, if someone skips a 
meal or is malnourished, or if they have constant inter-
rupted sleep or reduced amounts of rest, they can be 
more likely to have a migraine attack. A study done on 
fasting revealed that 50% of fasting participants had a 
migraine headache (Goadsby et al., 2017). In fact, during 
Ramadan and on Yom Kippur, many fasters report having 
migraine headaches.  An additional reason why fasting can 
cause a headache is due to caffeine withdrawal, as fasters 
miss their daily coffee. 
A person’s diet causes them to intake different amounts 
of needed vitamins and elements. Some foods will cause 
inflammation, release of nitric oxide, and vasodilation. 
A study conducted in Rome reported that increased 
consumption of whole-grain bread and pasta, thereby 
decreasing one’s intake of white bread, was associated 
with fewer migraines and a significantly smaller amount 
of people needing medication to help with migraine pain 
(Hindiyeh et al., 2020). 
Stress
Stress is another factor of disrupted homeostasis that can 
trigger a migraine. It seems that migraineurs are more 
susceptible to changes in the environment. When a mi-
graineur who has enhanced sensitization of brain stem 
pathways experiences stress, it can be misinterpreted as 
an unwanted intruder and can cause a migraine attack 
(Goadsby et al., 2017). A study reviewed a migraineurs 
stress levels over a period of time, and indeed, stress 
levels were high in the days leading up to the migraine 
(Schulte, Jürgens, & May, 2015).
Menstrual Cycle 
There is a 3:1 ratio of women getting a migraine ver-
sus men. This is most likely due to a woman’s menstrual 
cycle, which is reported to be the cause of more than 
60% of migraines in women (Silberstein et al., 1999). By 
their early 50’s, almost half of the world’s women will 
have experienced at least one migraine headache (Moy & 
Gupta, 2020). Although it is unconfirmed due to lack of 
successful studies, menstrual migraines seem to be due 
to estrogen withdrawal at the end of the menstrual cycle. 
Results of studies done, in which women were given 
estradiol, shows that their migraines were delayed until 
their estrogen levels dropped. In addition, women who 
were given gonadotropin-releasing hormone to help with 
in-vitro fertilization reported migraines as an aftereffect 
of a rapid estrogen level descend. When looked at from 
the other side, high levels of estrogen are shown to lessen 
the likelihood of migraines, like in women who are post 
menopause or in their second or third trimester of preg-
nancy (Sacco, Ricci, Degan, & Carolei, 2012). Towards the 
end of a woman’s menstrual cycle, she has low levels of 
estrogen and serotonin. This causes her trigeminal nerves 
to stimulate the production of substance P and calcitonin 
gene-related peptide (CGRP). These two substances 
cause vasodilation and sensitization to the trigeminal 
nerve, both of which are thought of as migraine triggers 
(Moy & Gupta, 2020).
Genetics
While an average individual will not be affected by trig-
gers, migraineurs, because of their sensitive protein re-
ceptors, will see these triggers as an enemy and cause 
an attack. The fact that some people are more prone to 
migraine headaches leads doctors to believe that there is 
some genetic factor (Nowaczewska et al., 2020).  
Those who are taking medications like a hormonal 
contraceptive, can be more prone to migraines as their 
estrogen levels fluctuate drastically. (Moy & Gupta, 2020) 
Other medications that can cause migraines are those 
that contain high doses of caffeine and can lead to a caf-
feine withdrawal migraine (Nowaczewska et al., 2020). 
Treatments
Although caffeine is most often known as a migraine trig-
ger, it can also be used to treat migraines. Caffeine can 
act as a vasoconstrictor which can lessen the migraine’s 
effect and is said to relieve head pain by 40% when com-
bined with other drugs like acetaminophen and aspirin. 
However, patients should be sure not to overuse this 
method as it can lead to a caffeine withdrawal headache 
if one consumes too much over a short period of time 
(Martin, 2019). Additionally, during a migraine, it is under-
stood that adenosine binds to specific receptor mole-
cules, causing a widening of blood vessels. Caffeine, as a 
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vasoconstrictor, can help bring the blood vessels back to 
their original size, thereby reducing the risk of having a 
migraine (Shapiro & Cowan, 2017).
Sleep is another well known treatment. Patients report 
sleep as having a therapeutic effect on headache pain. 
Therefore, doctors try to choose sedative medication 
when deciding what to give the patient to aid in healing 
the migraine (Vgontzas & Pavlović, 2018). Other treat-
ments include taking analgesics like acetaminophen, aspi-
rin, and Excedrin. Treatments are specific to each patient 
and their distinct migraine symptoms and should be dis-
cussed with a physician.
Discussion
Many migraineurs have been advised by physicians or 
by medical personnel to steer clear of objects or situ-
ations that usually cause them to experience a migraine. 
However, studies have shown that avoiding common trig-
gers can cause sensitization and an increased likelihood 
to have a migraine when one is later, perhaps unwillingly 
exposed to those triggers. Additionally, when people are 
constantly avoiding certain situations or specific foods, it 
can get frustrating and induce stress. This can be detri-
mental as stress is considered to be a migraine trigger 
as well. Furthermore, if we believe that migraines can be 
a consequence of sensory signals in the central nervous 
system overreacting to so-called ‘triggers’, getting the 
CNS used to these triggers and teaching it that they 
are not harmful, can be beneficial to those who suffer 
from migraines. Therefore, the public is recommended to 
continue their usual lifestyle, with these ‘triggers’ includ-
ed in their daily living, so long as one does not yet feel 
the beginning of a migraine (Nowaczewska et al., 2020). 
However, all physicians will agree, that once a migraine 
patient feels the onset of the ailment, he should imme-
diately do anything he can to avoid more pain, including 
staying away from things he knows can exacerbate his 
pain. Additionally, each individual is recommended to fol-
low his/her migraine adventure with their physician, as 
each case is unique in its own way. 
Conclusion
Scientists have not come across enough information re-
garding migraines to know if it is better to avoid trig-
gers, or to learn to live with the pain. More investiga-
tion needs to be done before a clear decision can be 
made. Researchers should try to find migraineurs who 
will not drop out of the study before the end (due to 
headache pain), as a means to discovering more informa-
tion on migraine headaches and their pathophysiology. To 
avoid the bias of migraineurs reporting triggers through 
a questionnaire, more investigations should be done via 
electronic diary, so the patients can report triggers as 
they are happening. This report includes data that helps 
the public better understand migraine triggers and their 
side effects. 
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Parkinson’s Disease is one of the most common neurological disorders which disrupts the everyday lives of millions of people.  This 
disease is categorized by the loss of dopamine in the brain, specifically the Substantia Nigra.  People diagnosed with PD suffer 
from motor and cognitive impairments .  While there is no one treatment which can completely cure the disease, there are many 
treatments available which can help alleviate symptoms .  However, most of the treatments cause many negative side effects . 
Recently, a new physical therapy treatment, LSVT BIG has begun to show its effects .  This revue describes the many factors and 
treatments of Parkinson’s disease and explains the newly discovered treatment of LSVT BIG.
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Introduction
Parkinson’s disease (PD) is a progressive neurological 
disorder which disturbs one’s motor cortex, thereby 
affecting one’s mobility. This disorder affects over one 
million people in the United States alone and more than 
ten million across the entire world (National Parkinson’s 
Foundation, n.d.). Unfortunately, this disease slowly wors-
ens from the time one is diagnosed. Even more, PD has 
a large range of indications and effects. While many with 
Parkinson’s disease have similar symptoms, no two indi-
viduals experience the illness in exactly the same way. If 
you see someone shuffling down the street taking small 
steps or shaking their hands quickly and repeatedly in 
their lap, you can suspect that this person is suffering 
from Parkinson’s Disease. What causes this neurological 
disease, and what can we do to slow the progression and 
treat the symptoms? 
Methods
The information stated in the following paper was ac-
quired through the Touro College Library, which grants 
its students access to many useful databases such as 
ProQuest, Ebsco, PubMed and others. 
Pathophysiology
Patients with Parkinson’s Disease are lacking in dopa-
mine, which is normally produced in the substantia nigra 
part of the brain. The thalamus must have access to the 
motor cortex in the brain, specifically to the basal ganglia, 
in order to produce movement. Within the basal ganglia 
there are two pathways which have opposite effects on 
movement. The direct loop promotes movement, while 
the indirect loop inhibits movement. In a healthy person, 
the dopaminergic pathway maintains the balance between 
the other two pathways, enabling the thalamus to have 
control over the motor cortex and over the person’s 
movements. This dopaminergic pathway works by excit-
ing the direct pathway, while inhibiting the indirect path-
way to promote movement. This happens in two ways. 
First, the substantia nigra sends dopamine to the stria-
tum which excites the striatum and causes it to inhibit 
the globus pallidus. Thus, the globus pallidus is unable to 
obstruct the thalamus. Second, the substantia nigra sends 
dopamine directly to the globus pallidus, inhibiting it, so it 
cannot prevent the thalamus from controlling the motor 
cortex. In those with PD, much of the dopamine in the 
substantia nigra is exhausted. Consequently, the globus 
pallidus is excited and inhibits the thalamus. Thus, the 
thalamus has little control over the motor cortex (Singh, 
2018). See Figure 1.
Figure 1: GPi = Globus Pallidus internus, GPe = Globus 
Pallidus externus, SNpr = Substantia Nigra, STN = 
Subthalamic Nucleous, MC = Motor Cortex, PMC = Pre 
Motor Cortex, SMA = Supplementary Motor Cortex 
The arrows thickness represents the amount of increase 
and decrease of neuronal actions. In the healthy person, 
the arrows of the direct and indirect pathways which are 
related to dopamine (explained above) are significantly 
thicker than the arrows in the PD patient. Furthermore, 
the Globus Pallidus internus has the power to inhibit the 
thalamus in the PD patient as demonstrated by the thick-
ness of the arrows (Singh, 2018).
The lack of dopamine causes akinesia, bradykinesia and 
other motor deficits which are so commonly found in 
patients with PD. As the levels of dopamine decrease, the 
levels of Acetylcholine (Ach) increase. The increased Ach 
is what causes the symptoms of tremors and rigidity in 
PD patients. In other words, the loss of the dopaminergic 
system leads to disinhibition of the cholinergic system 




Another major marker for Parkinson’s Disease is the 
existence of the Lewy Body. The Lewy Body is a “neuronal 
inclusion” which mainly contains a cluster of a-synuclein 
proteins (Bridi & Hirth, 2018).
Causes of Parkinson Disease
PD is believed to be an idiopathic disease being that 
scientists are unable to find one definitive cause of this 
Parkinson’s disorder. However, there are factors that 
increase one’s likelihood of developing Parkinson’s dis-
ease. First, there are those who have a genetic predispo-
sition. The most established or proven genetic cause of 
Parkinson’s is mutations in what is known as the Parkin 
gene (Park2) (Shadrina, et al., 2007) or the PINK1 gene 
(PARK6) as they both inhibit normal mitochondrial func-
tion (Seirafi, et.al. 2015). Additionally, people who experi-
ence a head injury are at a greater risk for developing PD. 
High milk and dairy intake and exposure to pesticides can 
also increase one’s risk for developing PD. Interestingly, 
research has found that there are certain steps one can 
take in order to reduce his/her risk of developing the dis-
ease, such as cigarette smoking and consumption of cof-
fee or other caffeinated drinks (Ascherio & Schwarzchild, 
2016).
Symptoms of Parkinson’s Disease
PD is a progressive disorder, meaning there is no cure 
and the disease slowly worsens over time. Most people 
consider PD a disease which only affects movement, how-
ever this is not the case. Rather, Parkinson’s causes a large 
range of symptoms and affects different systems in the 
body. Individuals suffering from PD perceive the world 
as much smaller than healthy individuals. Therefore, many 
of the symptoms are correlated to this viewpoint. For 
example, when a PD patient shuffles, one thinks that s/he 
is walking normally. (Fox, et.al. 2011). 
Motor Symptoms
There are two groups of symptoms caused by PD. First, 
and more well recognized, are motor symptoms. Up 
to 80% of dopamine in the Substantia Nigra is deplet-
ed before these motor symptoms become noticeable. 
However, in order to be diagnosed with PD, people must 
demonstrate some symptoms. First, they must exhibit 
slow movement and low amplitude of everyday move-
ments (shuffling of gait), otherwise known as bradykinesia. 
Then, they must also display one additional cardinal sign 
of Parkinson’s, which include rigidity, akinesia or unable to 
initiate movement, lack of balance or tremors. As men-
tioned above, about 80% of PD patients suffer from limb 
tremors, usually concerning the hand, which is caused by 
increased levels of Ach. Furthermore, several years after 
initial symptoms, 25% -60% of patients with PD exhibit 
frozen movements, while 40% – 80% of PD patients have 
swallowing issues and 25% drool. Additionally, more than 
50% suffer from speech impairments including quiet and 
hurried speech (Sveinbjornsdottir, 2016).  Additionally, 
those with PD display a masked expression, also known 
as bradykinesia of the face. This happens because when 
a person is suffering from Parkinson’s Disease, all move-
ments slow down including facial movements. The delay 
of the facial muscles is what causes PD patients to lose 
their ability to express themselves via facial expressions 
(Bologna, et al., 2013). 
Non-Motor Symptoms
Contrary to popular belief, Parkinson’s is not just a 
movement disease, rather it affects non-motor abilities 
as well. Even before the motor symptoms start and the 
person is diagnosed, patients may experience a variety 
of non-motor symptoms. These symptoms can be divid-
ed into three sections: autonomic function disturbanc-
es, sleep disturbances and neuropsychiatric symptoms 
(Sveinbjornsdottir, 2016). 
Autonomic Function Disturbances
Those with PD often experience rapid drops in blood 
pressure causing dizziness, visual troubles and weak-
ened cognition which can ultimately cause loss of 
consciousness. Furthermore, the movement of the 
gastrointestinal tract slows down. This can cause over-
stuffed feelings, gastric retention and constipation. 
Constipation occurs in over 75% of PD patients. Also, 
those with Parkinson’s suffer from an inability to con-
trol their urinary frequency and urgency. About 60% 
of PD patients display frequent nocturia, needing to 
wake up several times throughout the night to use the 
bathroom (Sveinbjornsdottir, 2016).
Sleep Disturbances
Roughly two thirds of PD patients suffer from an as-
sortment of sleep disorders. This can be due to physi-
cal or cognitive limitations of the disease itself, or due 
to the different medications and treatments which are 
being used to treat the patient’s symptoms. The most 
common ailment is fractionated sleep. Studies show that 
PD patients sleep lighter and have regular interruptions 
throughout the night. This fractionated sleep can also be a 
result of other PD sleep disorders such as frequent noc-
turia, difficulties with moving in bed and nocturnal trem-
ors. Depression caused by Parkinson’s can also disturb a 
patient’s sleep throughout the night.  Additionally, about 
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50% of people diagnosed with Parkinson’s undergo ex-
treme daytime sleepiness. Some say that this is somewhat 
caused by the dopaminergic drugs. Even more, 27-32% 
of PD patients kick and smack while dreaming and oth-
ers uncontrollably jerk while sleeping (Sveinbjornsdottir, 
2016). 
Neuropsychiatric Symptoms
Many with PD suffer from various Neuropsychiatric 
Symptoms. The earliest indications consist of executive 
functioning issues, visuospatial disfunction, weakened 
speech fluency and memory loss. Additionally, in more 
than a third of PD patients experience hallucinations 
and illusions. Also, as the disease progresses some de-
velop paranoia, particularly feeling suspicious towards 
their spouse. Moreover, dementia is also common in 
those with Parkinson’s. Other common Neuropsychiatric 
symptoms include depression and anxiety. One third of 
PD patients have clinically diagnosed depression and 17% 
were confirmed to have a major depressive disorder 
(Sveinbjornsdottir, 2016). All symptoms, whether they are 
movement related or not, adversely affects the lives of 
PD patients. 
Unified Parkinson’s Disease Rating Scale
For any disease, when testing a new treatment, or tweak-
ing a current treatment, there must be a way to measure 
the success. Specifically for Parkinson’s disease, there are 
different ways of measuring the severity of PD symp-
toms, thereby displaying the treatments progress. Most 
frequently used is the Unified Parkinson’s Disease Rating 
Scale (UPDRS). This rating tool is used to determine the 
severity of the PD patient’s symptoms. It is divided into 
four sections which evaluate the symptoms’ severity on 
a 0-4 scale. First, UPDRS I measures non-motor daily be-
haviors such as sleep, mood and brain activity. Second, 
UPDRS II assesses the patient’s motor abilities for daily 
living, such as speech, chewing, handwriting, walking and 
drooling. Third, UPDRS III is the section which includes 
motor evaluation such as rigidity, gait and tremors. Last, 
UPDRS IV calculates treatment complications such as 
pain (Kleiner-Fisman, et.al. 2010). 
Brief Overview of PD treatments
Although there is not a single cure for PD, there are 
different treatments which target specific symptoms of 
the disease. This includes both motor symptoms and 
non-motor symptoms. Furthermore, there are three 
types of treatments used to improve PD patient’s way of 
life. There are medicinal treatments, surgical intervention 
and physical therapies. 
Drug Therapy
Many of the medicinal treatments for Parkinson’s Disease 
patients target the dopaminergic pathway, working to 
increase the dopamine in the patient’s brain. While 
some medicines work better than others, no drug cures 
symptoms completely. The most commonly used drug 
is levodopa which increases the dopamine in the brain. 
Primarily, levodopa targets the movement disorders of 
PD. Although levodopa is still considered the most ef-
fective treatment, about 40% of patients develop motor 
complications after 4-6 years of levodopa treatments. 
There are other drugs taken to combat the side effects 
of levodopa (Dong, et.al. 2016). Another commonly used 
drug is amantadine. Many clinical trials have proved that 
amantadine can lessen the dyskinesia side-effect of the 
levodopa drug. It was also found to reduce the severity 
of freezing gait. Thus, improving PD patients’ abilities to 
perform daily activities. Additionally, there are less fre-
quently used drugs such as anticholinergic drugs. These 
drugs help by restoring the balance between dopamine 
and acetylcholine. Anticholinergic drugs are mostly used 
at the onset of the disease, when the primary symptom 
is tremors. The use of this type of medication is very lim-
ited, as there are many side-effects which some believe 
outweigh the benefits (Dong, et.al. 2016). Side-effects 
include decreased cognitive function, especially in older 
PD patients, constipation, blurred vision and tachycardia 
(Lertxundi, et al., 2015).
Surgical Treatments
There are many surgical interventions which were prov-
en to be beneficial for PD patients. One such method is 
called Deep Brain Stimulation (DBS). This surgery places 
electrodes at certain places in the brain which control 
movements. They are either placed in the subthalamic 
nucleus (STN), the globus pallidus interna (GPi), or the 
ventralis intermedius (VIM) nucleus of the thalamus. DBS 
improves patients’ movement abilities and may lessen 
tremor severity. Yet, unlike other pharmaceutical drugs, 
DBS has demonstrated little to no side-effects (Chou, 
Grube, & Patil, 2012, p. 15). Another surgical treatment 
is cell transplantation. This treatment has proven to be 
effective on motor symptoms of PD. This works as the 
transplanted stem cells can “infiltrate and integrate with 
diseased tissue, differentiate into dopaminergic neurons 
to replace damaged cells and reconstruct neuronal cir-
cuits to restore nerve function (Li, 2012).” 
Physical Therapy
A major issue with medication for PD patients is that the 
effectiveness of the medicinal drugs decreases over time. 
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As a result, the creation of different exercises and physical 
therapies have also proven to be an effective way of com-
bating Parkinson’s disease. First, basic exercises lessen the 
motor and even non-motor symptoms of those with PD. 
Exercise increases mitochondrial respiration and arouses 
neuroplasticity. Furthermore, recent clinical trials recom-
mend aerobic exercises. They claim that these exercises 
improve gait, physical performance and balance. They also 
state that they impact fatigue, depression and improve 
cognitive ability. Additionally, a Chinese exercise called 
Tai Chi, through breathing exercises combined with slow 
movements, has improved the balance of PD patients 
(Dong, et.al. 2016). Finally, LSVT BIG, a relatively new ap-
proach to physical therapy in PD, has begun to show its 
effectiveness.  
What is LSVT BIG?
LSVT Big was created based on the success of a treat-
ment called LSVT Loud. First introduced in 1995, LSVT 
Loud was proven to be an effective way of improving the 
strength and loudness of the voice of PD patients.  LSVT 
Loud is a treatment which focuses on how one feels and 
sounds when talking loudly. Unlike many speech treat-
ments which target many different speech systems, LSVT 
Loud primarily focuses on increasing movement in the 
respiratory and laryngeal systems. Currently, after con-
ducting many studies and experiments, LSVT Loud was 
proven to be a successful treatment (Fox, et.al. 2011). 
After the success of LSVT-Loud, in 2005 LSVT-BIG was 
first introduced (McDonnell, et al., 2017). 
LSVT-BIG was created to combat the hypokinesia or 
reduced amplitude movements which interfere with the 
everyday lives of people with PD.  The goal of the treat-
ment is to revise the way the patient perceives movement 
performance.  LSVT BIG therapy includes four consecu-
tive, one on one, 60-minute sessions per week in addition 
to one (on treatment day) or two (non-treatment days) 
15 to 20-minute home sessions per day. When performing 
any action, patients are told to conduct large amplitude 
movements. The beginning of each out-session includes 
seven whole-body exercises such as reaching in more 
than one direction, weight shifting and stepping. Next, the 
patient works on five every-day movements, such as shift-
ing positions, rolling over in bed and any others that the 
patient requests to improve. Third, the patient practices 
walking with larger amplitude, while standing straight. At 
the end of the session, the patient works on more compli-
cated tasks which are directly related to his/her goals and 
abilities. Later in the treatment, this final segment would 
increase in difficulty by either adding an additional task or 
by enhancing the existing mission (Isaacson, et.al. 2018). 
Experiments Conducted 
To prove the effectiveness of LSVT-BIG, there were nu-
merous studies and experiments done on all different 
types of people at all stages of Parkinson’s disease. One 
such experiment performed, compared the results of 41 
patients involved in general exercise to 43 patients par-
ticipating in the LSVT-BIG program. After sixteen weeks, 
they found the motor function of the LSVT-BIG patients 
to have improved significantly more than the other 41 
patients. Additionally, it was found that those participating 
in the program increased their speed of moving. Another 
study found that LSVT-BIG helped decrease response 
time when prompted (McDonnell, et al., 2017). 
Another study was done to see if LSVT-BIG also im-
pacted the duration of a patient’s ‘off time,’ meaning the 
time of day where one feels at his/her low. Eight patients 
participated in the study. Before starting treatment, each 
patient was required to report their ‘on’ and ‘off ’ dura-
tions for three days. Then they were evaluated under the 
UPDRS III scale on motor ability. Then they began treat-
ment. The changes were measured every four weeks by 
ministering different tests. The results proved that LSVT-
BIG therapy does lessen the duration of ‘off ’ time as it 
did significantly improves the UPDRS III scores (Ueno, et 
al., 2017). 
In addition, a non-controlled study was performed 
which examined the effects that LSVT BIG had on eigh-
teen PD patients. It was found that after just four weeks of 
therapy, the participants experienced a 12-14% increase 
in walking and walking rate (Fox, et.al. 2011). 
A different blind study was done which took sixty peo-
ple suffering from Parkinson’s disease and randomly as-
signed them to one of three therapies, LSVT BIG, Nordic 
Walking in a group setting, or regular exercise with no 
therapist. After four months of treatment, the average 
improvement of the scores on the UPDRS III on patients 
receiving LSVT BIG therapy was 5.05, while the scores of 
those undergoing Nordic Walking or domestic training 
worsened. This amount of scaled motor increase clinically 
proves that LSVT BIG does improve the symptoms of PD 
patients (Fox, et.al. 2011). 
Another case study included twelve idiopathic PD pa-
tients who underwent LSVT BIG therapy treatment. There 
were also two control groups: one with eight PD patients 
who did not undergo any physical therapy and the other 
included fourteen healthy individuals who experienced 
the same experiment as the case study. The PD LSVT BIG 
patients were given sixteen sessions, four sessions per 
week for four weeks. Each session was an individualized 
meeting with a licensed LSVT BIG therapist and lasted 
one hour each morning. Each appointment began with 
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using the patient’s entire body including “BIG” amplitude 
exercises and “repetitive multidirectional movements.” 
The second half of the meeting included daily activities 
according to what the patient wished to focus on such as 
buttoning shirts and putting on a coat. The results showed 
the gait speed and the step length of patients undergoing 
LSVT BIG increased. Furthermore, the LSVT BIG patients 
displayed better functional mobility as they were able to 
transition from sitting to standing faster and more often. 
The LSVT BIG patients’ improvements were significantly 
greater than the PD control group (Flood, et al., 2020).
Each of the experiments described above prove the 
effectiveness of LSVT BIG therapy. There were countless 
of other case studies conducted whose results were sim-
ilar to the outcomes stated previously. Thus, it is safe to 
conclude that LSVT BIG is an effective way of treating 
Parkinson’s disease.
Conclusion 
Parkinson’s Disease is a neurological disorder which af-
fects tens of millions of people across the world. Primarily, 
the disease is associated with progressive loss of dopa-
mine in the brain. People with PD are affected in many 
different areas of life including motor skills and cognitive 
abilities. Unfortunately, researchers have not found one 
perfect solution to completely cure Parkinson’s Disease. 
Rather, there are only palliative solutions, treatments 
which either ease the symptoms or slow the progression 
of the disease however, doctors don’t often give patients 
medication for two reasons. Often, many of the com-
monly used medicinal treatments can cause difficult side 
effects. Secondly, as time progresses, the impact the medi-
cine has on the body weakens as the patient becomes ac-
customed to the drug. Therefore, doctors and therapists 
are beginning to use more non-invasive treatments such 
as exercise and Physical Therapy. Recently, there has been 
a new treatment, LSVT BIG, which targets the ampli-
tude of the PD patients. This treatment has continuously 
proved itself effective and worthwhile. Every Parkinson’s 
patient should have the opportunity to undergo LSVT 
BIG treatment.
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Soy, which contains a form of phytoestrogen known as isoflavones, impacts the biological activity of humans at all stages. There 
are many aspects to consider when determining whether soy is beneficial. Since the hormone estrogen plays a significant role 
in maintaining the biochemical and homeostatic conditions of an individual, it follows that the disruption of estrogenic levels can 
be detrimental. There are many hormone- dependent diseases that can be linked to one’s diet, and the possibility of utilizing 
phytoestrogens, such as soy, to prevent or control hormonal irregularities is compelling . This paper explores the effects that phy-
toestrogens, specifically soy, can have at various stages of hormonal progression.
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Introduction
Recently, soy has been garnering attention for its estro-
gen-like qualities. One group of chemicals found in soy are 
phytoestrogens, a non-steroidal class of estrogens. Of the 
numerous phytoestrogens, the study of the role of isofla-
vones has been isolated because of their high concentra-
tion in soy. Crucial to understanding soy’s “estrogen-like” 
qualities is understanding isoflavones’ chemical makeup. 
In soy specifically, isoflavones present as glycosides, which 
are bound to sugar molecules. When the isoflavone gly-
cosides are digested and released, the isoflavone presents 
as aglycones. This includes compounds such as genistein, 
daidzein, and glycitein. 
Structurally, these isoflavones are similar to a form of 
estrogen, 17β-estradiol, as shown (fig, 1). The phenolic 
ring on the isoflavones is a crucial part of its structure 
which chemically allows the phytoestrogen to attach to 
estrogen receptors, thus promoting “estrogen-like” activ-
ity. Once the isoflavone is bound to an estrogen-recep-
tor complex, the phytoestrogen can act as an estrogen 
agonist or antagonist. Based on various factors, such as 
the concentration levels of the phytoestrogen and endog-
enous estrogen, the specificity of the receptor, and the 
particular tissue that the phytoestrogen is targeting, the 
soy will either act as an estrogen inhibitor or stimulant. 
This holds promise as a physiologically beneficial meth-
od of regulating hormonal abnormalities. Dietary estro-
gen has shown potential in alleviating postmenopausal 
symptoms, reducing the risk of breast cancer, and bone 
resorption. However, soy is dosage- dependent, and a 
high intake of soy in infancy may lead to some physical 
signs of sexual maturation at a young age. Soy has also 
been a contributing factor for both very early and late 
menarche. There is a concern for early maturation, as it 
can cause hormone- related cancers such as breast can-
cer. Therefore, the consumption of soy that leads to the 
binding of isoflavones to sex-hormone binding globulins 
(SHBG) necessitates much research to determine all pos-
sible outcomes (Setchell, 1998).
Methods
The following research is based on the analysis of numer-
ous articles from various databases, that include but are 
not limited to The Touro College Library online, PubMed, 
and ProQuest. The National Center for Biotechnology 
(NCBI), and BioMed Central (BMC) were additional 
sources of data as well.
Discussion 
Infants
Soy- based infant formula (SBIF) has been used for over 
100 years. SBIFs were developed as an alternative to 
cow’s milk-based formula for infants that were lactose in-
tolerant or required vegan replacement. Recent data has 
shown that SBIF is used by approximately 20%-25% of 
Americans. SBIF has a high concentration of isoflavones; 
the concentration levels vary from 32 to 47 mg isofla-
vones/L of formula. According to research, “infants fed 
SBIF are exposed to a 6–11 fold higher level of isoflavones 
on a body weight basis than adults. Additionally, circulat-
ing isoflavone levels of these infants were 13,000–22,000 
times greater than circulating levels of 17-β-estradiol.” 
(Dinsdale et al., 2010) The effect of an infant consuming 
and absorbing this high of a dosage of an estrogenic- 
like substance can have long-term consequences. This is 
because SBIF is primarily used from birth to one years 
old, which is a stage of development that is “particular-
ly sensitive to dietary and environmental compounds.” 
However, it is exceedingly difficult to track soy formu-
la’s precise long-term effects on reproductive health. In 
order to so, all participants must be monitored before 
reaching puberty and all through the child-bearing years; 
this would allow the possible differences in reproductive 
health and organ development to be determined. Since 
that would require long-term compliance, a retrospec-
tive approach has been taken to analyze the effects on 
those who consumed SBIF. However, as a retrospective 
study, there are the limitations of recall bias and environ-
mental differences, such as smoking, physical activity and 
history of diseases, which make it difficult to determine 




the accuracy of the results. No reports were given of 
long-term adverse effects for the male infants fed SBIF.  At 
six months of age, female infants were reported to have 
increased vaginal cell maturation. There did not seem to 
be any vaginal discharge or breast development that was 
out of the ordinary. However, when children at two- years 
-old were still fed SBIF, there was an increase in the per-
vasiveness of breast tissue development in these children. 
Furthermore, the study reported that formula feeding 
in general, whether soy- or cow’s milk-based, can cause 
greater ovarian volume, an increase in the numbers of 
ovarian cysts per ovary, and lower testicular volume. 
On the other hand, SBIF and soy in general seem to pre-
vent breast cancer. High levels of isoflavone enhance differ-
entiation of the mammary glands, which leads to greater 
protection against chemically-induced mammary cancer. 
This was proven through a study in which genistein treat-
ment was given, resulting in “fewer terminal end buds and 
advanced development and ductal elongation.” As the least 
mature terminal ductal structures, it follows that terminal 
end buds are the most susceptible to possible carcinogens. 
Therefore, reducing the number of terminal end buds can 
lead to lower incidences of breast cancer. This is due to 
the fact that, “Part of the terminal end bud differentiates 
according to each estrous cycle, giving rise to alveolar buds 
that consist of lobule structures that are more mature and 
less susceptible to chemical carcinogens.” This treatment 
of genistein increased the number of lobules, which shows 
that there is a potential protective effect against mamma-
ry cancer. The exact mechanism in which genistein affects 
mammary gland development is unclear; however, accord-
ing to these findings, genistein clearly displayed estrogenic- 
like behavior (Dinsdale et al., 2010). 
Further studies show that high soy exposure during the 
prenatal and infant stages can cause early onset puberty, 
specifically menarche. Early menarche (≤10-11 years old) 
is just one of the factors that are considered when de-
termining whether a female reached puberty; however, it 
is the most commonly used benchmark. There are many 
issues associated with early development, such as adult 
obesity, type 2 diabetes, metabolic syndrome, and other 
markers of cardiovascular disease. A study was done to 
determine the various factors involved in early menarche, 
soy being among them. The Sister Study enrolled 50,884 
American and Puerto Rican women between the ages of 
35-74. The study was interested in finding whether certain 
early-life exposures are related to the health conditions 
mentioned above. The authors conducted interviews that 
included a comprehensive family medical history. Anyone 
that did not have a mother to relate the early life events 
was excluded. The study combined those that said they 
“definitely” or “probably” had feeding exposures into one 
category, and those that responded that they “definitely 
did not” and “probably did not,” into another category. 
Race/ethnicity, maternal age menarche, birth weight, birth 
decade, and childhood family income were also factored 
into the results. Results showed that, “The frequency of 
early menarche (≤11 years) was 20%, with 7% reporting 
menarche at 10 years of age or younger. The frequency of 
late menarche (≥14 years) was 24%, with 10% reporting 
menarche at 15 years of age or older.” 
The table above shows that SBIF can cause both early 
(≤10 years old) and very late menarche (≥15 years old). 
Although age at menarche is not the only sign of puber-
tal development, it is a key component; therefore, these 
studies are an important resource to tracking pubertal 
development. These findings are 
consistent with animal data that 
proves that the dose of genistein 
impacts whether early or late 
puberty will occur. “Mice admin-
istered a higher dose of genistein 
had a delayed vaginal opening 
(marker of puberty), while mice 
given a lower dose had an accel-
erated vaginal opening. Neonatal 
administration of genistein to 
mice has also produced other 
alterations in reproductive char-
acteristics, including changes in 
estrous cycles, early reproductive 
senescence, and decreased fertil-
ity.” In other words, the effects 
of neonatal administration of 
Table 1
Relative Risk Ratios for Early and Late Menarche in Association with Early-Life Exposures in 
Women Aged 35 to 59 years at Baseline in the Sister Study, 2003-2009 (n = 33,501)  
(D’Aloisio et al., 2013)
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genistein were greater than when genistein was admin-
istered to older mice. This makes sense considering that 
soy formula delivers a high dosage of its estrogenic com-
ponents to infants “per unit body weight.” Additionally, 
genistein is highly digestible and has been found in high 
concentrations in infants’ urine and plasma. Thus, main-
taining that the genistein can influence the estrogenic- 
like effect on these infants (D’Aloisio et al., 2013). 
Furthermore, while there is no evidence that SBIF 
directly effects reproduction, SBIF does exert its influ-
ence on the menstrual cycle. Women who were given 
soy formula as infants reported prolonged menstruation 
and more discomfort. With all this data, the question of 
whether or not soy formula is safe remains. Many coun-
tries have regulations on the use of SBIF. For instance, in 
Europe, SBIF is a prescribed product. However, despite 
these regulations, there is a large percentage of infants 
each year that are fed SBIF (Dinsdale et al., 2010).
Male Reproduction
Considering isoflavones’ estrogenic qualities, it follows 
that there can be estrogenic effects on males that con-
sume high concentrations of soy. There are not many 
cases reported of soy stimulating feminizing effects on 
men, such as gynecomastia. However, a study was done 
on an instance of hypogonadism and erectile dysfunction 
that was linked to high intake of soy.  A 19-year-old male 
that was recently diagnosed with type 1 diabetes began 
experiencing complete loss of libido and erectile dys-
function. Until the previous year, he had been in perfect 
health. He stated he had a heterosexual preference, was 
sexually active, had satisfactory libido, denied any history 
of orchitis or undescended testicles, had normal testic-
ular size, and body hair pattern. Additionally, he denied 
any androgen abuse, hormonal medication, drug abuse, or 
psychiatric disorders. He had never had a sexually trans-
mitted disease, no visual or muscular mass and strength 
changes, and no headaches. The one notable difference in 
his lifestyle was that he had taken on a vegan diet, which 
included high levels of soy (360 mg/day), due to his recent 
diagnosis of diabetes. A lab assessment revealed that he 
had low free and total testosterone levels, with increased 
levels of dehydroepiandrosterone (DHEA). His symptoms 
began after he started his vegan diet, which included 
products such as soy milk, soy cookies, tofu, soy sauce, 
soy nuts, and soybeans. Beforehand, he had been consum-
ing the average American 2,000- kcal diet. After stopping 
his vegan and soy diet, his symptoms improved over the 
course of 12 months. These improvements were consis-
tent with the gradual normalization of his testosterone 
and DHEA levels. The table below shows the progression 
of the patient’s levels of total and free testosterone, as 
well as the levels of DHEA normalizing over a period. 
The insufficient blood levels of free testosterone, which 
causes hypogonadism and erectile dysfunction, normal-
ized after the cessation of the soy diet, indicating that the 
high levels isoflavones may have been the cause.
The correlation between testosterone and soy may be 
explained by research on animals. “Animal studies have 
shown that isoflavones can bind to the estrogen receptor 
expressed by testosterone-producing Leydig cells, there-
by affecting Leydig cell differentiation and testosterone 
production, which ultimately leads to reproductive tox-
icity.” Therefore, consuming high levels of isoflavones can 
stimulate similar bioactivity in males.  Another possibility 
is that the estrogen- like isoflavones can cause a nega-
tive feedback mechanism that interferes with the DHEA 
conversion to testosterone. As the DHEA converting 
enzymes 3-b-hydroxysteroid dehydrogenase and 17-b-hy-
droxysteroid dehydrogenase are inhibited through the 
isoflavones genistein and daidzein present in soybean, the 
negative feedback is facilitated. The inhibition is what can 
lead to a decrease in testosterone. Another possible way 
in which the isoflavones decreased the free testosterone 
levels can be through the increase of the sex hormone- 
binding globulin (SHBG), which is produced by the estro-
genic activities of isoflavones. The increase of SHBG leads 
to more binding of the SHBG with the total circulating 
testosterone, which means there will be less free testos-
terone; this also further explains why the total circulat-
ing testosterone levels were within 
normal range (table 2). However, 
because there were missing SHBG 
measurements during the vegan diet, 
this hypothesis cannot be confirmed. 
There were nine more studies done 
in which the highest level of isofla-
vone concentration given was 139 
mg/d, as opposed to the 360 mg/d 
given in this study. As this was the 
only study done that there was 
clearly a testosterone decrease with 
Table 2
(Partial) Hormone profile at cessation of vegan diet and during 2-y follow-up (Siepmann et al., 2011)
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the consumption of soy, researchers speculate that there 
is an “isoflavone intake threshold” for symptoms to occur. 
There is also the possibility that since the composition 
of soy products has evolved over the years, there might 
have been differences in the soy products of the previ-
ous studies. While further studies are necessary, this case 
report successfully indicates that a high consumption of 
isoflavones is related to hypogonadism and decreased 
free testosterone (Siepmann et al., 2011).
Menopause
Phyto-estrogens that are administered in an environment 
that has a high concentration of endogenous estradiol 
have an antagonist effect on the estrogen receptors. In 
that case, the isoflavones act as an inhibitor. However, 
when there is a decrease of endogenous estrogen, such 
as hypogonadism and menopause, an administration of 
isoflavones will stimulate estrogenic bioactivity (Casini et 
al., 2006). Menopause symbolizes the end of a women’s 
reproductive life and is characterized by the cessation 
of menstrual periods for 12 consecutive months, which 
normally occurs between 45-55 years of age. Aside from 
the cessation of menstrual periods, there are additional 
symptoms, such as hormonal disturbances, hot flashes, 
night sweats, sleeping disorders, vaginal dryness, joint pain, 
mood swings, reduced bone density, and cardiovascular 
disease (Sunita et al., 2011). This mainly occurs because 
the menopause transition results in estrogen deficiency. 
Estrogen regulates appetite, cholesterol levels, carbohy-
drate and lipid metabolism, and protects bone. Therefore, 
when a woman is estrogen- deficient, the possibility of 
obesity, osteoporosis, and cardiovascular disease is more 
prevalent. To combat the hormonal imbalance, there are 
various forms of hormone replacement therapies (HRT). 
However, there are a host of issues with the with the 
HRT available, because the treatments available can cause 
diseases such as thromboembolism, uterine hyperplasia, 
uterine cancer, increased risk of breast, ovarian, and en-
dometrial cancers, coronary heart disease, and stroke. 
Therefore, in more recent years women have been turn-
ing toward more natural methods of HRT, such as soy, 
to alleviate menopausal symptoms. Genistein promotes 
an inhibitory effect on many of the common menopaus-
al symptoms. “It should be noted that genistein acts on 
various molecular pathways to emulate the effects of es-
trogens, without being known to elicit any life-threatening 
adverse effects.” There have been studies done to deter-
mine how effective this form of therapy may be; howev-
er, this is still a relatively recent discovery and there are 
many aspects that need further exploration (Thangavel 
et al., 2019).
The Asian diet is heavenly concentrated with soy, rela-
tive to the European and American diet. Statistically, only 
20%-25% of Asian postmenopausal women experience 
hot flashes, whereas 70%-80% of European and Latin 
American postmenopausal women complain of hot flash-
es. Since these hot flashes are one of the main postmeno-
pausal symptoms that women seek HRT for, researchers 
were compelled to discover what caused Asian women 
to have a lower incidence rate (Thangavel et al., 2019). 
There are a few studies that have reported the effective-
ness of genistein in treating hot flashes. A study was done 
on Japanese women specifically, comparing soy intake to 
incidences of hot flashes. This study was conducted over 
six years, in which it was shown that the consumption 
of soy reduced the hot flashes considerably. Even at the 
lowest concentration of isoflavones (75.2- 115.9 g/day), 
the hot flashes were lower, but the response rate was 
definitely more successful in the women that consumed 
higher levels of soy (Nagata et al., 2001). Another study 
was done on menopausal women and found that the “ad-
ministration of 30 mg of genistein for 12 weeks reduced 
hot flashes by 51% (9.4–4.7/day), whereas the placebo 
group experienced only a 27% reduction (9.9–7.1/day).” 
(Braxas et al., 2019) Furthermore, a randomized trial was 
conducted in which hot flashes were alleviated by the 
consumption of 54 mg/day over the course of a year. The 
mechanism in which genistein can inhibit the hot flashes is 
unclear. However, researchers speculate that the genistein 
diffuses through the cell’s lipid bilayer “due to genistein 
being an effective ER (estrogen receptor) modulator.” 
This will set off the mRNA synthesis and production 
of tissue-specific proteins (Crisafulli et al., 2004). While 
there is no definite conclusion as to why genistein inhibits 
hot flashes, it seems to be a successful method based on 
the results of the numerous studies above. 
Another effect that occurs because of estrogen deple-
tion is the change in metabolism, such as the slowing down 
of the body’s ability to metabolize carbohydrates and lipids. 
Consequently, women in the menopause stage are suscep-
tible to weight gain. Genistein was found to stimulate a 
metabolic rate of carbohydrates and lipids to help prevent 
weight gain. This occurs because genistein regulates ad-
ipose tissue by restricting lipogenesis and enhancing lip-
olysis in adipocytes (Szkudelska et al., 2007). Furthermore, 
phytoestrogen treatment “reduced obesity markers, such 
as total cholesterol and low-density lipoprotein (LDL) cho-
lesterol.” These are common markers that are associated 
with obesity and cardiovascular health (Jayagopal et al., 
2002).  Additionally, another study reported that after 6 to 
12 months of 54 mg/day of genistein treatment there was a 
significant reduction in triglycerides, total cholesterol, and 
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LDL-cholesterol (Squadrito et al., 2013). Conclusively, soy 
treatment can potentially improve cardiovascular health 
and prevent obesity.  
There seems to be a positive correlation between a 
soy rich diet and the inhibition of cancers, specifically 
breast cancer. SBIF can inhibit breast cancer as well. Most 
of the studies compared the association of soy-rich diet 
with reduced breast cancer in Asian women, compared to 
those in the Western world. In one case, an Asian woman 
who migrated to a Western country showed an increased 
risk for cancer. The risk of breast cancer increases with 
age, and this form of cancer has become one of the most 
common forms of cancer affecting women. As the com-
mon forms of HRT are known to increase the risk of 
developing breast cancer, natural methods are a compel-
ling substitute. Genistein, the form of isoflavone that is 
the most abundant in soy, has shown anticancer prop-
erties in preclinical trials, thereby opening the option of 
attempting clinical trials. Since this bioactive compound, 
soy, induces apoptosis in various cancer cell lines, such as 
HepG2 and Hep3B, in- vitro studies have proven the effi-
cacy of genistein as a promising chemotherapeutic agent 
against cancer. Table 3 summarizes some of the common 
menopausal symptoms and how genistein can alleviate 
the symptoms (Thangavel et al., 2019). 
In addition to the diseases mentioned above, osteo-
porosis is another disease that postmenopausal women 
are prone to. Since estrogen has bone- protecting prop-
erties, it follows that a lack of estrogen puts menopausal 
women at risk of developing osteoporosis. Soy has been 
reported to reduce the risk of osteoporosis in peri- and 
post-menopausal women. A study was done examining 
the effects of a heavy soy diet on the overall bone densi-
ty and strength of postmenopausal women. Eighty-seven 
women were eligible and were assigned to consume soy 
or control foods daily for one year. “Bone mineral density 
(BMD) and bone mineral content (BMC) of the whole 
body, lumbar (L1-L4), and total hip were measured using 
dual energy x-ray absorptiometry at baseline and after 
one year (Arjmandi et al., 2005).” Additionally, urine and 
blood markers of bone metabolism were assessed. Of 
the eighty-seven women, sixty-two completed the one-
year long study. Results showed that whole body and 
lumbar BMD and BMC decreased in both the soy and 
control groups. However, the total hip BMD and BMC 
did not change in either group. “Both treatments posi-
tively affected markers of bone formation as indicated 
by increased serum bone specific alkaline phosphatase 
(BSAP) activity, insulin-like growth factor-I (IGF-I), and 
osteocalcin (BSAP: 27.8 and 25.8%, IGF-I: 12.8 and 26.3%, 
osteocalcin: 95.2 and 103.4% for control and soy groups, 
respectively).” (Arjmandi et al., 2005) Neither group had 
any effect on urinary deoxypyridinoline excretion, which 
is a marker of bone resorption. However, according to 
epidemiological data, populations with soy rich diets, such 
as the Asians, do have a lower incidence of 
osteoporotic fractures. On the other hand, 
there are numerous factors that contribute 
to skeletal health; therefore, the credit of the 
lower rates of fractures in these populations 
cannot be fully attributed to soy consumption. 
There are a number of animal studies that did 
show how isoflavones positively influenced 
BMD. However, when it comes to human 
studies there are a limited number of studies 
that examined the effects of soy on bone. A 
study was set up in which the identity of the 
individual treatments was only revealed after 
the analysis was complete, to keep the results 
as accurate as possible. Compliance of the 
participants was measured based on whether 
participants recorded the amount of soy they 
consumed and if they returned the uneaten 
food to the study site to be tallied. This study 
did not show that soy protein alone can sub-
stantially prevent bone loss. However, another 
study did indicate that a consumption of 40 mg/day to 80 
mg/day for a year resulted in positive increases in BMC 
of the hip of the women who are at least four years post 
menopause. Additionally, these women were of low body 




done in which there was no substantial effect of soy on 
reversing bone loss, most of the participants were four 
years post-menopause; however, many did not have low 
body weight or calcium intake. Therefore, it is possible 
that the differences in these factors are what created the 
discrepancy of the observed results of the bone (Chen 
et al., 2004). As far as which form of isoflavones is the 
most beneficial when it comes to affecting the bone, ac-
cording to studies genistein is the single isoflavone with 
the greatest effect. A study demonstrated that genistein 
at a dose of 54 mg/d combined with HRT increased BMD 
in early postmenopausal women. Genistein was proven 
to increase the BMD of the femoral neck by 3.6% and 
the lumbar spine by 3.0%. HRT increased femoral neck 
and lumbar spine BMD by 2.4 and 3.8%. The researchers 
speculated that the genistein “reduces bone resorption 
markers” and “enhances new bone formation parame-
ters.” As a result, there is a bone mass net gain (Morabito 
et al., 2002). According to the circulating sex hormone 
levels that were assessed after examining the changes in 
the participants after a year, the soy did not produce any 
estrogenic effects. However, the soy did decrease SHBG 
concentrations, which increases the availability of circu-
lating estrogens. Therefore, the soy did affect estrogen 
levels, even though it may not have directly exhibited es-
trogenic qualities. However, to confirm this, it would be 
necessary to measure the endogenous estradiol that is 
circulating. While there are certainly a number of studies 
that show correlation between bone protection and soy, 
there are still too many factors that require closer exam-
ination (Arjmandi et al., 2005).
Conclusion
Many soy- related articles are published annually; howev-
er, there are still numerous questions that require further 
exploration. Questions include whether SBIF is indeed 
harmful or not, how effective of an HRT is soy when it 
comes to menopausal symptoms, whether the effect of 
isoflavones on bone is transitory, and whether soy iso-
flavones and lower doses of antiresorptive agents can 
prevent postmenopausal bone mineral loss. In the United 
States, advisory groups gave their recommendation 
regarding the safety of soy infant formula. “The North 
America Committee on American Academy of Pediatrics 
recommends soy formula only for infants with galacto-
semia or hereditary lactase deficiency and mentions that 
soy formula might be useful for families wishing to avoid 
formula containing animal products.” (Adgent et al., 2018) 
While high consumption may not be advisable for infants, 
Asian postmenopausal women with soy rich diets benefit 
from the isoflavones as shown by the studies mentioned 
above. The efficacy of soy and its isoflavones as an al-
ternative to HRT and as a natural estrogenic source for 
treatment has yet to be determined. 
Although the biological effects of soy hold potential, 
there are limitations, such as low bioavailability and low 
biological estrogenic activity. This has limited the clinical 
applications of genistein to some extent. However, the 
components of soy are promising in terms of being a nat-
ural source of preventative care.
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Autoimmune disease refers to a systemic immune response by the body against its own healthy tissue and cells . This results in 
various non-specific and systemic inflammatory processes that evolve into more than 100 individual diseases. Numerous bio-
logical similarities exist between the different pathophysiological pathways, including biochemical cascades and inflammasome 
mediators . This paper aims to investigate whether contracting one form of autoimmune disease can lead to the development of 
polyautoimmunity and multiple autoimmune syndrome. Scientists have identified chronic levels of high stress as a contributor to 
higher levels of C-reactive protein and several immune modulating interleukins, which can lead to both autoimmune and polyau-
toimmune processes (Steptoe et al ., 2007) . Immunologists and virologists have established how viruses can lead to autoreactive 
immune activity through molecular mimicry and epitope spreading. These same processes are found in all forms of inflammation 
and may explain the connection between undiagnosed adult-onset celiac disease and multiple autoimmune syndrome . Many 
genetic pathways have been identified as drivers of both individual autoimmune conditions and specific inflammasome mediators 
that could be responsible for familial based autoimmunity and specific subtypes of multiple autoimmune syndrome. Collectively, 
these studies underlie and illustrate a direct connection between several contributors that definitively link autoimmunity with 
polyautoimmunity .
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Introduction
Autoimmunity is defined as the misdirected immune re-
sponse by an organism against its own healthy tissue and 
cells. Encompassing as many as one hundred individual 
diseases, autoimmune disease affects nearly 23 million 
Americans of all ages and has been referred to by many 
as the next frontier in the battle for longevity (NIH 2012). 
Some of the more common manifestations of autoim-
munity include Crohn’s disease, colitis, systemic lupus 
erythematosus, Sjogren’s syndrome, celiac disease and 
type 1 diabetes. The specific mechanisms and causes of 
these diseases are still the subject of investigation, some 
of which will be explored in the following discussion. It is 
widely recognized that autoimmune disease is on the rise 
across nearly all age groups and social categories (Dinse 
et al., 2020). The reason for this increase is unclear, though 
many believe that environmental conditions as well as be-
havioral factors may be to blame. 
As the general rate increases, an important question 
arises. Does contracting one form of autoimmune disease 
raise the risk of developing another? Since many symp-
toms of autoimmune disease overlap with one another, 
perhaps a connection between them exists. For instance, 
Sjogren’s, Behcet’s and celiac disease all present with aph-
thous ulcers in the mucosal lining of the oral cavity. Even 
though overlapping symptoms clutter the differentials and 
make a definitive diagnosis more elusive, these common-
alities may demonstrate a connection between the vari-
ous diseases.  In addition to overlapping symptoms, many 
autoimmune diseases share specific pro-inflammatory 
cytokines such as IL-1, IL- 6, and TNF-alpha, which trigger 
the release of inflammation markers like CRP, Fibrinogen, 
and Haptoglobin (Castro, Gourley, 2010). Another study 
found that specific CD4+ T lymphocytes responsible for 
misidentifying healthy tissue as foreign were found in 3 
separate autoimmune diseases (Christophersen et al., 
2019). Using mass cytometry and RNA sequencing, the 
CD4+ T lymphocytes were first identified in celiac pa-
tients but were later linked to Systemic lupus and mul-
tiple sclerosis. While only a correlation, the findings may 
explain why some immune modalities are more suscep-
tible to make mistakes and whether contracting one dis-
ease such as celiac raises the risk of more activity.
Since there are multiple drivers of disease, the inves-
tigation into polyautoimmunity and how its diseases are 
linked will need to focus on several factors, including the 
environment, hormones, and genetic predispositions. 
Perhaps the environment and exposure to chemicals and 
pollution are interfering with a healthy immune system? 
Maybe bacterial diseases and viruses are propelling the 
immune system to turn on itself in multiple ways? Lastly, 
can specific genes be contributing to patterns that have 
been established between specific conditions such as ce-
liac and type 1 diabetes?
Methods
The research reviewed in this article was obtained using 
several online databases and search tools, including 
Pubmed, JSTOR, and Google Scholar. Information was 
also accessed through the Touro College Libraries data-
base using EBSCO and ProQuest. 
Discussion  
Mechanisms of Autoimmunity
Before exploring the polyautoimmunity connection, it is 
important to first analyze and define the autoimmune 
response itself. Over the last several decades, scientists 
have formulated several explanations to illustrate the 
specific pathways and mediators responsible for a typical 
immune reaction in the body’s tissues. Researchers isolat-
ed and identified one such pathway using cytometry and 
RNA sequencing on tissue derived from inbred C57BL 
mice. Upon initial activation, CD4+ T cells produce cy-
tokine tumor necrosis factor (TNF), which engages its 
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TNF receptor on mononuclear phagocytes (MP). This 
leads to the synthesis of pro-cytokine interleukin (IL)-1B. 
Concurrently, CD4+ cells also express membrane-bound 
Fas-Ligand (FasL), a subgroup of the tumor necrosis re-
ceptor family, which activate death receptor Fas signaling 
in nearby macrophages, leading to the induction of the 
inflammation process. This eventually results in Caspase-
8-dependent-pro-IL-1B cleavage. Caspase-8 is believed to 
regulate inflammation through the modulation of mRNA 
expression in inflammasomes (Gurung, Kanneganti, 2015). 
The researchers concluded that the inflammasome-inde-
pendent cytokine interleukin 1B was believed to be re-
sponsible for the systemic inflammation found in general 
autoimmune responses. Consequentially, when tumor 
necrosis factor receptors or Fas signaling was inhibited in 
the population, the mice were protected from cell-driven 
immunity (Jain et al., 2019). 
These cytokine interleukins (IL-1B, IL-18, IL-6) have 
been identified in further studies to be a central player 
in innate immune responses due to their interaction with 
inflammasomes. Broadly speaking, cytokine interleukins 
have been found to be present in almost every immune 
reaction. However, what makes each reaction unique and 
specific to individual tissues and organ systems is the type 
of inflammasome involved in the response (Rathinam et 
al., 2012). Inflammasomes were first discovered in 2002 as 
a prominent component of type 2 diabetes and systemic 
gout. As a type of macrophage, these inflammasomes are 
a key player in cytosolic surveillance, constantly scan-
ning the interstitial space for signs of tissue injury or 
infection. The human genome has been found to contain 
twenty-three Nod-like-receptor (NLR) nucleotide-bind-
ing and oligomerization domains (Nods), many of which 
codify and assemble into inflammasome complexes. Each 
of these different complexes interacts with and control 
for the release of cytokine interleukins in response to 
various bacterial pathogens, viruses, and even cancer 
(Rathniham et al., 2012). In a healthy individual, these spe-
cific pathways of inflammatory signaling are kept in check 
in order to respond only to the invading microorganism. 
When this process breaks down, autoimmunity develops. 
It is important to keep these unique pathways and cellu-
lar components in mind when investigating polyimmunity 
and the link between individual diseases. 
Stress and Poly-Autoimmunity
During the last several decades, significant research has 
been directed on the role that stress plays in the devel-
opment of autoimmune disease. Various forms of both 
short-and-long-term stress exacerbate already exis-
tent conditions such as rheumatoid arthritis (RA). One 
twelve-week study involving forty-one women suffering 
from RA found a significant relationship between even 
minor stress and joint pain (Zautra et al., 1997). However, 
these studies were unable to provide an association 
between chronic stress and the initial manifestation of 
diseases. Researchers focused on four common pro-in-
flammatory cytokines in patients with increased levels of 
acute stress, IL-1B, IL-6, TNF-alpha, and C reactive pro-
tein (CRP), and cortisol. One meta-analysis examined 30 
studies in order to determine the effects that stress had 
on these robust effects for higher levels of IL-1B, IL-6 
and TNF-alpha while the results for CRP were mixed 
(Steptoe et al., 2007). It is possible that these higher lev-
els of interleukin exasperated by stress leads to multi-
ple autoimmune conditions being contracted. One 2018 
study aimed to investigate the link between stress and 
developing autoimmunity. The retrospective cohort study 
followed 1,171,104 people, 106,464 of whom were diag-
nosed with a stress-related disorder. The results showed 
that the stressed patients were almost three times more 
likely (95% Cl, 9.2 per 1000) to develop some form of 
autoimmunity versus the non-stressed cohort (95% Cl, 
2.99-3.25 per 1000). In addition, patients were also more 
likely to develop multiple autoimmune conditions, espe-
cially when they did not seek any treatment for anxiety 
(Song et al., 20 Though this study did not investigate why 
stress causes autoimmune disease, the correlation clearly 
indicates that stress plays a prominent role in the de-
velopment of multiple autoimmune conditions and more 
research will be needed to establish why this occurs.
Viruses and Polyautoimmunity
There are two main hypotheses proposed to explain the 
connection between viral pathologies and autoimmuni-
ty. One coined “molecular mimicry” by Robert Fujinami 
in 2006 refers to the misrecognition of an antigen by a 
memory B-cell. The belief is that immunological mem-
ory is achieved after initial microbial and viral infection 
by a host-pathogen. Antigens from the initial infection 
stimulate humoral immunity and the production of plas-
ma cells and memory B-cells. If these antigens reappear 
during the secondary response, they will reactivate the 
plasma B-cells to proliferate and then destroy the in-
vading pathogen. If an organism’s self-antigen mimics the 
viral antigen in some way, then a secondary response is 
likely to occur against the body’s own tissues (Kim et 
al., 2007). There are three identified ways that this might 
occur. The first is when the original antigen and the 
self-antigen share identical amino acid sequences in their 
primary protein structure. A second possibility is when 
secondary and tertiary structures mimic each other, such 
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as with similarities regarding polarity, hydrogen, and di-
sulfide bonding. A third type of molecular mimicry exists 
when one antibody becomes capable of recognizing two 
or more antigens with completely different structures 
(Cunningham 2009). Researchers now believe that this 
third mechanism is the result of individual T-cells exhibit-
ing receptors for both foreign and self-antigens. When a 
foreign insult triggers the T cell, it then moves to attack 
healthy body tissue as well. This third mechanism has con-
sistently been linked to multiple autoimmune diseases or 
polyimmunity (Cusick et al., 2012). For instance, studies 
have linked Herpes simplex virus to stromal keratitis and 
type 1 diabetes, streptococcus to rheumatoid myocarditis 
and poststreptococcal autoimmune disorder, as well as 
many others (Munz et al., 2009).
Another hypothesis that explains how viruses gener-
ate autoimmune disease is that a virus induces a systemic 
and non-specific activation of the immune system that 
eventually leads to an overexcitability state and autore-
active immunopathology (Munz et al., 2009). Known as 
the “bystander activation,” this line of reasoning stems 
from the fact that, similar to stress, those already suffer-
ing from autoimmune conditions tend to fare worse with 
their symptoms whenever they are infected with a virus. 
Scientists believe that the pro-inflammatory environment 
in the body initiates a release of self-antigens from in-
fected tissue. The antigens are then mistakenly taken up 
by major histocompatibility complexes (MHC) or anti-
gen-presenting cells (APC), which then present these 
self-antigens to autoreactive T cells that have already 
migrated to the damaged tissue (Fujinami 2006). This can 
sometimes lead to a concatenation of events known as 
“epitope spreading,” where these T cells begin attacking 
other self-antigens that mimic the previous one, further 
inflaming the tissue and releasing even more self-epitopes. 
This phenomenon has been observed in multiple sclero-
sis, autoimmune encephalomyelitis and myasthenia gravis 
and has been linked to viruses such as EBV, rotavirus 
and cytomegalovirus (Smatti et al., 2019). It is important 
to note growing evidence that viruses may also play a 
protective role in preventing autoimmunity by activating 
regulatory immune responses that work to suppress in-
flammation and inhibit cytokine interleukins. In addition, 
scientists still do not know whether higher viral loads or 
compromised immune systems during the infection peri-
od, raise the risk of autoimmunity. 
This second idea regarding how bystander activation 
and molecular mimicry leads to multiple autoimmune 
syndrome (MAS) illustrates how inflammation leads to 
more inflammation. This concept may explain the essence 
of another important phenomenon. For many years, 
doctors have emphasized  the  importance of treating 
previously diagnosed autoimmune conditions and disor-
ders in order to improve a patient’s prognosis and quality 
of life. These treatments have included the use of bio-
logics, corticosteroids, dietary modifications and lifestyle 
changes. Scientists have long believed that inflammatory 
processes that are left unchecked can lead to the devel-
opment of coronary artery disease and even cancer. Now, 
researchers have discovered another important reason 
to aggressively treat these immunological processes: un-
treated autoimmunity increases the risk of developing fur-
ther autoimmune conditions. In 1999, researcher Andrea 
Ventura postulated that for individuals with celiac disease, 
the later the age of diagnosis, the greater the risk of devel-
oping a second autoimmune condition as well as cancer 
(Ventura et al., 1999). For example, those who were diag-
nosed between the ages of four and twelve had a 14% risk 
of developing another condition, while those over twenty 
years of age had a 34% risk. For each one-year increase in 
age at diagnosis, the chances for developing another dis-
ease increased by 1.1% regardless of gender or weight. In 
his study, Ventura explained that the longer the duration 
of exposure to gluten, the higher the prevalence of other 
autoimmune conditions developing. Further studies by 
other researchers revealed that 15% of untreated celiac 
patients eventually developed type 1 diabetes and that 
26% percent developed autoimmune thyroid disease such 
as Hashimoto’s thyroiditis and Graves’ disease (Lauret, 
Rodrigo, 2013). These studies were significant because 
most of these patients were asymptomatic and prior to 
that, many questioned the importance of adhering to a 
strict gluten-free diet. In a later paper published in the 
Journal of Pediatrics, Ventura advocated for the strict 
use of a gluten-free diet to reduce and even prevent the 
manifestation of secondary autoimmune activity, after he 
demonstrated that celiac patients who followed a strict 
gluten-free diet for two years were more than 50% less 
likely to develop other autoimmune conditions. (Ventura 
et al., 2000). Additionally, other studies also reported sim-
ilar findings regarding Crohn’s disease and colitis. In one 
study, patients were found to be 2.5 times more likely 
to develop a co-morbid inflammatory disease within five 
years after an initial diagnosis (Bernstien et al., 2005).
While the absolute reason for this phenomenon hasn’t 
yet been identified, many hypothesize that the prolonged 
state of inflammation, caused by high concentrations of 
glutamine and proline found in the protein fraction of 
rye, wheat, spelt and barley contribute to other diseases. 
Specifically, these residual peptides and amino acids initi-
ate a cascade of interleukins (IL-1B, IL-6 and IL-18) that 
trigger the proliferation of other inflammatory markers, 
including inflammasomes and C-reactive protein (CRP). 
Higher levels of CRP have been implicated in coronary 
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artery disease as well as rheumatoid processes. In ad-
dition, specific phenotypes of CD4+ helper T-cells that 
are activated in celiac disease are of the same subtype 
involved in some of the other conditions such as sys-
temic lupus and multiple sclerosis (Christophersen et 
al., 2019). (Though these specific T-cells comprise less 
than 2% of all the Helper T-cells in the body, they are 
disproportionately responsible for the identification of 
most self-antigen responses that take place within these 
inflammatory pathways.) This phenomenon seems to be 
related to the mechanism of molecular mimicry and dual 
T cell activation discussed earlier, which takes place in 
response to viral infections. However, in this scenario, an 
initial autoimmune condition takes the place of the virus 
and contributes to a set of circumstances where the body 
continuously mistakes healthy tissues as foreign and as 
a threat. It is clear from these studies that untreated or 
resistive autoimmune processes have a direct effect on 
the risk of further developing other forms of chronic in-
flammation which may lead to the manifestation of other 
autoimmune conditions. 
Genetics and Polyautoimmunity
Upon examination, autoimmune diseases appear to man-
ifest in clusters. Though Ventura investigated all forms 
of autoimmunity, he reported that individuals with celi-
ac were much more predisposed to developing type 1 
diabetes and thyroid disease versus ulcerative colitis or 
Addison’s disease. Rheumatoid arthritis has been linked 
to Sjogren’s syndrome, while systemic lupus erythemato-
sus has been linked to multiple sclerosis. Indeed, so specif-
ic are these clusters that investigators have now classified 
these groups into three clinical subtypes (Cojocaru et al., 
2010). Of note, each of these subtypes contain at least 
one skin condition and one connective tissue disease. 
I. Type 1 is comprised of polymyositis, thymoma, giant 
cell myocarditis and myasthenia gravis. 
II. Type 2 consists of rheumatoid arthritis, Hashimoto’s, 
scleroderma, and Sjogren’s syndrome.
III. Type 3 is the largest subgroup and includes Addison’s 
disease, type 1 diabetes, vitiligo, psoriasis, autoim-
mune hemolytic anemia, dermatitis herpetiformis, 
idiopathic thrombocytopenic purpura (ITP), Sjogren’s 
syndrome, myasthenia gravis and systemic lupus 
erythematosus.
Patients diagnosed with having more than one auto-
immune condition are said to have polyimmunity, while 
patients diagnosed with more than two are classified as 
having multiple autoimmune syndrome (MAS) type i, ii, or 
iii. These classifications are not absolute; however, they 
provide clinicians and scientists with an understanding of 
what to look out for and how to treat each patient based 
on their specific classification. Researchers have discov-
ered that families also seem to develop these illnesses as 
a group. For example, a mother may develop Addison’s 
disease while a daughter is diagnosed with lupus and a 
grandson has vitiligo (Cardenas-Roldan et al., 2013). This 
occurrence seems to confirm that in addition to the envi-
ronment, genetics play a broad and important role in the 
development of multiple autoimmune syndrome which 
will be discussed. 
Scientists employed genome-wide association study 
(GWAS), genome scans and RNA sequencing to investi-
gate common genetic etiologies that contribute to auto-
immune diseases and polyautoimmunity. They identified 
loci responsible for the human leukocyte antigen (HLA) 
region on DNA that contribute to autoimmunity.  The 
researchers also identified loci shared between the most 
common autoimmune conditions which included IL23R, 
OLIG3/TNFAIP3 and IL2RA. The study revealed that type 
1 diabetes was genetically associated with rheumatoid ar-
thritis and that Crohn’s disease was linked with ulcerative 
colitis. It also underlined how some diseases seem capa-
ble of developing without any genetic links, particularly 
systemic lupus erythematosus (SLE) and systemic sclero-
sis. This would suggest that not all forms of autoimmune 
disease are caused by genetic heritability and phenotype. 
Rather, genes play a sizable role in the broader picture of 
how autoimmunity manifests (Ramos et al., 2011). 
The Major Histocompatibility Complex (MHC) gene 
has been investigated as an important factor in autoim-
munity. Located on chromosome 6, the locus codes for 
cell surface proteins found on numerous lymphocytes 
as well as receptors found on almost every living cell in 
humans. Scientists performed a genome-wide associa-
tion study (GWAS) on the MHC gene which compares 
the allele/genotype frequency between individuals that 
have been affected by disease and those who have not. 
The study visually confirmed that the MHC locus is a 
major predicator in most autoimmune conditions (Kochi, 
2016). The most common MHC genes include HLA-A, 
HLA-B and HLA- DP/DQ/DR. Since these genes play a 
crucial role in the adaptive immune response, perhaps it 
is possible to surmise that MHC genes are involved in 
the formation of autoimmunity in general. However, this 
does not explain why one patient develops Crohn’s dis-
ease and one Hashimoto’s disease.  The development of 
a specific disease or condition can be caused by a single 
allele, yet this does not prove that a single allele can cause 
polyautoimmunity. For example, rheumatoid arthritis has 
been linked to multiple HLA-DRB1 alleles such as *01:01, 
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*04:01, *04:05 and *09:01 while Ankylosing spondylitis is 
known to be caused by the allele, HLA-B27 (Newton et 
al., 2004).
Researchers have identified a mutation in the genetic 
factor PTPN22 as an important driver of multiple auto-
immune syndromes. PTPN22 is responsible for encoding 
lymphoid-specific tyrosine phosphatase, a critical regula-
tor of T-cell receptor signaling pathways. A single nucleo-
tide missense mutation involving PTPN22 has been linked 
to rheumatoid arthritis, type-1 diabetes and systemic 
lupus erythematosus. FC receptors (FcRs) on the surface 
of immune cells recognize immune complexes comprised 
of autoantigens and autoantibodies. After the immune 
complex binds to the receptor, FcRs release Src and Syk 
family kinase which leads to antigen uptake, presentation 
and secretion of interleukins and proteins that initiate 
an immune response. Tyrosine phosphatase encoded by 
PTPN22 inhibits the release of Src and Syk kinase, there-
by regulating the FcR immune response in dendritic cells. 
In one study, patients who had a C1858T missense poly-
morphism in PTPN22, were found to have higher levels 
of Scr and Syk kinase as well as higher instances of type 
1 diabetes. In another study, bone marrow derived den-
dritic cells of wild type mice (PTPN22-/) were compared 
with dendritic cells from knockout mice with PTPN22-/-. 
The PTPN22-/- dendritic cells had higher levels of T cell 
proliferation and activity (Clarke et al., 2018).
Studies examined innate immunity to determine if 
genes responsible for the initial immune response play 
a role in autoimmune development. In innate immunity, 
macrophages and dendritic cells express toll-like recep-
tors which recognize patterns on virus antigens and then 
activate type 1 interferons responsible for immunomod-
ulatory and antiviral responses. These interferons or 
cytokines bind to receptors on white blood cells which 
activate a cascade of secondary messengers which inter-
fere with the further proliferation of the invading virus. A 
subgroup of the interferon proteins, the type 1 interferon, 
has been implicated in myositis and systemic lupus er-
ythematosus. Research demonstrated that patients with 
lupus displayed higher levels of type 1 interferons at diag-
nosis when compared with individuals without symptoms 
of disease (Padilla, Niewold, 2016). Additionally, genome 
wide association studies for systemic lupus erythematosus 
discovered multiple gene and loci sites that were directly 
linked with type 1 interferons and its associated signaling 
pathways. These included IFIH1, IRF5, IRF7, TLR7, IRAK1 
and TYK2. Other studies using GWAS identified these 
loci sites in other autoimmune conditions. For example, 
type 1 diabetes, psoriasis and Addison’s disease have been 
linked to IFIH1. Interestingly, these three diseases are all 
included in the type 3 subgroup of multiple autoimmune 
syndrome (MAS) described earlier. Similarly, the IRF5 loci 
was correlated with primary biliary cirrhosis, Crohn’s dis-
ease, colitis and rheumatoid arthritis. 
Patients with lupus who presented with the IRF5 risk 
haplotype also had higher levels of signal transducer and 
activator of transcription 4 (STAT4). STAT4 is a tran-
scription factor involved in the differentiation of T-helper 
1 (Th1) cells. Researchers believe that increased levels 
of STAT4 may increase the activity and proliferation of 
these T cells leading to autoimmunity (Kochi Yuta, 2016). 
STAT4 is activated by type 1 interferons and is respon-
sible for the synthesis of IFN-y, another interferon type. 
This discovery highlights how one gene factor can drive 
multiple different components that lead to disease. IRF5 
produces excess interferons that may exacerbate an au-
toimmune response in the innate immune system, while 
simultaneously activating STAT4 which is involved in 
adaptive immunity. Also noted in the literature, was that 
lupus patients who presented with the PTPN22 muta-
tion discussed had reduced levels of TLR7 induced type 
1 interferons, possibly indicating heterogeneity of disease 
expression (Wang et al., 2015). These studies clearly in-
dicate that genetics play a role in both innate as well as 
adaptive immunity and that there are several overlapping 
genetic variances that contribute to the manifestation of 
multiple autoimmune conditions. 
Studies performed using genome-wide association 
studies (GWAS) identified and linked individual genes with 
specific autoimmune conditions. Researchers investigated 
whether one gene can be responsible for general autoim-
munity encompassing a broad number of non-specific au-
toimmune conditions. One study focused on the ITGAM 
gene, a genetic region responsible for the alpha-chain 
subunits found in a cell surface receptor of neutrophils 
and monocytes named Integrin-aMB2. A variant at exon 
3 (rs1143679) within the ITGAM gene was thought to 
up-regulate the binding capacity of Integrin-amB2 which 
would increase the susceptibility to multiple autoimmune 
syndromes. However, SNP genotyping, statistical and me-
ta-analysis of the gene region confirmed that there was 
no significant association between systemic sclerosis, 
scleroderma, rheumatoid arthritis and the ITGAM gene. 
Only systemic lupus erythematosus was found to be 
directly correlated with the re1143679 mutation found 
in the population (Anaya et al., 2011). Still, researchers 
have identified a general autoimmune contributor using 
GWAS. As previously discussed, pro-inflammatory cy-
tokines play a major role in the development of auto-
immune conditions. Researchers studying the origins of 
celiac disease discovered an association between celiac 
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disease and the receptor for Interleukin-23 (IL-23). Two 
subunits (p40 and p19) within IL-23 are found within the 
IL-12 and IL-1B receptors as well. (IL-12 receptors are 
composed of p40 and p35 heterodimers while IL-1B con-
tains p19 dimers.) Additionally, the p19 (IL23R) subunit 
on IL-23 is located just 3’downstream to the p40 subunit 
(12RB1) on IL-12. This highlights just one of the many 
connections between cytokinetic interleukins and auto-
immune disease. Indeed, the IL-23 receptor has also been 
linked to psoriasis, rheumatoid arthritis, Crohn’s disease 
and multiple sclerosis (Tang et al., 2012). Other diseases 
have been linked to specific interleukins as well. IL-2 and 
IL-2R were found to have a direct connection with pso-
riasis, Gaucher disease, rheumatoid arthritis and type 1 
diabetes while IL-21 was linked with multiple sclerosis 
as well as inflammatory bowel disease. The studies did 
not investigate or confirm whether contracting one of 
the autoimmune conditions raised the risk of developing 
another. However, it seems plausible that if genetic and 
environmental conditions caused one disease, they could 
lead to a second one. 
Researchers at the Benaroya Research institute at-
tempted to map the many genetic connections between 
each autoimmune disease in order to determine how 
one may lead to the other. They began by investigating 
why patients with Down syndrome are 15-100 times 
more likely to develop some form of autoimmunity, many 
of whom develop polyautoimmunity as well. Additionally, 
these disorders are varied, affecting both endocrine and 
non-endocrine systems. Diseases commonly seen include 
thyroid disease, type 1 diabetes, scleroderma, Sjogren’s 
syndrome, systemic lupus erythematosus, autoimmune 
hemolytic anemia and celiac disease. A biorepository of 
blood and tissue samples was established using tissue 
extracted from the Down syndrome population as well 
as from their healthy siblings. Since Down syndrome is 
caused by trisomy 21 (HSA21) and is genetic in nature, 
researchers focused on the genetic drivers in these pa-
tient’s immune responses and composition. They also in-
vestigated whether one gene could be the driving force 
behind all these illnesses. The data identified a gene called 
dual-specificity tyrosine-(Y)-phosphorylation-regulated 
kinase 1A (DYRK1A) as a possible driver of autoimmuni-
ty. Previously, this gene was linked to the cognitive decline 
and neuro-developmental conditions found in most pa-
tients with Down syndrome (Feki, Hibaoui, 2018). Patients 
with Down syndrome express an excessive amount of 
DYRK1A as a result of the extra chromosome HSA21, 
leading to a buildup of proteins that lead to memory 
deficit and motor abnormalities. Scientists hypothesized 
that DYRK1A produces excess proteins that prevent the 
body from shutting off unnecessary inflammatory im-
mune responses leading to autoimmune disease. 
In a separate study, researchers worked to identify sub-
stances that could increase the number of Treg cells, white 
blood cells that suppress other immune cells, in order 
to prevent autoimmunity. The scientists believed that by 
increasing Treg cells while maintaining or even inhibiting T 
helper cells, a novel therapeutic approach to autoimmu-
nity could be found. Using Similarity Ensemble Approach 
(SEA) and chemoinformatic methods involving 3,100 sub-
stances, the team isolated a chemical called B-carboline 
alkaloid harmine and discovered its ability to reduce 
autoimmune activity in induced inflammatory reactions 
in vitro. Further studies demonstrated that harmine acts 
in part by inhibiting DRYK1A which led to differentia-
tion of Treg cells. More importantly, when DRYK1 was 
inhibited, T1 helper cell and T17 helper cell differentiation 
remained constant or was reduced. The team then tested 
harmine’s impact on Treg and T helper cells in vivo, using 
three separate subtypes of inflammation; type 1 diabetes, 
colitis and asthma. The three inflammatory diseases were 
chosen for their T cell properties, diverse genetic back-
grounds and distinct tissue types. When Foxp3 mice were 
induced with type 1 diabetes, the mice developed diabe-
tes approximately 10 days after injection. When the mice 
were induced under TregHarmine conditions, onset was 
delayed by a minimum of seven days. Next, when mice 
with ulcerative colitis were injected with TregHarmine, 
mucosal inflammation in the intestines was significantly 
reduced. Finally, researchers induced Foxp3 mice with 
airway inflammation using intratracheally administered 
ovalbumin. When these mice were treated with Harmine, 
a significant suppression of inflammation was noted (Kohr 
et al. 2015). These findings benefit the hypothesis that 
the overexpression of DYRK1A in patients with Down 
Figure 1 illustrates the various linkages between differentially 
expressed genes and five common autoimmune conditions.
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syndrome may contribute directly to the development 
of autoimmune disease by increasing differentiation of T1 
helper cells, while simultaneously preventing the expres-
sion of anti-inflammatory Treg cells. This might explain the 
broad spectrum of disorders seen in Down syndrome 
since helper T cells and Treg cells are involved in almost 
all autoimmune disorders. Additionally, as a DYRK1A in-
hibitor, B-carboline alkaloid harmine should be further in-
vestigated as a therapeutic for Down syndrome patients 
with autoimmune conditions. Another potentially im-
portant question is whether inhibiting DYRK1A can also 
decrease some of the neurological symptoms seen with 
Down syndrome cases, since DYRK1A has also been as-
sociated with the mental retardation and cognitive delay 
that is prevalent in these cases. 
GWAS was able to identify and establish a substan-
tial link between genetics and autoimmune disease. In 
addition, many of these genes have also been linked to 
multiple autoimmune syndromes and illnesses. However, 
just because an individual is genetically predisposed does 
not guarantee the development of one or several auto-
immune conditions. Epigenetically, these genes can be reg-
ulated due to several mechanisms and several epigenetic 
processes have been linked to autoimmune disease. These 
include DNA methylation, post-translational histone pro-
tein modifications, chromatin remodeling and RNA regu-
lation of gene expression. DNA methylation involves the 
addition of a methyl group to carbon 5 on the cytosine 
molecule of cytosine phosphate-guanosine resulting in 
5-methylcytosine. The methyl groups occupy the major 
groove of DNA, thereby silencing the gene by blocking 
proteins and transcription factors from forming transcrip-
tion complexes on the DNA helix. DNA demethylation 
can also occur through the enzyme-catalyzed removal of 
cytosine methyl groups. Researchers studying systemic 
lupus erythematosus were able to identify specific epi-
genetic processes by focusing on the development of 
peripheral blood mononuclear immune cells of patients 
affected with lupus and then comparing them to their 
identical monozygotic twin siblings. The results identified 
approximately 50 instances of DNA hypomethylation in 
the gene regions of the lupus patients. Absolute cause for 
the hypomethylation was not identified, although possi-
bilities that were mentioned include UV exposure, age, 
viruses and environmental stress (Surace and Hedrich, 
2019). More research is needed to investigate DNA 
methylation in other autoimmune conditions as well as 
other immune cell types. 
Histone modifications occur via covalent posttransla-
tional alterations of amino acids at the N-terminal end 
of histone proteins. These changes include adding or 
removing a phosphate, acetyl and methyl group that trans-
forms the chromatin structure, making the DNA unavail-
able for transcription. A similar concept called chromatin 
remodeling occurs when ATP-powered protein complex-
es attached to chromatin, alter, remove or transfer the 
nucleosome to another part of a chromosome. Scientists 
explored the genetic links of Cryopyrin-associated peri-
odic syndrome (CAPS), a rare autoimmune disease that 
consists of three phenotypic processes: Muckle-Wells 
syndrome, neonatal-onset multisystem inflammatory 
disease and familial cold autoinflammatory syndrome. 
The results of one study revealed a down-regulation of 
numerous genes which included the histone proteins 
SUMO1 and HIST2H2AC as well as histone deacetylase 
enzymes HDAC1/2 (Surace and Hedrich, 2019). However, 
a second study involving CAPS demonstrated excessive 
levels of DNA demethylation which results in an epigen-
etic up-regulation of genes as the driver of the inflamma-
tory process (Tormo et al., 2017). These studies illustrate 
the immense complexity of histone modifications and 
epigenetics in general. Though the two studies appear to 
contradict each other, it is highly plausible that epigenetic 
events not only vary considerably between diseases but 
even between individuals as well. Still, these studies were 
limited in scope and design and more research is needed 
to fully understand the epigenetic connection to CAPS 
and how different events drive the genetic expression of 
inflammatory processes. 
RNA regulation involves the repression of gene expres-
sion through long and short noncoding RNAs (ncRNA). 
Long ncRNA’s are silent and lack an extended open 
reading frame required for translation. Short ncRNA’s 
include micro-RNAs (miRNAs), short interfering RNAs 
(siRNAs) and piwi-interacting RNAs (piRNAs). Micro-
RNAs are transcribed as precursor molecules 80-100 
bases long and after hydrolytic cleavage are processed to 
contain 20-23 bases. The shortened span allows them to 
interfere with DNA methyltransferase thereby inhibiting 
DNA methylation. During the CAPS studies mentioned 
earlier, researchers were able to identify a direct asso-
ciation between miRNA and upregulation of the STAT4 
gene responsible for CD4+ T helper 1 cell proliferation. 
In addition, STAT3 and STAT1 were also upregulated, re-
sulting in increased cytokinetic activity, specifically IL-6 
and IL-17A (Surace and Hedrich, 2019). Since epigenetics 
contain many factors, it is difficult to determine the exact 
role it plays in polyautoimmune disease. However, epigen-
etic processes have been identified in some of the uni-
versal genes described earlier. For example, the ITGAM 
gene that contributes to multiple autoimmune diseases 
contains approximately 40 sites of DNA methylation and 
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histone modifications. Though scientists are unsure of 
the specific effects and links for these sites, many roles 
and possibilities exist. As science continues to explore 
the complex concept of gene expression and epigene-
tic factors, researchers will surely uncover many other 
associations between multiple autoimmune diseases and 
epigenetics. 
Conclusion
Research has identified several risk factors for developing 
polyautoimmunity. It is clear from the data that the pres-
ence of one autoimmune disease raises the risk for devel-
oping further illnesses. Chronic and acute forms of stress 
facilitate autoimmune processes by raising inflammatory 
markers in the bloodstream. Though viruses and bacteria 
typically prime the adaptive immune system for future 
responses, molecular mimicry, bystander activation and 
epitope spreading can direct a vulnerable immune system 
to turn on itself. Furthermore, untreated and protracted 
forms of inflammation might lead to autoimmune disease 
through bystander activation or similar forms of immune 
dysfunction. Genetic processes involving interleukins 
and inflammasome signaling, regulate the many compo-
nents responsible for managing a healthy immune system. 
Mutations and hereditary factors involving these genes 
can directly contribute to multiple autoimmune diseases. 
Lastly, epigenetic elements driven by DNA methylation 
and hypomethylation of cytosine bases as well histone 
modification and RNA regulation can lead to the develop-
ment of multiple autoimmune diseases, though the exact 
connection is not yet fully understood. The data does 
not establish absolute causation of any one contributing 
factor for developing polyautoimmunity; however, each 
additional variable enhances the risk over time. Patients 
who are genetically predisposed to autoimmune disease 
and are chronically stressed or have contracted multiple 
viruses in their lifetime,  have a significant risk of develop-
ing an autoimmune disease. If inflammation levels of the 
initial disease are not managed, patients face an increased 
risk of developing another condition. It is important for 
physicians and healthcare professionals to be aware of 
their patient’s genetic profile, susceptibility and history to 
determine the probability of further autoimmune devel-
opment. Communication among the healthcare team is 
essential since patients may have multiple doctors treat-
ing several conditions, each without knowledge of the 
patient’s complete history. Finally, through more research 
into the causes and associations of polyautoimmunity and 
multiple autoimmune syndrome, doctors will be able to 
better diagnose, treat and eventually prevent this abstruse 
and perplexing condition. 
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Abstract
Infantile colic (IC) is an important area of current research due to the extreme distress it causes parents and their infants . It is vital 
that a cause is isolated so that treatment can be found because IC is a risk factor for child abuse . In this paper, two major theories 
were posed to elucidate the underlying cause of IC—the gastrointestinal model and the neurological model . The gastrointestinal 
model suggests that IC stems from issues such as an immature gut . The neurological model suggests that infantile migraines are 
the causative agents of IC . Both theories supply correlational evidence but are subject to scrutiny because they are incomplete . A 
third theory, the fourth trimester theory, is suggested to fill in the gaps found in the two major models. Due to the novelty of this 
area of research, additional studies, such as genetics studies are suggested for future IC research .
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Introduction
Infantile colic (IC) is defined as recurrent periods of 
crying, fussing, or irritability, for a minimum of three 
hours per day, three days per week, for at least three 
weeks per month. This syndrome is unique to infants 
between approximately three weeks to three months 
of age. The symptoms persist even though the infants 
are well-fed and do not present with any other signs 
of illness (Levinsky, et al 2020). IC leaves parents feeling 
helpless and pediatricians lack success in treatment of 
the phenomenon. 
Although there is insufficient supporting evidence, IC 
has long been assumed to have a gastrointestinal (GI) eti-
ology. Attempts to treat IC have included GI drugs treat-
ments such as simethicone, probiotics, dicyclomine hy-
drochloride, and proton pump inhibitors. In drug studies, 
it was determined that treatments did not cause better 
outcomes than placebo. Other treatments have includ-
ed diet modification. Diet modification treatments have 
not been successful, and pediatricians do not believe that 
there is sufficient evidence to recommend this to parents 
(Gelfand…, et al 2016). 
More recently, it has been hypothesized that the under-
lying problem in IC is neurologically based. Amy Gelfand, a 
pediatric resident, noticed that many infants in the NICU 
who presented with IC had mothers who suffered from 
migraines. This theory suggests that IC is a premature 
form of a migraine. Studies conducted have confirmed 
that the symptoms, such as cyclic vomiting, are consistent 
with those of an adult migraine. 
If IC is indeed neurologically based, treatment with ac-
etaminophen—which is known to be a safe treatment of 
other infantile illnesses—would be a potentially effective 
treatment. Acetaminophen is used in children as young 
as 4 years of age for migraine disorder treatment (with 
and without aura).  Studies recommend against treatment 
with triptans, a class of medications commonly used to 
treat migraines, as there is no known evidence of its safe-
ty for infantile use (Gelfand…, et al 2016). 
The aim of this meta-analysis is to review the existing 
literature to determine if there is a basis for IC being 
caused by neurological phenomenon. 
Methods
To gather evidence-based research for this meta-analysis, 
scholarly search engines, such as EBSCO and ProQuest 
were used to sort and gather all relevant research and 
publications available on infantile colic. Google Scholar 
was utilized as well.
Discussion 
The Gastrointestinal Basis of Infantile Colic
Gastrointestinal distress has long been considered the 
cause of infantile colic. Physicians have postulated that 
gas, an immature gut, and an unbalanced gastrointestinal 
microbiome serve as the culprit. IC typically subsides 
after three months of life and is benign in nature (Qubty 
et al…, 2016). Supporters of a gastrointestinal etiology 
suggest that since it is well known that newborns suffer 
from a sensitive and underdeveloped digestive system, it 
is the likely cause of IC. Problems, such as swallowing air 
during feedings can cause painful gas in newborns which 
can lead to the uncontrollable crying spells. In addition, 
reflux, a condition in which stomach acid or bile ascends 
from a baby’s stomach, is often cited as a possible cause.
A study which fed the fecal matter of babies suffering 
from IC to mice led to the presentation of visceral hyper-
algesia in the mice. Visceral hyperalgesia is a condition in 
which the nociceptors of the internal organs’, specifically 
the intestines, are activated and amplified (Qubty et al…, 
2016). The study suggests that perhaps infants suffering 
with IC experience pain related to digestive processes. This 
is credible because visceral hyperalgesia is present in other 
GI disorders, including irritable bowel syndrome (IBS). 
The bowels of infants’ lack a diverse microbiome. 
Specifically, species of bifidobacteria and lactobacilli, which 
act as anti-inflammatory agents in the gut, are missing. On 
the other hand, species such as proteobacteria, which pro-
duce gas and inflammation are present in higher numbers 
than adults. Therefore, scientists can infer that infants have 
a higher propensity of GI inflammatory syndromes that do 
adults. Based on this evidence, it would be reasonable to 
infer that IC can have a gastrointestinal basis.
The GI basis of IC falls short in a few areas. Firstly, 
while babies suffering from reflux should exhibit crying 
as a symptom, it is unlikely that crying should be the only 
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manifestation of the dysfunction. Therefore, reflux as an 
isolated cause is unlikely. Secondly, if IC is a disorder of 
the digestive tract, it would be reasonable to assume 
that breastfed and formula fed babies would be affect-
ed differently. However, this is not the case. Both types 
of feeding options have similar rates of IC. Additionally, 
altering maternal diet in breastfed babies does not pose 
significant improvement in crying spells (Qubty et al…, 
2016). Changes to partially hydrolyzed formula for for-
mula fed babies, a transition known to help reflux, does 
not relieve IC either. This further indicates that diet and 
reflux are perhaps not the causative agents. Lastly, drugs 
that reduce GI distress, such as probiotics, simethicone (a 
drug that reduces surface tension and breaks down gas 
bubbles), dicyclomine hydrochloride (an anti-spasmodic 
agent), and proton pump inhibitors (PPI) which aim to 
reduce the crying spells, do not reduce the symptoms of 
IC. This poses the obvious question—if IC is caused by a 
gastrointestinal cause alone, then why do drugs known to 
help with those issues not help?
The Neurological Basis of Infantile Colic
Alternatively, physicians have wondered if perhaps there 
is something else entirely that is causing the distress. 
Based on Dr. Gelfand’s observations of the relationship of 
maternal migraines and IC, a longitudinal study was initi-
ated and replicated by other researchers and physicians, 
to unveil the potential relationship between migraine dis-
order and IC.
Efforts to reduce the symptoms of IC using meth-
ods such as shaking and shushing babies in brightly lit 
rooms have only exacerbated symptoms. Using the mi-
graine-based approach this would make sense, as meth-
ods such as shushing and shaking would only worsen the 
headache. However, treating the colic in a way that mi-
graine sufferers prefer, such as being placed in a cool, dark 
room and being put to sleep, have reduced IC significantly 
(Gelfand…, et al 2016).
A study was published in 2015 that related IC with mi-
graines. In this study, 1267 infants were assessed for IC 
and 13% were IC candidates. Of the infants participating, 
787 of the infants were followed to the age of 18 years 
and reassessed for migraine disorder. Of the infants stud-
ied, 16% had developed a diagnosable migraine disorder, 
and 22% of those had a history of IC. Interestingly, IC 
was the only statistically significant predictor of migraine 
disorder in these adults. Moreover, migraine sufferers 
only developed migraine without aura (aura is described 
as visual sensations, such as flashing light, that precede 
neurological events.) There was no statistical correlation 
between IC and migraine with aura (Sillanpaa, 2015). This 
is important because migraine with aura and migraine 
without aura are correlated with different genetic muta-
tions. Therefore, perhaps there are migraine genetics that 
are significant in IC. This would be an excellent hypothesis 
to study in future research of IC.
An earlier cross-sectional survey was done in 2012. 
This survey followed 154 mother-infant pairs of which 
14% of the infants were determined to have IC. To allow 
for more accuracy in the self-reporting process, the in-
fants were re-screened at two months when IC is at its 
worse. Maternal migraine disorder conferred a 2.6-fold 
likelihood of having a baby with IC (Gelfand et al…, 2012).
Another study conducted in 2013 compared 208 chil-
dren with migraine disorder to 471 controls. The study 
found that 72.6% of children with migraine had a history 
of IC compared to the 26.5% likelihood of IC history of 
the control group (Romanello et al…, 2013).
In a study conducted, children ages 6-18 who were ad-
mitted for migraine disorders were screened for a histo-
ry of IC. The positive correlation was significant (p=.001). 
Such a correlation was not found for other types of 
tension-type headaches (p=.10) (J, G. M…, et al 2013). 
This is important because it isolates migraine headaches 
as the only type of headache related to IC. As mentioned 
previously, there is plenty of genetic research available for 
migraine disorders which can provide more insight on 
potential genetic mutations related to IC.
Furthermore, there is reason to believe that IC is 
maternally inherited. A survey conducted in 2019 asked 
parents if their infant has cried for at least three hours a 
day for a minimum of three weeks. A follow up question 
asked if the parent had a known migraine disorder. Of the 
respondents, 827 mothers responded yes to the initial 
question. Of those respondents, 33.5% had a migraine 
problem. Of these mothers, a frequency of 15 or more 
migraines a month corresponded to a higher likelihood 
of IC. In the same study, 592 fathers responded yes to the 
initial question. However, paternal history of migraine dis-
order was not correlated to higher probability of IC. This 
was especially true if the infant was a female, suggesting 
that being female was protective (Gelfand…, et al 2019). 
This information strongly suggests that the relation be-
tween IC and migraine disorder is potentially maternally 
inherited. This study is important because while it is com-
monly known that migraines are genetically inherited, it 
was not known that it is specifically inherited maternally.
A recent cross-sectional historical study looked to 
compare pediatric headache types to a history of IC. The 
study included 219 patients between the ages of 3-18 
years. Prevalence of a positive history of IC was compared 
for children with migraine and other types of primary 
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headaches. The results showed an association of IC to 
pediatric migraine but not to other types of pediatric 
headaches. The study included 132 females and 87 males. 
The mean age was 12.8 ± 3.48 years. Migraine headaches 
were diagnosed for 170 patients (77.6%). Other types of 
primary headaches were diagnosed in 49 of the patients 
(22.3%). There were 51 patients with a history of IC. Of 
these patients, 45 were in the migraine group. The statisti-
cal significance in the rate of colic for the migraine group 
was extraordinarily strong (p=.0196), building on the hy-
pothesis that migraines and IC are related (Levinsky et 
al…,2020).
In a study conducted in 2013, IC was determined based 
on parental responses and physician diagnosis. The study 
included 208 children—66 with aura, 120 with tension 
headache—and compared them to 471 controls. The 
prevalence of IC was 72% in children with migraine—70% 
with aura and 74% without aura. The results showed a 
33% prevalence of IC for those with tension type head-
aches, and 27% for the controls. Interestingly, a pulsating 
quality of headache pain was significantly more common 
for those with colic than those without. This study con-
firmed the association on between childhood migraine 
headache and IC (F, B. S et al…, 2013).
A meta-analysis conducted in 2019 included seven large 
studies looking at the relationship between IC and mi-
graine headaches. The study found an increased incidence 
of infantile colic history for migraine groups (p=.05) than 
for those with tension type headaches (p=.51) (Zhang et 
al…,2019).
Conclusion
The causative agent of IC is yet to be fully elucidated. 
However, there is promise in the neurologically based 
theory of IC. The main critique of the studies on the neu-
rological basis of IC is that many of them include too few 
patients. Additionally, many of the results are based on 
surveys which are subject to inaccuracy due to self-re-
porting. Lastly, the neurological basis of IC fails to include 
tangible and measurable elements that the gastrointes-
tinal basis of infantile colic addresses, such as bacterial 
imbalance in the gut. 
The gastrointestinal basis of IC has many components 
which make it a reasonable causative agent of IC, but it 
is similarly incomplete. Many of the studies are based on 
trials preformed on mice. The results of such trials can-
not be simply assumed to be identical in human infants. 
Additionally, the fact that drugs aimed to reduce gastroin-
testinal distress are ineffective poses a suspicion regarding 
its accuracy. This can be because gastrointestinal distress 
is not the only cause of IC.
Many physicians suggest that perhaps it is a combina-
tion if the two theories. There may even be more causes 
that we are currently unaware of. More research on the 
topic of IC is warranted to make definitive statements. 
However, based on the studies cited it can be said with 
certainty that there is a correlation relationship between 
IC and migraine disorder.
Another theory has been posed by a group of pedi-
atricians consulted on this meta-analysis. This theory 
suggests that the “4th  trimester”, or the first 3 months 
of life, is a sensitive time for the newborn. The infant is 
familiar only with the quiet, warmth, and darkness of the 
amnion. These conditions are comfortable for the baby. 
The harsh transition from womb to the bright and often 
noisy external world is the suggested causative agent of 
IC. Perhaps the reason that colic subsides while swaddled 
in a quiet and dark room is due to the infants’ comfort 
and recognition of a familiar and safe space. This theory 
perhaps serves as the missing part to the gaps found in 
the gastrointestinal and neurological basis if infantile colic. 
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The immunological paradox of nurturing a fetus with paternal antigens poses some perplexing questions . Peter Medawar, an 
immunologist, asked at a lecture, “How does the pregnant mother contrive to nourish within itself, for many weeks or months, a 
fetus that is an antigenically foreign body?”  Researchers have since then struggled to answer this question . The research on this 
topic has led to a few general hypotheses that try to explain this phenomenon . The downregulation of T cells toward paternal 
alloantigens is an accepted hypothesis. Another hypothesis discusses the significance of the decidua and its ability to impair den-
dritic cells, which are potent antigen presenting cells and critical in initiating an immune response (Ehrlbacher, 2010) . Mechanical 
barrier and cytokine-shift hypotheses also attempt to explain the “riddle of the fetal allograft .” Research is ongoing as there is 
no one clear answer to this query. Some of these hypotheses have flaws in them while others don’t explain enough in regard 
to the safety of a woman and her fetus. There is one hypothesis that appears to hold the greatest significance in understanding 
the maternofetal relationship and the successful births of millions of children each year: local active suppression in the decidua .
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Introduction
Most living organisms have some form of an immune 
system that protects it  from foreign entities. Humans 
have a complex immune system that protects us on a 
daily basis. The notion that an antigenic foreign entity can 
exist within a human for many months and develop is 
astonishing. However, this occurs daily with millions of 
pregnant women across the globe. More than fifty years 
ago, Peter B. Medawar raised the question of how a semi-
foreign transplant with paternal antigens can survive the 
immune system. Seventy years later, a few hypotheses and 
the resultant research is available for analysis. This paper 
will explore and evaluate these hypotheses.
Methods
Information discussed in this paper was compiled from 
various published articles, taken from Touro’s database, in-
cluding Proquest Science, EBSCO, and PubMed, or Google 
searches.  This paper compares and contrasts the  various 
hypotheses explaining the immunological paradox of a 
pregnancy and evaluating which are the most siignificant. 
Discussion 
The Immune System
The main purpose of the immune system is to identify 
non-self from self and defend the body against non-self 
proteins, viruses, bacteria, fungi, parasites, tumors and 
other pathogens. Substances that the body doesn’t rec-
ognize as its own can activate the immune system. These 
are called antigens. Proteins on the surfaces of bacteria, 
fungi and viruses are examples of antigens. When these 
antigens attach to special receptors on the immune cells 
(immune system cells), a whole series of processes are 
triggered in the body. Once the body has come into con-
tact with a disease-causing germ for the first time, it usu-
ally stores information about the germ and how to fight 
it. Then, if it comes into contact with the germ again, it 
recognizes the germ and can initiate a quicker attack. The 
body’s own cells have proteins on their surface as well: 
self proteins. Sometimes the immune system mistakenly 
thinks that the body’s own cells are foreign cells. It then 
attacks healthy, harmless cells in the body. This is known 
as an autoimmune response (IQWIG 2020).
As soon as the body recognizes a “non-self” entity the 
immune system will set out to remove the pathogen from 
the body. The immune system consists of many parts that 
work together to defend the body against invaders. Two 
separate, but interacting defensive systems that provide 
an array of defensive weapons are innate and adaptive im-
munity. An innate response, neutralizes invading pathogens 
before they can harm the body. For example, in a wound, 
white blood cells known as macrophages engulf invading 
microorganisms as well as release cytokines, signaling 
proteins, to activate other parts of the immune system. 
Natural killer cells are an example of immune cells that 
destroy any pathogen in its path with no need for prior ex-
posure to the invader (Mor, 2007). Adaptive immunity is a 
more specific response toward a pathogen and is acquired. 
Activated T and B lymphocytes are specialized white blood 
cells that are involved in dealing with specific antigens. 
Antigens (Ag), molecules on foreign organisms that con-
tain distinct epitopes or sites that can initiate an immune 
response, activate B cells and T cells that “remember” the 
specific antigens thereby reacting quicker and more vigor-
ously toward the pathogen (Sela, 1998). 
The Initial Stages of Pregnancy 
After an egg is fertilized it forms a blastocyst that is im-
planted in the uterus. The sphere consists of an inner cell 
mass, which becomes the fetus after 8 weeks of concep-
tion, and an outer layer that forms the trophoblasts (Mor, 
2007). Trophoblasts aid in implantation within the uterus. 
Syncytiotrophoblasts are multinucleated trophoblasts 
that form finger-like projections reaching into the moth-
er’s bloodstream thereby forming the placenta and aiding 
in nutrient and gas exchange. With this, understanding 
the conceptual framework of reproductive immunology 
is redefined. The trophoblast cells are the only part of 
the differentiating blastocyst that interacts directly with 
the mother’s immune system. The embryo itself—and 
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the fetus to which the embryo gives rise—has no direct 
contact with maternal immune cells.  As a result, the  real 
puzzle is  not  why the mother’s immune system toler-
ates the fetus, but why it tolerates the trophoblast cells 
(Colbern, Main, 1991).
Proposed Hypotheses 
Downregulation of T cells
One study attempted to prove the hypothesis of down-
regulation of T cells. They discovered that macrophages, 
an important immune cell involved in antigen presenta-
tion, can disable killer T-cells. This, in turn, will prevent the 
T cells from attacking any object that is recognized as 
non-self (Anonymous, 1999). In order for this to occur, 
the syncytiotrophoblasts in the placenta produce an en-
zyme known as indoleamine 2,3-dioxy-genase (IDO). The 
function of IDO is to inactivate tryptophan, an amino acid 
required by T cells to destroy a foreign object (Munn, 
1999). In 1990, Andrew Mellor, a colleague of Munn, con-
cluded that IDO inhibits a mother’s T cell response to-
wards a genetically different fetus. Miscarriages occurred 
in the absence of IDO. (Munn et. al., 1998). 
In another study he and his colleagues conducted exper-
iments to prove their hypothesis. They used two groups 
of pregnant mice; one group had been bred to genetical-
ly identical fathers of the same strain while the second 
group was bred to fathers from a genetically different 
strain (Munn, 1998). The experimenters then embed-
ded time release-capsules consisting of either 1-methyl 
tryptophan, which is an IDO inhibitor, or a control sub-
stance underneath the skin of the pregnant mice. Results 
showed that only the mice carrying genetically different 
fetuses that had been given the inhibitor rejected their fe-
tuses (Munn, 1998). Interestingly, the embryos developed 
normally until inflammatory cells migrated to the implan-
tation site and caused hemorrhaging around the embryo. 
Munn proposed “the mother is rejecting the placenta and 
eventually the embryo chokes off and dies” (Munn, 1994). 
From the data collected, they concluded that after im-
plantation, an embryo starts making connections with the 
mother’s blood supply. Sequentially, syncytiotrophoblasts 
will start producing IDO, destroying tryptophan and sup-
pressing the maternal immune system (Munn, 1998).
To support the above hypothesis, researchers showed 
that the antigen receptors of maternal T lymphocytes that 
recognize paternal alloantigens are specifically downreg-
ulated during pregnancy, reducing their ability to initiate 
an immune response against the fetus (Simpson, 1996). 
During pregnancy, a semi-allogeneic fetus survives despite 
the presence of maternal T cells specific for paternally in-
herited histocompatibility antigens. A mouse transgenic for 
a T cell receptor recognizing the major histocompatibility 
(MHC) antigen H-2Kb was used to follow the fate of T 
cells reactive to paternal alloantigens. In contrast to synge-
neic and third-party allogeneic pregnancies, mice bearing a 
Kb-positive embryo had reduced numbers of Kb-reactive 
T cells and accepted Kb-positive tumor grafts (Tafuri et. 
al., 1995). T cell responsiveness was restored after delivery. 
Thus, during pregnancy maternal T cells acquire a transito-
ry state of tolerance specific for paternal alloantigens. 
However, other researchers have reservations about this 
hypothesis. In “Pregnancy Reconceived”, Mor argues that if 
the maternal immune system is suppressed, exposure to 
any pathogen would be fatal (Mor, 2007). With evidence 
of Kb-positive tumor grafts growing in mice (because of 
its commonality with paternal alloantigens and the risk of 
a pathogen) it would be nearly impossible for a mother 
and its fetus to survive. Research showed that presence 
of immune cells at the implantation site is not associated 
with a response to the ‘foreign’ fetus but to facilitate and 
protect the pregnancy. Therefore, the immune system at 
the implantation site is not suppressed, on the contrary it 
is active, functional and is carefully controlled (Mor, 2010).
Mechanical Barrier
Another hypothesis explains that the fetal tissue is un-
recognizable as “nonself” by the mother’s immune cells due 
to a mechanical barrier (Mor, 2007). Syncytiotrophoblasts 
around the fetus contribute to the mechanical barrier be-
tween the uterus of a pregnant mother and the rest of her 
body. This trophoblast-immune interaction includes three 
stages. Stage one is attraction, the trophoblast cells secrete 
chemoattractants that will signal immune cells to migrate 
to the implantation site. The area of the uterus in which 
the trophoblasts invade is referred to as the implantation 
site. Stage two, recruitment and/or education, the tropho-
blasts produce cytokines that regulate the differentiation 
of immune cells. Upon completion of these two steps, the 
response can take place. In this final stage, the immune cells 
from stage two respond to different signals (Swain, 2013). 
After completion of all three stages, the mechanical barrier 
is formed. This in turn prevents the movement of activated 
T cells from the periphery to the implantation site and en-
ables antigens that are inside the barrier to be undetected 
by the mother’s immune system. 
In conflict with this hypothesis, researchers have found 
that the barrier between fetal and maternal is limited at 
best- fetal cells can be found in the maternal circulation 
and vice versa, indicating that there is only a partial phys-
ical separation between mother and fetus. Furthermore, 
although placental trophoblasts have reduced antigenici-
ty and attenuated expression of MHC genes, an array of 
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transplantation antigens is clearly expressed (Fernandez et. 
al., 1999). A study showed that women produce antibodies 
and exhibit lymphocyte reactivity against fetal human leu-
kocyte antigens (HLA)  (Hunt et. al., 2003). This forces us 
to recognize that the immune system is not ignorant of, but 
instead recognizes and responds to these antigens.
Cytokine Shift Hypothesis
The immune system can generally be divided into the 
innate and adaptive immune system. The former is a 
nonspecific system providing immediate defense against 
pathogens, while the latter is more targeted, consisting of 
T and B lymphocytes. Although communication between 
these lymphocytes exist, B cells and their antibodies mainly 
contribute to humoral immunity, whereas T cells primarily 
provide cell mediated immunity (Abrams, Miller, 2011). T 
helper cells (CD4+) form a subset of T cells and can be fur-
ther subdivided, depending on their cytokine production, 
into T helper 1 cells (Th1) and T helper 2 cells (Th2). Th1 
cells secrete interferon gamma (IFN-γ) and tumor necro-
sis factor alpha (TNF-α) which are proinflammatory cy-
tokines, whereas the Th2 cells secrete interleukin 4 (IL-4), 
IL-10, and IL-13, anti-inflammatory cytokines (Sykes et. al, 
2012). A mutually exclusive interaction exists between the 
Th1 interleukin, IFN-γ, and the Th2 interleukin, IL-4. IL-4 is 
the dominant factor for promoting growth and differentia-
tion from the Th0 to the Th2 subtype, and directly inhibits 
the development of the Th1 cells (O’Garra and Arai, 2000). 
IFN-γ indirectly promotes Th1 differentiation by upregulat-
ing the IL-12 receptor whilst inhibiting the growth of Th2 
cells (O’Garra, 1998). 
Pregnancy is a complex immunological state and this 
hypothesis suggests that a shift towards T helper 2 (Th2) 
protects the fetus. When a foreign object enters the 
body of a woman who is not pregnant, Th1 cells will 
secrete proinflammatory cytokines that will signal for 
a cel-mediated response to occur. However, according 
to the cytokine-shift hypothesis, the balance of Th1 and 
Th2 will go towards the secretion of cytokines by Th2, 
resulting in a suppressed inflammatory response (Mor, 
2007). Additionally, inhibition of the production of TNF-β 
and IFN-γ is aided with IL-4 secreted by Th2 cells.The 
production of IFN-γ,TNF-β and IL-2 are believed to be 
damaging to pregnancy. In an experiment studying preg-
nant mice, these cytokines were injected into the mice 
and caused fetal loss (Koch and Platt, 2003). 
Many studies have been conducted in an effort to 
better understand this cytokine shift. In an experiment 
conducted by Sykes, et. al. (2012), subjects included 
pregnant women at 28 weeks and term (prelabour and 
in labour) and nonpregnant women of child bearing age. 
The experiment consisted of the isolation of Peripheral 
Blood Mononuclear Cells (PBMCs). In this study, they 
employed flow cytometry to examine the effect of 
stimulation by the mitogen PMA/ionomycin on cytokine 
production at different gestational stages of pregnancy 
and during labour (see Figure 1). Th1 cytokine profiles of 
CD4 positive cells were assessed for intracellular IFN-γ 
and TNF-α and compared to levels of nonpregnant con-
trols. The percentage of peripheral T cells producing 
IFN-γ in response to stimulation reduced in pregnan-
cy from 10.7% in nonpregnant women to 6.7% at 28 
weeks, 5.1% at term, and 5.6% at term in labour (Sykes, 
et. al. 2012). Additionally, there was a reduction in the 
proportion of TNF-α producing cells, although not sig-
nificantly, from 20.6% in nonpregnant women to 14.5% 
at 28 weeks, 15.8% at term and 13.3% at term in labour. 
Overall levels of Th1 cytokine production (expressed as 
mean fluorescence intensity), in the CD4+/IFN-γ+ or 
CD4+/TNF-α+ cells, remained consistent throughout 
gestation. The Th2 cytokine, IL-4, was similarly assessed 
in CRTH2 positive cells. While PMA/ionomycin stimula-
tion did not increase the percentage of IL-4 expressing 
cells, the mean fluorescence intensity of IL-4 was signifi-
cantly increased in samples collected from women at 28 
weeks (39.3, ) and at term (39.4, ) compared to levels 
of nonpregnant controls (37.1) (see Figure 1). Levels of 
IL-4 in term labouring samples were consistent with non 
labouring samples (37.1). The ratio of the IFN-γ : IL-4 
producing cells reduces during pregnancy, due to the 
suppression of the Th1 rather than the promotion of 
the Th2 cytokine production (Sykes, et. al. 2012).
Many researchers agree that cytokines play a crucial 
role during pregnancy. Koch and Platt mutually agree that 
a Th2 response is necessary for the fetus to survive in 
the womb. Results from an experiment with mice showed 
that there was a 20-50% rate of fetal loss due to a lack of 
Th2 cytokine production. Furthermore, they applied this 
idea to humans and suggested that irregularities with Th2 
cytokine response may lead to miscarriages. However, the 
researchers advise for additional investigation in order to 
validate the cytokine-shift hypothesis.
Local Active Suppression of Decidua
In addition to the general suppression of a mother’s im-
mune system, researchers have found that an important 
role in the maternofetal interaction is the local active 
suppression by cells in the decidua (Chaouat, 1990). The 
decidua is the thick layer of modified mucous membrane 
which lines the uterus during pregnancy and is shed with 
the afterbirth. This lining allows for nutrition and gas ex-
change before the placenta is functional (Mizugishi, et. 
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al. 2007). Despite its importance for embryogenesis, the 
development and function of the decidua remains very 
poorly understood. “On the one hand, we are pursuing 
the possibility that decidual tissue impairs the overall 
function of dendritic cells’’ (Erlebacher, 2010). Critical for 
initiating T cell-mediated immune responses within lymph 
nodes, these cells are the most potent antigen-present-
ing cells. The research team has discovered, in a mouse 
model, that the onset of pregnancy causes the genes that 
are responsible for recruiting immune cells to sites of 
inflammation to be turned off within the decidua. As a 
result of these changes, T cells are not able to accumulate 
inside the decidua and therefore do not attack the fetus 
and placenta. Informatively, they revealed that the implan-
tation of an embryo changes the packaging of certain 
chemokine genes in the nuclei of the developing decidua’s 
stromal cells. The change in the DNA packaging perma-
nently deactivates, or “silences,” the chemokine genes. 
Consequently, the chemokines are not expressed and T 
cells are not recruited to the site of embryo implantation 
(Erlebacher, 2010). Therefore, local active suppression 
versus systemic suppression aids in the prevention of for-
eign objects attacking the mother’s immune system and 
fetal rejection (Chaouat, 1990).
Also of note, the observed change in the DNA packaging 
was an ‘epigenetic’ modification, meaning a modification 
that changes gene expression without the presence of a 
heritable gene mutation. This explains the mechanisms of 
fetal-maternal immune tolerance as a modality for limit-
ing the trafficking of activated T cells. They concluded that 
the decidua appears as a zone of relative immunological 
inactivity due to the fact that the cells that typically se-
crete the chemoattractants to bring the T cells to sites of 
inflammation are inhibited from doing so in the context 
of the pregnant uterus. (Nancy, et. al., 2012). Inappropriate 
regulation of this process, Dr. Erlebacher explained, could 
cause inflammation and the accumulation of immune cells 
at the maternal-fetal interface, which could lead to com-
plications of human pregnancy, including preterm labor, 
preeclampsia and spontaneous abortion. 
While this hypothesis holds the most significance 
and the least flaws it still needs to be adjusted. A study 
showed that removing macrophages (an immune cell) 
caused pregnant mice to miscarry (Mor, 2007). This, along 
with the antibodies produced, as mentioned above, high-
lights the immune system activity that exists among the 
maternofetal relationship. 
Conclusion
The phenomenon of a pregnancy and what it entails is 
astounding. Attempting to understand the intricacies of 
the maternofetal relationship forces us to realize the 
vastness of this topic and how much more research is 
needed to unravel this complex “riddle”. With many theo-
ries being investigated, it appears that the hypothesis that 
holds most credence in explaining how a fetus with for-
eign antigens survives the mothers immune system is the 
local active suppression within the decidua. Nevertheless, 
amongst these hypotheses, there is more research that 
needs to be done concerning the role of the immune 
system in pregnancy. Pregnancy is complex and is divided 
into stages. Many researchers believe that labour, which 
brings the pregnancy to completion, is an immune re-
sponse. There seems to be the need of a balance between 
the immune system activity versus inactivity depending 
on the stage of pregnancy. 
References
Abrams, E. T. and E. M. Miller, (2011) “The roles of the 
immune system in Women’s reproduction: evolutionary 
constraints and life history trade-offs,” American Journal 
of Physical Anthropology, vol. 146, supplement 53, pp. 
134–154,. https://doi.org/10.1002/ajpa.21621Anonymous.
(1999).Tiny invader. Discover. ;20(2):14. https:// search.
proquest.com/docview/205991449?accountid=14375.
Chaouat, Gérard.The Immunology of the Fetus. CRC 
Press, 1990
Colbern, Gail & Main, Elliott. (1991). Immunology of 
the maternal-placental interface in normal pregnancy. 
Seminars in perinatology. 15. 196-205.https://www.re-
searchgate.net/publication/2143782
Erlebacher Lab. (2010). Maternal/Fetal Immune 
Interactions: Why Doesn’t the Mother Reject the Fetus? 
Med.Nyu.Edu https://med.nyu.edu/pathology/print/243
Fernandez, N., Cooper, J., Sprinks, M., Abdelrahman, M., 
Fiszer, D., Kurpisz, M. and Dealtry, G. (1999). A critical re-
view of the role of the major histocompatibility complex 
in fertilization, preimplantation development and feto- 
maternal interactions. Hum Reprod Update 5: 234-248. 
https://pubmed.ncbi.nlm.nih.gov/10438108/
Hunt, S. J.L. Pace, P.J. Morales, C. Ober, (2003). 
Immunogenicity of the soluble isoforms of HLA‐G, 
Molecular Human Reproduction, Volume 9, Issue 11, 
November Pages 729–735, https://doi.org/10.1093/
molehr/gag087
Koch, Cody A., and Jeffrey L. Platt. (2003). Natural mecha-
nisms for evading graft rejection: the fetus as an allograft-
Natural mech- anisms for evading graft rejection: the 




Mizugishi K, Li C, Olivera A, et al. (2007). Maternal dis-
turbance in acti- vated sphingolipid metabolism causes 
pregnancy loss in mice. J Clin Invest.;117(10):2993-3006. 
https://search.proquest.com/docview/200521471?ac-
countid=14375. Mor G.(2007) Pregnancy reconceived. 
Natural History. ;116(4):36-41,8. https://search.proquest.
com/ docview/210638045?accountid=14375.
Mor, G. Cardenas, I. (2010). The immune sys-
tem in pregnancy: A unique complexity. Wiley 
Online Library. https://onlinelibrary.wiley.com/doi/
full/10.1111/j.1600-0897.2010.00836.x
Munn et. Al., Zhou M, Attwood JT, Bondarev I, Conway SJ, 
Marshall B, Brown  
C, Mellor AL. (1998). Prevention of allogeneic fetal rejec-
tion by tryptophan catabolism. https://pubmed.ncbi.nlm.
nih.gov/9712583/
Munn, David. (1999), Inhibition of T Cell Proliferation 
by Macrophage Tryptophan Catabolism Journal of 
Experimental Medicine | Rockefeller University 
Press. Rupees.Org, 3 May, https://doi.org/10.1084/
jem.189.9.1363 
Nancy, P. E. Tagliani, C.-S. Tay, P. Asp, D. E. Levy, A. Erlebacher.
(2012) Chemokine Gene Silencing in Decidual Stromal 
Cells Limits T Cell Access to the Maternal-Fetal Interface. 
Science,; 336 (6086): 1317 https://doi.org/10.1126/
science.1220030
O’Garra, A. and N. Arai,(2000).The molecular basis of T 
helper 1 and T helper 2 cell differentiation, Trends in Cell 
Biology, vol. 10, no. 12, pp. 542–550.
O’Garra, A. (1998). Cytokines induce the development 
of functionally heterogeneous T helper cell subsets, 
Immunity, vol. 8, no. 3, pp. 275–283, 1998.https://www.cell.
com/immunity/pdf/S1074-7613(00)80533-6.pdf
Quality and Efficiency in Health Care (IQWiG); (2006). 
How does the immune system work? [Updated 2020 Apr 
23].https://www.ncbi.nlm.nih.gov/books/NBK279364/
Sela, M. (1998). Antigen. Science Direct. https://www.sci-
encedirect.com/topics/medicine-and-dentistry/antigen
Simpson, Elizabeth. (1996) Why the baby isn’t thrown 
out, Immunology Volume 6, Issue 1, Pages 43-44. 
https://www.sciencedirect.com/science/article/pii/
S0960982202004189
Swain D.(2013) Why doesn’t mother reject fetus? the im-
munological concept of pregnancy.Asian Journal of Nursing 
Education and Research.;3(3):7-187. https://search.
proquest.com/ docview/1464739846?accountid=14375..
Sykes, Lynne, David A. MacIntyre, Xiao J. Yap, Sathana 
Ponnampalam, Tiong Ghee Teoh, Phillip R. Bennett,(2012). 
Changes in the Th1:Th2 Cytokine Bias in Pregnancy and 
the Effects of the Anti-Inflammatory Cyclopentenone 
Prostaglandin 15-Deoxy--Prostaglandin, Mediators of 
Inflammation, vol 2012, Article ID 416739, 12 pages. 
https://doi.org/10.1155/2012/416739
Tafuri, A., Alferink, J., Möller, P., Hämmerling, G. J., & Arnold, 
B. (1995). T cell awareness of paternal alloantigens during 




The SARS-CoV-2 virus has spread rapidly, resulting in a global pandemic . There is a great need for an effective drug cocktail ther-
apy to combat Acute Respiratory Distress Syndrome (ARDS), a major cause of death due to COVID-19 . The two drugs examined 
are metformin, an antidiabetic medication, and rapamycin . Rapamycin is often prescribed for transplant patients as it has an 
immunosuppressive effect. The aim of the investigation was to determine the efficacy of metformin and rapamycin in treating 
COVID-19, and to examine what an effective protocol would look like . These two drugs both inhibit mTOR and can reduce the 
body’s auto-immune response, which destroys bronchial cells via cytokine storms. Both drugs have a long history of clinical use and 
have sufficient evidence of efficacy. They possess antiviral properties and downregulate inflammatory markers, making them ex-
cellent candidates for further study, both individually and in combination . Rapamycin has been shown to reverse markers of aging 
and can help repair organ damage . Importantly, metformin can help negate the toxic side effects of the potent rapamycin, while 
still preserving the positive effects of the compound . Metformin also has been shown to aid those who are at risk of developing 
ARDS due to comorbidities such as diabetes or hypertension . As such, using metformin as a preventative therapy, either alone or 
with small doses of rapamycin, may be warranted in patients at risk (Hussain et al, 2020) (Malhotra et al, 2020) .
Rapamycin and Metformin in Treating COVID-19 
Avrohom Karp
Avrohom Karp will graduate with a Bachelor of Science degree in May 2021 and will be attending medical school
Introduction
The SARS-CoV-2 virus’s lethality can be largely owed to 
Acute Respiratory Distress Syndrome (ARDS), a major 
cause of death due to COVID-19. The lungs become in-
flamed and are heavily damaged as fluid from the blood 
vessels leaks into the lungs, obstructing breathing and de-
priving the organs of adequate amounts of oxygen. This 
results in high morbidity and mortality rates. The overall 
percentage of mortality in patients with ARDS was 40 
percent, making the disorder of primary importance in 
the search to reduce deaths in the patient population 
(Tzotzos et al., 2020). 
The ability to repurpose drugs is vitally important to 
combat novel pathogens and can shorten the amount of 
time and money required to develop an effective proto-
col. Novel viruses often use elements of central pathways 
that are commonly used by other viruses. Therefore, drugs 
that have been previously developed can prove efficacious, 
as they target the same pathway. Additionally, the drugs 
that are currently in use have already been proven to be 
effective and safe, which allows their immediate use until 
another, more pathogen-specific, drug can be developed. 
Furthermore, modeling the drug after an existing thera-
peutic agent can shorten the amount of time and energy 
required to develop a new agent, as portions of the previ-
ous drug can be used as a starting point. This can all add to 
an advantage that may save countless patients’ lives as they 
wait for a new drug to be developed (Husain et al, 2020). 
One of the more interesting drugs proposed as a thera-
peutic involves the use of metformin, an anti-diabetic med-
ication. This drug has been touted for its anti-inflammatory 
effects and seems to have a positive effect on the mortality 
rate of patients suffering from COVID-19, even though the 
exact mechanism of action remains contested. Possible 
theories range from its ability to act as a strong base, dis-
rupting the viral envelope, to its ability to up-regulate the 
ACE-2 enzyme, the critical binding site for the spike pro-
tein that serves as the virus’ entry point (Scheen, 2020).
Another potential drug being offered as therapy is rapa-
mycin. Rapamycin first gained recognition as an anti-re-
jection medication for transplanted organs. It suppresses 
the immune system, resulting in less inflammation, and 
has a protective effect, shielding the patient from ARDS. 
Rapamycin can ensure that even if a cure for the virus 
remains elusive, we can mitigate the negative physiological 
effects of the illness on the patients. It would therefore be 
advantageous to examine the differing protocols involv-
ing metformin and rapamycin for their efficacy in treating 
COVID-19 generally, and ARDS specifically, in vulnerable 
patient populations (Husain et al, 2020). 
Methods
Several databases (PubMed, Medscape, clinicaltrials.gov) 
were systematically reviewed for the relevant literature. 
Papers concerning the effects of metformin and rapamy-
cin were studied extensively, both in relation to COVID-
19 as well as other illnesses. 
Discussion
Metformin is a drug that is generally used in the treatment 
of type 2 diabetes as well as other metabolic conditions. 
Its widespread use and its minor side effects have led to 
it being christened the “aspirin of the 21st century.” It 
was originally introduced as an anti-influenza medication 
before being used for its effects on glucose reduction. It 
works primarily by decreasing the production of hepat-
ic glucose while simultaneously increasing the action of 
insulin on tissues, combatting a major factor of type 2 
diabetes. Metformin did not achieve widespread use in 
the United States until 1995, yet by the year 2017, it was 
the fourth most prescribed medication in the United 
States. Even though the exact mechanisms of metformin 
are unknown, there are multiple proposed mechanisms 
of action, including inhibition of the respiratory chain in 
complex I of the mitochondria and lowered production 
of cyclic AMP. Cyclic AMP is the major activating factor for 
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protein kinase A, an essential part of the second messen-
ger pathway involved in hormonal regulation. This greatly 
assists the uptake of glucose, preventing insulin resistance, 
the primary cause of type 2 diabetes. Insulin resistance is 
caused by an overproduction of insulin, which causes the 
bodily tissues to require more of the molecule to uptake 
glucose, resulting in the increasing inability of glucose to 
migrate into the resistive tissue (Sharma et al, 2020). 
The SARS-CoV-2 virus initially binds to the angioten-
sin-converting enzyme 2 (ACE2). The virus uses its spike 
protein (S) region to bind to the enzyme, forming a com-
plex that allows the virus entry into the cell. After gaining 
entry to the host, the virus will downregulate the ACE2 
receptor, leading to excessive inflammation, including car-
diovascular damage and ARDS. The inflammation is due to 
ACE2/Ang (1-7)/Mas acting within the Renin Angiotensin 
Aldosterone System (RAAS) as the anti-inflammatory 
element to counteract the ACE1–Ang II pro-inflammato-
ry arm. The inflammatory arm causes elevated systemic 
blood hypertension and inflammation. Metformin is hy-
pothesized to be able to counteract the downregulation 
of the ACE2 receptor through stimulation of the AMPK/
mTOR pathway. The AMPK/mTOR pathway is thought to 
be involved in increasing the upregulation and stability of 
ACE2, by phosphorylating ACE2 Ser680. (Malhotra et al, 
2020). Although clinical evidence in vivo is required, there 
is strong evidence that Metformin upregulates ACE2, 
from studies with human umbilical vein endothelial cells 
(HUVECs) and human embryonic kidney 293 (HEK293T) 
cells (Zhang et. al. 2018b). Additionally, phosphoryla-
tion decreases ubiquitination, extending its half-life. 
Furthermore, the phosphorylation of the ACE2 enzyme 
by a large negative phosphate group would change its 3D 
conformation and sterically hinder the binding complex 
that the virus uses for entry. In this way, metformin can 
decrease the ability of the virus to enter the host and 
reduce mortality through its upregulation of the ACE-2 
receptor (Malhotra et al, 2020). 
There is evidence that by upregulating ACE-2, 
Metformin can exhibit a protective effect on the cardio-
pulmonary system through the AMPK pathway. AMPK 
activation often leads to ACE2 conformational changes 
leading to SARS-CoV-2 having a greater difficulty binding 
to the receptor (Malhotra et. al. 2020). A study found that 
in animal models “Transgenic mice overexpressing the 
phosphomimetic ACE2 S680D exhibit less damage in pul-
monary vasculature under injurious conditions” (Zhang 
et al., 2018). Metformin has also been shown to have a 
healing effect on the pulmonary system in lipopolysaccha-
rides in animal models (Jian et al., 2013).  
The glucose-lowering effects of metformin seem to 
have a significant effect on survivability. Hyperglycemia 
has been labeled a major risk factor in various Chinese 
studies studying pulmonary illnesses. (Chen et al, 2015). A 
study of patients with diabetes and COVID-19 found that 
patients with well-controlled blood glucose levels had a 
much better prognosis and overall reductions in mortality 
(Crouse et al, 2020). As such, metformin’s proven ability to 
aid in the treatment of type 2 diabetes is important for dia-
betic patients that contract COVID-19. Another study has 
demonstrated that there is a direct correlation between 
the SARS-CoV-2 virus and diabetes, leading to speculation 
that the virus can enter the cells of the pancreatic islets 
where there is an expression of the ACE2 enzyme. This 
leads to damage to the pancreatic beta cells, which produce 
insulin, leading to transient type 2 diabetes mellitus (Yang, 
2010). This would indicate that the regulation of diabetes 
is of primary importance for the treatment of COVID-19. 
Metformin’s previously stated effects on insulin sensitivity 
would make it an ideal candidate. 
Two retrospective studies of COVID-19 patients with 
diabetes from China in early 2020 found that Metformin 
could provide benefit. In a study of diabetic patients, the 
mortality rate for patients on metformin was lower than 
the group that did not receive the drug. This was despite 
the metformin patients having higher levels of fasting glu-
cose on admission. The length of the hospital stay was 
the same between the two groups. (Luo et al. 2020). The 
SARS-CoV-2 and Diabetes Outcome study in France ini-
tially showed that patients who were given metformin 
before admissions had a lower mortality rate after seven 
days (Cariou et al, 2020).  However, multiple confounding 
factors needed to be accounted for, which once consid-
ered, rendered the findings no longer significant. 
In a retrospective analysis studying whether Metformin 
had any favorable effects 1,213 type 2 diabetic patients 
with COVID-19 in 16 hospitals in Hubei, China were 
examined. They excluded confounding variables such as 
eliminating patients with a glomerular filtration rate of 
less than 30ml/min or who had cirrhosis. Patients ex-
clusively using insulin were also eliminated. They looked 
at patients treated with metformin and other drugs 
compared to just other diabetic medications. They used 
propensity score matching to adjust for confounding 
variables and used a Cox regression model to account 
for the changes in clinical conditions throughout the pa-
tients’ stay. They discovered that the length of stay and 
the 28 days all-cause mortality rate were both unchanged, 
though metformin was associated with higher levels of 
acidosis (Lui et al, 2020). Metformin had a protective 
effect, guarding against heart failure and the body’s var-
ious inflammatory responses. Markers of heart failure, 
45
Rapamycin and Metformin in Treating COVID-19
inflammation, and cardiac injury were examined, and all 
were found to be lower. With these data taken together, 
according to the results of the study, Metformin exhibits a 
positive effect on cardiac failure and inflammation (Cheng 
et al., 2020). This was particularly true in severe cases but 
did not translate into an overall reduction in mortality. 
The studies’ discovery that Metformin does not influence 
mortality was contrasted by alternate findings in which 
researchers had found an improvement in patients using 
Metformin (Luo et al.2020). It is possible that since in 
the Luo study, patients on insulin were included in the 
non-Metformin group, there was a confounding variable 
that biased the results.  
The poor outcomes of diabetic patients can be ex-
plained by several factors. Patients with diabetes gener-
ally live with greater levels of overall inflammation daily, 
putting their already inflamed tissues at an increased 
risk of destruction of the bronchial epithelium by the 
body’s immune system, resulting in ARDS (Azar et al, 
2020). Elevated levels of glucose in patients with dia-
betes is an additional risk factor as high blood glucose 
levels have been shown to depress the immune system 
(Ceriello et al, 2020). These reasons make metformin a 
viable candidate for the treatment of diabetes in COVID-
19 patients, particularly as its glucose-lowering effects 
can help mitigate the negative role of diabetes (Kow et 
al, 2021). Additionally, there seem to be positive effects 
independent of the reduction of blood glucose. Various 
biochemical mechanisms are involved in Metformin’s sup-
pression of inflammatory cytokines, which would aid in 
the prevention of an overwhelming immune response on 
the part of the host (Lui et al, 2020).
Metformin’s can play a role in the reduction of inflam-
mation in patients either with or at a high risk of con-
tracting ARDS (Acute Respiratory Distress Syndrome). 
Metformin has proven to be effective at diminishing 
cytokine storms, an immune response that damages the 
body’s cells. It does this by inhibiting interleukin 1α and 
1β, important kinases for pro-inflammatory action. The 
standard measure of systemic inflammation is the neu-
trophil to lymphocyte ratio, which is used as a marker. 
Tracking these markers showed an overall reduction of 
inflammatory cytokines. In a follow-up study of nondi-
abetic patients with heart failure, it was demonstrated 
that metformin suppressed plasma cytokines (Cameron 
et al, 2016). This makes metformin a viable choice in the 
prevention of inflammation and the formation of ARDS.  
The pathway that metformin uses in its anti-inflamma-
tory effects is by the inhibition of tumor necrosis fac-
tor-α–dependent IκB (IkappaB kinase) degradation. In 
an experiment, researchers treated mouse hepatocytes 
with metformin. They found that “Metformin treatment 
for 3 hours suppressed TNFα-induced degradation of 
the NF-κB negative regulator IκB while modulating 
AMPK and mammalian target of Rapamycin signaling 
in a dose-dependent manner” (Cameron et al, 2016). 
Metformin also inhibited signaling downstream by inhib-
iting the cytokines that are normally produced and ac-
tivated, 5’ AMP-activated protein kinase (AMPK). AMPK 
is an enzyme that increases glucose uptake and is often 
thought of as a negative regulator of inflammation. In the 
same vein, IL-1β (interleukin-1-β), and IL-6 (interleukin-6) 
which are both markers of TNF-α–dependent inhibition, 
were greatly reduced (Cameron et al, 2016). 
A 30-day study examining the mortality of nursing 
home patients found that metformin was associated with 
significantly less mortality (Lally et al, 2020). Additionally, 
a retrospective analysis was made of claims made by the 
United Health group’s Clinical Discovery database. This 
study analyzed the records of enrollment of COVID-
19 patients across all 50 states, as well as the various 
pharmacy claims and laboratory reports. They found that 
when metformin was given to adults with type 2 diabe-
tes mellitus or obesity there was a marked decrease in 
mortality exclusively for women, with men receiving no 
benefit. This finding partially confirms the proposed theo-
ry that metformin would be beneficial based on its known 
effects of decreasing levels of tumor-necrosis-factor α 
(TNFα). TNFα is of particular importance as patients with 
COVID-19 have shown to have remarkably high levels of 
it in their lung tissue. Patients with diabetes also have high 
levels of TNFα, as diabetes has been shown to further el-
evate levels. Metformin also promotes the upregulation of 
anti-inflammatory cytokine, IL-10. Additionally, The study 
found that TNFα inhibitors were associated with reduced 
mortality (Bramante et al, 2020). 
This study, while interesting, has several noticeable 
flaws, including the obese and overweight patient samples 
and the lack of strength associated with retrospective 
analysis. Additionally, patients may have been prescribed 
Metformin previously, due to its prevalence, which may 
have gone unreported. It is important to stress that al-
though a helpful effect was observed, these were individ-
uals with other comorbidities such as T2DM and obesity. 
The protective effect may be much less pronounced with 
a patient group that has a lower risk factor and absence 
of these comorbidities. 
Another factor in analyzing the results of the study is 
the difference in the sensitivity required to activate mast 
cells between males and females. Mast cells are an early 
indicator for the SARS-CoV2 immune response. Females 
exhibit a far greater increase in TNFα than their male 
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counterparts. Metformin would therefore exhibit a great-
er positive effect in females, as they are naturally predis-
posed to a more severe reaction that can be inhibited 
by the drug. Women and men differed in their cytokine 
responses even though the levels of the ACE2 receptor 
were equal (Bramante et al, 2020). 
Rapamycin or Sirolimus is a potent anti-transplant re-
jection drug that can suppress and inhibit mTOR. mTOR 
is a serine/threonine-protein kinase that is composed 
of a two-part protein complex named mTORC1 and 
mTORC2. mTORC1 is the complex that is sensitive 
to rapamycin and other more common factors such as 
oxygen, glucose, and various amino acids. mTORC2 is 
insensitive to rapamycin and acts as an effector of insu-
lin/IGF-1 (Insulin-like growth factor-1). The proteins s6, 
p70S6K and 4E-BP1 are the point of control for many 
cellular functions when phosphorylated by mTORC1.
This controls protein synthesis and the cell’s self-destruc-
tion mechanism known as autophagy. mTORC2 is mostly 
required for other kinases such as Protein Kinase B. One 
of the reasons that the mTOR pathway is so vital is that it 
regulates pivotal moments in the life cycle of a cell includ-
ing metabolism, transcription, proliferation, and eventually, 
cell death. This has led mTOR, and by extension, rapamy-
cin to be often studied in the examination of aging, also 
known as cellular senescence (Husain et al, 2020). 
Rapamycin first rose to prominence when it was dis-
covered to block the immune system generally, and T cell 
proliferation specifically. Additionally, mTOR is involved in 
the cellular division cycle, playing a role in the transition 
of the G1 to the S phase. Rapamycin as an inhibitor blocks 
the cell cycle. This would suggest that mTOR can serve as 
an important chokepoint in mitigating the spread of the 
virus as it could block the proliferation of infected cells 
(Husain et al, 2020).  
In numerous studies examining the mortality of patients 
with COVID-19, it was found that that a primary factor in 
the occurrence of infectious diseases was blood Vitamin 
D concentration. In a study of elderly patients, Vitamin D 
helped reduce the inflammatory response in the upper 
respiratory epithelium and lowered the risk of developing 
intense symptoms (Grant et al , 2020). Vitamin D has also 
been shown to interact with the ACE2 enzyme, limiting 
the virus’s entry into the cell, as this serves as the entry 
point for the SARS-COV-2 virus. Evidence would suggest 
that the mechanism of action for the positive effects 
of Vitamin D is the suppression of the mTOR pathway 
through multiple mechanisms. One of these mechanisms 
involves a regulator known as “regulated in development 
and DNA damage response 1 (REDD1), a suppressor of 
mTOR activity”, which is stimulated by the 1,25(OH)2D 
form of Vitamin D (Husain et al, 2020). 
In all, it would be reasonable to suggest that the numer-
ous benefits of Vitamin D are achieved through the inhibi-
tion of mTOR and can therefore be stimulated directly by 
an mTOR inhibitory agent such as rapamycin. 
The anti-aging effects of Rapamycin can be of great use 
as well, with the drug being shown to extend the life of 
mice significantly (Harrison et al, 2009). But, important-
ly for the treatment of COVID-19, Rapamycin has been 
shown to rejuvenate damaged tissues such as damaged 
cardiac cells and increase the vitality of hematopoietic 
stem cells (Guarda et al, 2004). It may be that  as proteins 
are continuously synthesized, they acquire damage and 
various misfolding that inhibit their function and are the 
prime indicators of age-related diseases. The domain that 
is affected by rapamycin is mTORC1. Inhibiting mTORC1 
reduces protein synthesis and causes the cell to induce 
autophagy, thereby recycling the damaged components. 
COVID-19 has been proven to affect the elderly popu-
lation at an increased rate, with higher mortality being 
attributed, making rapamycin a potential anti-aging drug 
that can mitigate the negative effects of age-related vul-
nerabilities (López-Otín et al, 2013). Additionally, it might 
go some way in aiding with the reversal of organ damage 
that is a hallmark of critical cases of COVID-19. 
mTOR regulates metabolic processes that help to serve 
as signaling for anabolic (building) and catabolic (dismantling) 
processes in the cell. mTOR inhibition has been shown to 
protect against high fat-induced obesity in mice by regulating 
the breakdown of glycogen and other processes involving 
glucose. This could make rapamycin useful in mitigating the 
negative effects associated with insulin resistance and obesi-
ty in COVID-19 patients, which has been proven to result in 
negative health outcomes (Saxton et. al. 2017). 
Acute respiratory distress syndrome (ARDS) is caused 
by the breakdown of upper respiratory epithelia that 
results from a cytokine storm that destroys the body’s 
tissues. This can lead to multi-organ failure that can often 
be fatal. The various cytokines that are released are “IL-2, 
IL-7, IL-10, MCP-1 (monocyte chemoattractant protein), 
MIP1A (Macrophage Inflammatory Proteins) and TNF-α 
(Tumor Necrosis Factor-α)”. Rapamycin’s primary effect 
as an immunosuppressive drug can decrease the levels 
of the cytokines in the body, making it a useful tool for 
dealing with cytokine storms (Costela-Ruiz et al., 2020). 
Rapamycin’s targeting and inhibition of a wide variety of 
cytokines make it an ideal drug for the suppression of 
harmful immune responses, making it potentially more 
useful than the drug Tocilizumab and other monoclonal 
antibodies that merely target individual cytokines. 
Rapamycin’s inhibition of the mTOR pathway remains 
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very promising not only for its pleiotropic effects on the 
cell’s regulatory mechanisms but also for its anti-immune 
properties. It is important to mention, however, that 
rapamycin’s side effects can be rather unpredictable. This 
makes it necessary to monitor the effects of rapamycin 
in each patient and to educate them about the potential 
negative side effects. There has been a proposal to exam-
ine upstream mutations in mTORC1 signaling to deter-
mine ideal candidates for therapeutic interventions using 
rapamycin. This would help mitigate the negative side ef-
fects experienced by members of the patient population. 
T-cell senescence is prevalent in long term infections 
and cancer and is a state of T-cell dysfunction. Cytokine 
storms can play a role in inducing T-cell apoptosis and ne-
crosis, leading to overall lower T-cell counts. Patients with 
COVID-19 have been observed to have lower CD4+, 
CD8+, and total T-cell numbers which are all implicated in 
lowering the survival rate of patients with the illness. Even 
when the CD4+ and CD8+ cells are present in severely 
ill COVID-19 patients, they exhibit less function overall 
and are unable to secrete perforin, granzyme, and IFN-γ, 
all of which are cytotoxic molecules. The senescent mark-
ers PD-1 and Tim-3 are also present at higher levels. Cells 
that are senescent release certain cytokines and molecules 
that are indicative of the cell’s status and are known as 
the “senescence-associated secretory phenotype (SASP)”. 
Rapamycin, being an mTOR inhibitor, can suppress SASP 
and by extension the cytokine storm that results from 
T-cell senescence. Therefore, administration of Rapamycin 
in the early phase of the cytokine storm might prevent the 
emergence of a severe form of COVID-19 through the 
downregulation of SASP (Omarajee et al, 2020). 
Rapamycin has a history of being beneficial regarding 
respiratory infections, and has been shown to reduce the 
recovery time in H1N1 and SARS patients.  study that 
examined 38 patients with H1N1-induced pneumonia, 
reported  that Rapamycin was associated with positive 
outcomes in the overall prognosis of patients and short-
ened their time on a ventilator. It also was associated 
with significantly increased viral clearance, lower rates of 
hypoxemia, and reduced multiple organ dysfunction. Both 
H1N1 and SARS-CoV-2 activate mTOR, leading to lung 
inflammation, fever, and other intense immune reactions. 
Rapamycin may provide a significant benefit by inactivat-
ing mTOR and therefore IL-1β secretion, the mediator of 
inflammation (Wang et al., 2014).  
Rapamycin is currently undergoing phase two clinical 
trials to determine its efficacy in a 30-patient sample 
that seeks to improve clinical outcomes in COVID-19 
patients (NCT04341675). The study will last for 14 days 
with 2mg being given orally daily. The primary outcome is 
to determine the proportion of patients that do not need 
advanced respiratory support by 28 days. The secondary 
outcomes involve tracking changes in lymphocyte con-
centrations as biomarkers as well as the proportion of 
patients requiring general respiratory support. 
There have already been numerous studies done on 
the use of rapamycin and metformin in the treatment of 
a plethora of cancers and tumors, including pancreatic and 
breast cancers (Faria et al, 2019; Amin et al, 2019). These 
studies have determined the combination to be safe and 
effective, with the combination able to target slightly differ-
ent pathways than any of the two drugs alone. Rapamycin 
can cause glucose intolerance and insulin resistance if 
taken long term. These effects may be mitigated by met-
formin, due to metformin causing increased insulin sen-
sitivity in tissues. The ITP (Intervention Testing Program) 
reported that the effect of both rapamycin and metformin 
on longevity when taken together was far superior to the 
effect of each drug alone. It should be noted that in mice 
the combination of the two drugs did reduce the effective 
concentration of rapamycin in females and metformin in 
both sexes. The final concentrations were still within the 
range to be clinically useful (Strong et al, 2016). 
In a study conducted on mice, examining the effects 
of metformin on glucose, the animals were given both 
rapamycin and metformin. Interestingly, in contrast to 
studies that had been conducted previously, the research-
ers found that metformin did not inhibit mTOR and 
stopped rapamycin from inhibiting mTOR in the liver. The 
researchers theorized that metformin could alleviate the 
disfunction in gluconeogenesis that was found in other 
mTOR mutant mice (Kim et al, 2020).   
Metformin and rapamycin would seem uniquely suited 
for COVID-19 patients with obesity and diabetes. These 
patients can be aided by glucose mitigation of metformin 
but can also cycle lower doses of rapamycin for the potent 
mTOR effects. In a study of rats being given rapamycin, the 
researchers attempted to see if they could mitigate the 
increased hepatic gluconeogenesis caused by rapamycin 
administration by combining it with metformin. The female 
mice in the study exhibited significantly lower gluconeo-
genesis, thereby implying that the metformin served to 
remove the harmful side effects of rapamycin (Weiss et al, 
2018). Here, as in our previous discussion, the effect was 
sex-specific for many of the reasons outlined previously. 
In a study examining metformin and rapamycin on the 
proliferation of pancreatic cancer cell growth, the optimal 
therapeutic dosage was determined to be (20 mmol/l) 
Metformin + Rapamycin (200 ng/ml) in vivo. The study dis-
covered that the combination was vastly more effective 




In all, given the evidence that metformin reduces the 
mortality and morbidity in diabetic patients, it should 
remain a drug of primary importance in the treatment 
of COVID-19 in diabetic patients. The effects of the drug 
on insulin resistance can play an important part in re-
ducing the immunosuppression found in diabetic patients 
due to the abundance of glucose in the bloodstream. It 
should be noted that the guidelines urging concern about 
metformin inducing acidosis in patients was specifical-
ly applicable to patients already in multi-organ failure. 
Additionally, even though the prevalence of acidosis was 
higher in patients that were given metformin, it did not 
affect the mortality rate(Cheng et al, 2020). As such, the 
positive effects of metformin would make it an excellent 
candidate for further study, not only in patients with pre-
existing comorbidities but as a possible therapeutic given 
its anti-inflammatory properties. Metformin’s significant 
effects on the RAAS system can make it an important 
agent in the reduction of inflammatory cytokines that are 
the hallmarks of COVID-19.
Regarding metformin in the treatment of patients with 
COVID-19 and diabetes, it should be noted that many of 
the studies are retrospective and examine patient out-
comes using statistical analyses. They seek to determine 
the efficacy of metformin in mitigating the detrimental 
effects of diabetes on COVID-19 patients. The positive 
effects of metformin previously noted, there is a paucity 
of data of metformin being given to COVID-19 patients 
without diabetes. Many of the studies specifically look 
at the outcomes of patients who were previously given 
metformin to control diabetes before the virus and were 
then examined to determine the beneficial effects specif-
ically on patients with diabetes and COVID-19. But for 
such a widely prescribed drug such as metformin, it is 
shocking that there exists so few clinical trials for indi-
viduals without diabetes as a comorbidity. Many papers 
propose that metformin’s anti-inflammatory effects could 
be of use to the wider population to reduce the negative 
immune response, but as of the date of this paper, there 
have not been any clinical trials examining the exact out-
comes of the drug on a non-diabetic patient population. 
There may be several reasons for the lack of clinical tri-
als, among them, that even if metformin does show some 
benefit in its ability to prevent an overzealous immune 
response, other drugs currently being used or examined 
in the treatment of COVID-19 are even more effective 
through a similar mechanism. Tocilizumab, for example, 
has already been shown to help in CAR T-cell-induced 
cytokine release syndrome, which bears many similari-
ties to the cytokine storm that can occur in COVID-19. 
A common side effect of Tocilizumab, however, is an el-
evation in blood pressure, which has proven damaging 
in COVID-19 patients (Jones et al, 2010). Therefore, it 
would be efficacious to conduct a thorough study of met-
formin, given its ability to be tolerated by a wide subset of 
the population and its proposed benefits in its ability to 
downregulate the immune system. 
Additionally, many of the monoclonal antibody ther-
apies that are being examined specifically exert their 
effects on one target, while metformin has been shown 
to operate across many different pathways. Metformin 
lowers inflammation and oxidative stress, all the while 
enhancing the immune system of patients.
Rapamycin can be a dangerous compound that must be 
handled with caution due to its ability to act as a potent 
inhibitor of mTOR. While mTOR inhibition can be ben-
eficial in the reduction of inflammation, it is important 
not to inhibit the pathway completely. A study examining 
the effects of rapamycin on elderly patients discovered 
that total inhibition of mTOR stops the function of T cells 
and leads to complete immunosuppression. While some 
suppression of the immune system is favorable due to 
its effect on cytokine storms, the body’s natural defens-
es must remain viable. As such, the dose of rapamycin 
must be carefully monitored to be safe and effective. In 
that same study, they determined that the most effective 
dose at promoting a healthy immune response in elderly 
patients was the lowest dose of rapamycin followed by 
a flu shot (Mannik et al., 2014). This has a great deal of 
significance as of early 2021, due to the availability of the 
mRNA COVID-19 vaccine currently seeing widespread 
use. The use of rapamycin followed by a vaccine should 
possibly be explored as a method of enhancing immunity 
in vulnerable patient populations. This could maximize 
the effectiveness of a protocol involving not only the cur-
rently available vaccine, but also carries implications for 
other protocols involving vaccinations. 
The combination of rapamycin and metformin used in 
pancreatic cancer has been proven to be safe and effec-
tive. The dose used was the optimal dose to lower the 
expression of mTOR in pancreatic cells, and it stands to 
reason that this dosage would work in other cases where 
mTOR should be partially inhibited, such as in COVID-19. 
Rapamycin inhibits mTOR directly, while metformin does 
it through the AMPK pathway (Zheng et al, 2020).
The dose of rapamycin administered must be carefully 
controlled to avoid negative side effects. Metformin can 
temper some of these effects, which can include insu-
lin resistance and glucose intolerance, through its ability 
to promote insulin sensitivity. Rather than administering 
the two drugs as a cocktail, risk can be assessed by the 
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administration of each drug separately. This would allow 
a thorough examination of the differing effects while still 
allowing metformin to counter the deleterious side ef-
fects of rapamycin. 
An important point in discussions concerning the 
treatment of viruses is the health of the host. It has been 
demonstrated that immunocompromised patients and 
those with significant comorbidities fare far worse than 
patients without these complications. Metformin has the 
dual role of not only directly combatting the virus, but 
also reinforcing the immune system of the host. The abil-
ity to reduce comorbidities (e.g.: diabetes) should not be 
treated flippantly. A major factor in the morbidity rate 
in the United States has been a large proportion of the 
population with high blood pressure and obesity (Azar 
et al, 2020). These conditions have been proven to have 
significant negative effects. If metformin can provide a 
mechanism to reduce these additional comorbidities, the 
patient’s health outcomes could be vastly improved. 
Taking metformin to prevent an extremely negative 
reaction to COVID-19 should be considered. Being that 
metformin is a mild mitochondrial toxin that blocks 
mTOR, it would be a useful preventative drug. mTOR 
inhibitors have been shown to block viral action and ex-
press innate antiviral gene expression. In previous studies, 
mTOR inhibitors were effective against other coronavi-
ruses. Prescribing metformin to vulnerable patient pop-
ulations as a preventative drug may grant the benefits of 
mTOR inhibition without rapamycin’s toxic side effects 
(Benedetti et al, 2020).  
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Preeclampsia is a complication of pregnancy primarily characterized by hypertension and proteinuria and affects other organs as 
well . The underlying causes are not yet fully understood . However, it is suggested that angiogenic factors of the placenta, genetic 
factors, a malfunctioning immune system, and oxidative stress all play a role in causing preeclampsia. Currently, the only definitive 
cure known for preeclampsia is delivery of the baby .  Management of the condition includes taking preventative measures as well 
as drugs such as labetalol and MgSO4 . This paper analyzes mechanisms of preeclampsia and determines the possible causes 
and most effective ways to manage the condition .
What are the Possible Causes and Effective Therapeutic 
Approaches of Preeclampsia?
Adina Hadi
Adina Hadi graduated with a Bachelor of Science degree in Biology in January 2021, and is accepted to the SUNY 
Downstate Medical Center Physician Assistant program.
Introduction
Preeclampsia (PE) is a multisystem complication that 
occurs during pregnancy and is primarily characterized 
by elevated blood pressure and abnormally high levels of 
protein in the urine.  The disorder manifests itself after the 
20th week of gestation and can lead to serious complica-
tions, possibly even fatality of the mother and the baby.  It 
can also cause long-term health conditions.  The disease 
has a worldwide prevalence of 5-8% of pregnancies and 
currently ranks as one of the leading causes of maternal 
and perinatal morbidity (Pennington et al., 2012).  In ad-
dition to hypertension and proteinuria, afflicted patients 
may undergo other symptoms including edema of the face 
and hands, headaches, dizziness, decreased urination, nau-
sea, and vision changes.  Furthermore, 10-20% of women 
with severe cases of PE can develop a potentially lethal 
condition known as the HELLP syndrome, characterized 
by the fundamental features of “hemolysis, elevated liver 
enzyme levels, and low platelets.”  If PE progressively 
worsens, it can turn into eclampsia, where the elevated 
blood pressure causes the mother to experience seizures 
and may result in a coma (Preeclampsia. 2016). 
The exact etiology of PE remains unknown.  The pur-
pose of this review is to determine the possible causes of 
PE and the most effective therapeutic approaches avail-
able to manage the condition.
Methods
This comprehensive review was conducted based on critical 
analyses of data collected from various databases accessed 
through Touro College’s online library, such as ProQuest 
and PubMed. The National Center for Biotechnology 
(NCBI) website was also a useful tool in providing addi-
tional sources. Key words and phrases used to retrieve 
data include “mechanisms of preeclampsia,” “causes of pre-
eclampsia,” and “management of preeclampsia.”
Discussion
PE can be classified into an early onset and late onset 
form.  Women suffering from early-onset PE are diagnosed 
before their 34th week of pregnancy and symptoms of 
low birth weight and intrauterine growth restriction will 
manifest.  Conversely, the late onset form expresses itself 
after the 34th week and its cause is generally associated 
with various maternal conditions including obesity, diabe-
tes, and chronic kidney diseases.  Regardless of the sub-
type, it is evident in all cases of PE that the placenta plays a 
central role in its pathophysiology (Lisowska et al., 2018). 
In normal pregnancies, an increase in blood flow to the 
uterus will occur to ensure sufficient supply for the in-
tervillous spaces and overall proper fetal development. 
Cytotrophoblasts invade deep inside the maternal spiral 
arteries to establish a vascular network and remodeling 
subsequently takes place to form high-capacity blood ves-
sels. This mechanism is defective in the placentas of indi-
viduals destined to develop PE. In such cases, the cytotro-
phoblasts fail to entirely convert from their proliferative 
epithelial form into their invasive endothelial form. As a 
result, remodeling of the spiral arteries is greatly hindered 
and the restricting maternal vessels will lead to placental 
ischemia (Rana et al., 2019).
Another identifying feature found to be associated with 
the pathogenesis of this disorder is elevated levels of an an-
tiangiogenic protein called soluble fms-like tyrosine kinase 
(sFLT1) in the placenta (Roberts & Bell, 2013). This was 
furthered studied on non-human primates. A group of ani-
mals was induced with uteroplacental ischemia (UPI) while 
a Sham group of animals was not. The concentration of 
plasma sFLT1 of both animal groups was measured over a 
two-week period and the results were compared. As seen 
in Figure 1, the UPI animals showed a significant increase 
in sFLT-1 over time, whereas the Sham group’s sFLT1 levels 
remained roughly unchanged (Makris et al., 2007). This ex-
periment shows how reduced blood flow directly increas-
es the amount of circulating sFLT1 in the plasma.
SFLT-1 is a soluble receptor that binds to the angiogen-
ic factors, vascular endothelial growth factor (VEGF) and 
placental growth factor (PlGF), and inhibits them from in-
teracting with their receptors, Flt1 and Flk1. When they 
cannot bind to their receptors, the angiogenic factors are 
incapable of carrying out their function of promoting the 
growth of new blood vessels. Therefore, the presence of 
sFLT1 inhibits the growth of blood vessels. In PE, the exces-
sive amount of sFLT1 abnormally constricts the mother’s 
blood vessels, leading to hypertension, in addition to affect-
ing the function of various other organs. The constricted 
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blood vessels are also responsible for causing the kidneys 
to release proteins into the urine (Roberts & Bell, 2013).
Etiology of PE
The causes of placental malformation are still being re-
searched and currently remain unclear. It is understood, 
however, that anything causing oxidative stress to the 
placenta is likely to cause PE. Oxidative stress is when 
there is an imbalance between reactive oxygen species 
(ROS) and antioxidants which disrupts metabolism and 
cell signaling in aerobic organisms.  Several cell compart-
ments can produce ROS, such as the mitochondria, endo-
plasmic reticulum, and nuclear membrane. They produce 
O2•− anions as a byproduct of auto-oxidation during the 
electron transport chain. ROS can also be produced as a 
result of arachidonic acid metabolism. Oxidative stress 
regulates the transcription factors NRF2 and FoxO which 
control the expression of genes that detoxify oxidizing 
molecules. Thus, the imbalance causes an interruption in 
the detoxification process and can lead to structural and 
physiological damage to DNA, RNA, proteins, and lipids. 
(Auoache et al., 2018). Oxidative stress is known to cause 
endothelial cell dysfunction which can contribute to PE 
(Duhig et al., 2016).
Risk Factors for PE
Several principle risk factors were found to be associated 
with the onset of PE. The presence of certain medical con-
ditions can make a woman more prone to developing PE. 
Hypertension has strongly proven to be correlated with 
an increase in one’s risk of developing PE. To be diagnosed 
with hypertension, there must be a “systolic 
blood pressure greater than or equal to 140 
mmHg and/or diastolic blood pressure great-
er than or equal to 90 mmHg” (Hinkosa et al., 
2020). A retrospective study of the databases 
from two hospitals identified 362 women 
who had chronic hypertension that required 
treatment prior to their pregnancies were 
analyzed. The data revealed that the percent-
age of superimposed PE in these women was 
23.2%, a percentage notably higher than that 
of the general population. (Lecarpentier et al., 
2013).
Autoimmune diseases like systemic lupus 
erythematosus and antiphospholipid anti-
body syndrome, diabetes type 1 or 2, and 
chronic arterial hypertension are other con-
ditions classified as high-risk factors for PE 
(Mayrink et al., 2018). 
Other risk factors known to be linked 
with PE include nulliparity, maternal age over 35, multi-
fetal pregnancy, prior case of PE, chronic kidney disease, 
prior stillbirth, and a pre-pregnancy BMI over 25. Data 
was extracted and pooled from 92 studies regarding the 
relative risk of developing PE for women with each risk 
factor. Pooling of the data is helpful in bringing about re-
sults that are as reliable as possible. 
Genetic Factors
Currently, there are no identified genes that are direct-
ly responsible to cause the disorder. However, because 
clustering of PE among families is common, it is suggest-
ed that there must be a genetic etiological component 
involved. Women with a first relative that developed PE 
have a three to five-fold increased risk of getting it as 
well (Hansen et al., 2018). There is also research suggest-
ing that paternal genes may be a contributing risk factor 
for the development of PE as well. Women who became 
pregnant from a man that has had a previous partner with 
preeclampsia were seen to be at a slightly higher risk for 
PE (Galaviz-Hernandez et al., 2018).
Mother’s Immune Responses
PE is thought to be a disorder that may be due to mal-
functioning of the mother’s immune system. The syncytial 
surface of the placenta sheds particles, ranging from large 
deported multinuclear fragments to sub-cellular com-
ponents, and it is suggested that these particles contain 
proteins that trigger an inflammatory response.  In PE, the 
number of circulating particles present increases, indicating 
a relationship between excess particles and the pathology 
Figure 1: The concentration of plasma sFLT1 levels are significantly elevated in the UPI 
group in comparison to the sFLT1 of the Sham group (Makris et al ., 2007) .
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of the disease. Thus, preeclampsia is characterized by an 
exaggerated inflammatory response (Palei et al., 2013). 
Furthermore, complications of the maternal immunity 
mechanisms can be a causing factor of PE. During pregnan-
cy, it is essential for the mother’s regulatory CD4 + T cells 
to interact with the uterine natural killer cells in order to 
recognize and accept the fetal antigens and enable placen-
tal growth. Failure of this process leads to a spontaneous 
miscarriage, while a partial failure leads to poor placenta-
tion and dysfunction of the placental perfusion and chronic 
immune activation that stems from the placenta. Women 
with PE were found to have decreased levels of circulating 
regulatory CD4 + T cells. Additionally, they have increased 
levels of T helper 17 cells, cells that are also upregulated in 
various autoimmune disorders (Palei et al., 2013).
Possible Complications of PE During Pregnancy
When symptoms of PE become severe, it can lead to 
dangerous complications for both the mother and the 
fetus, including fatality. Severe PE is when one or more of 
the following conditions is present: blood pressure of 160 
mmHg or higher for systolic and 110 mmHg diastolic on 
at least two occasions that are at least 6 hours apart, at 
least 2 g of proteinuria in a 24 urine specimen or on two 
urine samples collected at least 4 hours apart, oliguria of 
less than 500 mL in 24 hours, cerebral or visual issues, 
pulmonary edema, pain in the epigastric or right upper 
quadrant, fetal growth restriction, a persistent and severe 
headache, or medical issues involving acute renal insuffi-
ciency, hepatic hematoma, and HELLP syndrome (Nankali 
et al., 2013). It is said that 25% of PE cases are classified as 
severe (Minire et al., 2013). 
The mother may develop HELLP syndrome, which 
causes mortality in 25% of affected women. This can bring 
about a variety of complications that can affect many dif-
ferent organ systems such as the central nervous system, 
renal system, respiratory system, and liver. Complications 
include stroke, cerebral edema, retinal blindness, pulmo-
nary edema, laryngeal edema, jaundice, renal failure, liver 
failure, HELLP syndrome, and eclampsia. Globally, pre-
eclampsia and eclampsia are responsible for 10-15% of all 
maternal deaths (Nankali et al., 2013)
As for the fetus, the baby is often deprived of receiving 
a sufficient amount of blood and does not get the oxygen 
and nutrients it needs. Development under such condi-
tions will be hindered, and the baby will have fetal growth 
restriction, causing it to be very small at birth. Often, these 
babies will need to be hospitalized for a period following 
their birth. A stillbirth can happen if the placenta sepa-
rates from the uterine wall, causing the mother to heavily 
bleed. This is more likely to happen if the mother has a 
more severe case of PE, including the HELLP syndrome 
(Preeclampsia research at the NICHD.2012). Infants 
whose mothers had PE during their pregnancy also have 
an increased risk of developing some long-term health 
conditions due to the lack of proper development, such 
as “learning disorders, cerebral palsy, epilepsy, deafness, 
and blindness. Later on, they may be at risk for diabetes, 
congestive heart failure, and hypertension. Infant death is 
also a possible occurrence (Preeclampsia research at the 
NICHD.2012).
Management Options for PE
Because of the severity of the complications that pre-
eclampsia may cause, women should take several precau-
tions to help lower their risk of developing the disorder. 
Antiplatelet drugs, primarily low dose aspirin, are useful 
preventative agents as they reduce the risk of PE by 19% 
as well as decreasing the risk of stillbirth or neonatal death 
by 16% (Duley et al., 2006). Aspirin is effective because it 
reduces platelet aggregation, but it is also a risk of in utero 
cerebral hemorrhage (Atallah et al., 2017). It is advised 
that women at high risk should begin taking this before 
12 weeks until 36 weeks of gestation (English et al., 2015).
Calcium supplementation during pregnancy also ap-
pears to reduce the risk of hypertensive disorders in 
pregnancy, including PE. A group of 579 women were 
assigned as a placebo group and a group of 588 women 
were given calcium supplementation. When comparing 
the percentage of hypertensive disorders of pregnancy 
in the placebo and calcium groups of women, the calci-
um group had a significantly lower risk of hypertensive 
disorders, particularly after the 28th week of gestation. 
There seem to be no side effects associated with calcium 
supplementation (Belizan et al., 1991).
There is also some research suggesting that antioxidant 
supplementation of vitamins C and E may be useful in 
lowering one’s risk of PE.  These agents are thought to 
prevent ROS from inflicting oxidative damage and overall 
restoring the redox equilibrium. This therapy aims to ul-
timately prevent endothelial cell dysfunction, which is an 
important pathological feature of PE (Aouache R. et al., 
2018). However, there are studies that show contradic-
tory results about the effectiveness of these supplements 
on reducing risks of PE. To test their outcomes related 
to PE, women who were 9 weeks to 16 weeks pregnant 
were examined until delivery. 5,088 women were given 
daily antioxidant supplementation of vitamins C and E, 
whereas 5,066 women served as a placebo group. The 
vitamins did not have much of an effect on the risk of de-
veloping PE. Based on such findings, they do not seem to 
serve any significant preventative purpose (Preeclampsia 
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Early and accurate detection of the disorder is im-
portant in order to provide immediate optimal man-
agement. Therefore, closely monitoring changes in preg-
nancy, especially for women who classify as high-risk, is 
recommended. Regularly assessing blood pressure can 
catch any hypertension which is a good indicator of 
PE (Mayrink et al., 2018). Consistent urinary analyses 
should be performed in order to check for proteinuria, 
another big marker of PE. Monitoring growth often is 
useful in identifying signs of fetal growth restriction as 
well (English et al., 2015). 
It is certain that the only definitive cure for PE is 
delivery. The decision to deliver the fetus prematurely 
is often based on two factors, estimated fetal weight 
and the severity of the disorder. If the mother is ex-
periencing “uncontrolled severe hypertension that is 
not responding to therapy, eclampsia, acute pulmonary 
edema, abruptio placentae, subcapsular hepatic hemato-
ma, or thrombocytopenia <50,000/mm3 ”, then that in-
dicates a need for immediate delivery (Uzan et al., 2011). 
Nevertheless, there are various ways to help control the 
condition during the pregnancy. Premature birth of the 
fetus is almost always inevitable, since the mother will 
most likely be unable to survive the full pregnancy peri-
od due to her destructive conditions. However, it is ideal 
to allow the baby to develop for as long as possible to 
improve neonatal outcomes. Mainly, it is important to 
allow the fetal lungs to mature. Prolonging treatment 
for as much as possible will result in the most beneficial 
outcome for the fetus (Le et al., 2019).
If blood pressure reaches the level of 160/110 mmHg 
or higher, antihypertensive treatment is a necessity as this 
is considered a medical emergency. Oral antihypertensive 
medications such as labetalol, methyldopa, and nifedipine 
should be administered. If the oral therapy fails to elicit 
a response, intravenous medication such as a labetalol 
infusion or hydralazine should be given. However, the 
commencement of treatment may result in a drop in 
blood pressure that can affect uteroplacental circulation 
and cause fetal distress; hence, the dosage of these drugs 
should be titrated gradually (English et al., 2015).
Magnesium sulfate (MgSO4) is a drug that aids in pre-
venting eclampsia. The drug should be administered to 
women at high risk for eclamptic seizures. It has also been 
shown to lower the risk of cerebral palsy in the offspring. 
MgSO4 does have some adverse effects and can lead to 
paralysis, an absence of reflexes, a lower respiratory rate, 
and arrhythmias. Therefore, patients will need to have 
their pulse, respiratory rate, and reflexes continuously 
monitored in the time following. In the case that toxicity 
does occur, it can be corrected by giving the patient calci-
um gluconate (English et al., 2015).
Conclusion
PE is a disorder that is not fully understood yet. Due to 
the limited knowledge of its precise mechanisms, it remains 
difficult to determine the exact etiology of the disorder. 
However, the reviewed research articles were all consis-
tently in agreement that women with the disease have 
a common pathophysiological finding.  Elevated levels of 
sFLT1 are present in the placenta, which suggests the dis-
ease is largely due to dysfunctional angiogenic factors. The 
inability of the mother’s angiogenic factors to bind to their 
correct receptors causes her blood vessels to constrict 
and leads to manifestations of PE (Roberts & Bell, 2013). 
This seems to be the major factor behind the disorder. 
PE does not have any known cures; the only way to 
successfully stop the disease would be to terminate the 
gestation period and deliver the baby. The goal would 
be to manage and prolong the pregnancy for as long as 
possible in a way that takes both the mother’s and fetus’ 
safety into account (Uzan et al., 2011). After reviewing 
the various treatment options available, it seems that a 
combination of therapeutic agents would be the most 
viable approach for PE. Taking low-dose aspirin is a useful 
protecting drug as it reduces platelet aggregation (Atallah 
et al., 2017). Anti-hypertensive medication is essential 
to control the mother’s blood pressure in cases when 
it reaches 160/110 mmHg or higher. The use of anti-hy-
pertensives can lead to a sudden drop in blood pressure 
that can cause fetal distress, so it is important to respon-
sibly monitor women’s blood pressure when they are on 
these medications. Additionally, MgSO4 is important for 
preventing or treating seizures in eclampsia (English et al., 
2015). Side effects that may present include paralysis, an 
absence of reflexes, a lower respiratory rate, and arrhyth-
mias. However, the drug is vastly advantageous, and moni-
toring the patient and regulating drug administrations will 
eliminate most of the harm it can cause (English et al., 
2015). Knowledge of the various factors that put women 
at high risk for PE is also useful for preventative care. 
Women should have their blood pressure monitored to 
check for hypertension, and urinalyses monitored to look 
for proteinuria, two major symptoms of PE. (Mayrink et 
al., 2018). Taking these steps can help in early detection 
and management of PE.
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Systemic Lupus Erythematosus is a disease that manifests in many different ways . The cause of lupus still remains elusive . 
However, many of the pathologies associated with the disease as well as the disease process have been described . The patho-
physiology of the disease as well as its effects on specific patient groups will be discussed below. More specifically, Systemic Lupus’ 
effect on pregnancy with current diagnostic and treatment modalities will be the focus of this paper .
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Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune 
disease that is common and affects around 400 per 
100,000 people in certain populations.  SLE mainly affects 
African or Hispanic women, especially during their repro-
ductive years.  The telltale sign of SLE is the production of 
autoantibodies, specifically antinuclear antibodies (ANAs). 
The most common method for detecting these ANAs is 
indirect immunofluorescence, which can recognize anti-
bodies that bind to nuclear antigens, such as DNA, RNA, 
and proteins.  Besides ANAs, patients with SLE have a va-
riety of other autoantibodies that fight against red blood 
cells, platelets, and lymphocytes.  The causes of SLE, like 
most autoimmune diseases, are unknown.  However, ge-
netic, environmental, and immunological factors seem to 
play a role (Kumar, et. al. 2018).  Fatigue, joint pain, and rash 
are the most common symptoms of SLE.  SLE is unique 
because of the disease’s ability to appear and disappear 
called flares.  Flares are known to occur during rapid hor-
monal changes, as occurs in pregnancy.  For women with 
SLE, pregnancy is a major concern.  Pregnancy is a high-
risk time for SLE patients because flares during pregnancy 
may be related to increased irreversible organ damage 
(Ateka-Barrutia, Khamashta, 2013).  The risk of flare 
during pregnancy depends on the disease activity 6-12 
months before conception; the risk is higher in those 
who have had repeated flares preconception.  Therefore, 
women living with SLE who are thinking about conceiving 
should consult their rheumatologist prior to conceiving, 
so that they can monitor disease activity to ensure the 
best outcome for mother and baby. 
Methods
The data in this paper was compiled using Pubmed, 
ProQuest, and Google Scholar.  PubMed and Proquest 
were accessible through Touro College’s Online Library 
system. Key terms used to search were: “SLE pregnancy”, 
“SLE”, “hydroxychloroquine”, and “autoimmune diseases”.
Discussion 
Pathogenesis of Systemic Lupus Erythematosus
The principle deficiency in SLE is the failure of the mecha-
nisms that maintain self-tolerance.  Although the cause(s) 
of the lack of self-tolerance remains unknown, there are 
several genetic, environmental, and immunological factors 
that seem to play a role.  
There is a lot of evidence that suggests a genetic pre-
disposition to SLE.  Family members have a higher risk of 
developing SLE, and even twenty percent of uninfluenced 
first-degree family members have autoantibodies.  The 
concordance of SLE in monozygotic twins is twenty-five 
to fifty percent and around five percent in dizygotic twins, 
which suggests that genetic factors play a crucial role in 
the predisposition of SLE (Kumar, et. al. 2018).  The above 
said indicates a polygenic inheritance of the disease- it 
is approximated that at least 4 susceptibility genes are 
required in order to develop SLE (Schur, 1995). 
Studies reveal that SLE susceptibility involves human 
leucocyte antigen (HLA) class II gene polymorphisms.  In 
patients from different backgrounds, a relation between 
HLA DR2 and DR3 with SLE is a regular finding with an 
odds ratio for developing SLE of roughly 2 to 5 (Pisetsky, 
1997).  Which means, a person with HLA DR2 and DR3 are 
two to five times more likely to develop SLE than a person 
without HLA DR2 and DR3.  HLA class II genes have also 
been linked to the presence of some autoantibodies, for 
example: anti-Sm, anti-Ro, anti-La, anti-nRNP, and anti-DNA 
antibodies.  HLA class III genes, specifically those “encoding 
complement components C2 and C4”, are major contrib-
utors in the development of SLE.  Patients with homozy-
gous C4A null alleles, regardless of their background, have 
a higher risk of having SLE.  Additionally, SLE is connected 
to inherited deficiencies of C1q, C1r/s, and C2 (Mok, Lau, 
2003).  A reduction in complement activity could encour-
age SLE susceptibility by damaging the neutralization and 
removal of foreign and self-antigens.  “When the antigen 
burden overwhelms the clearance capacity of the immune 
system, autoimmunity may ensue” (Mok, Lau, 2003).  Other 
polymorphic genes have been linked to SLE such as: tumor 
necrosis factor alpha, interleukin six, the T cell receptor, 
CR1, Fc gamma RIIA and Fc gamma RIIIA, immunoglobu-
lin Gm and Km allotypes, and heat shock protein seventy 
(Sullivan, 2000).  Nonetheless, in majority of cases, consis-
tent results were not reported in studies of patients from 
different ethnic backgrounds. 
 Although genetic factors play a crucial role in regard to 
the predisposition towards SLE, the start of the disease 
stems from environmental triggers.  Infectious agents, 
such as bacterial DNA/endotoxins and retroviruses, may 
cause particular reactions by molecular imitation and dis-
rupt immunoregulation.  Viruses might set off or induce a 
flare in lupus by harming tissues to release autoantigens, 
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triggering B cells, and inducing SLE by molecular imita-
tion.  But, viral findings have not been consistent in the 
tissues of people with lupus (Herrmann, et. al. 1996). 
Therefore, there is not enough evidence to defend that 
any one infectious agent causes SLE.  Certain diet choic-
es, like alfalfa sprouts and high intake of saturated fats, 
influences the making of inflammatory mediators.  Alfalfa 
sprouts contain L-canavanine which has been associat-
ed with the development of SLE-like symptoms (Prete, 
1985).  Procainamide, hydralazine, chlorpromazine, iso-
niazid, phenytoin, and penicillamine are drugs that alter 
“cellular responsiveness and immunogenicity of self-an-
tigens” (Mok, Lau, 2003).  Procainamide and hydralazine 
are aromatic amines or hydrazines, and they can cause 
an SLE-like disorder (Adams, Mongey, 1994).  Ultraviolet 
light may aggravate SLE in many patients. UV light can 
trigger inflammation, promote cellular apoptosis, and in-
duce tissue damage.  Exposure to the sun’s light causes 
and aggravates SLE.  Exposure of skin to ultraviolet light 
changes the location and/or chemistry of DNA, Ro, and 
nRNP antigens, and also amplifies their immunogenicity. 
Recent studies have shown that ultraviolet light causes 
the apoptosis of human keratinocytes, which brings about 
the development of clusters on the exterior of dying cells, 
that hold nuclear and cytoplasmic antigens.  This supplies 
a method for the exposure of self-antigens to the im-
mune system and evokes autoimmunity (Mok, Lau, 2003). 
To summarize: UV light and other environmental fac-
tors cause the apoptosis of cells.  Insufficient removal of 
the nuclei of these cells leads to a large burden of nucle-
ar antigens.  Underlying abnormalities in B lymphocytes 
and T lymphocytes are accountable for flawed tolerance, 
and, as a result, self-reactive lymphocytes live on and stay 
functioning.  Said lymphocytes are activated by nuclear 
self-antigens, and antibodies are made to fight the an-
tigens. Complexes of the antigens and antibodies stick 
to Fc receptors on dendritic cells and B cells and might 
be engulfed.  The nucleic acid elements engage toll-like 
receptors (TLRs) and trigger B cells to create more au-
toantibodies.  TLR stimuli also trigger dendritic cells to 
make interferons and other cytokines, which intensifies 
the immune response and induces more apoptosis.  The 
overall result is a “cycle of antigen release and immune 
activation resulting in the production of high-affinity au-
toantibodies” (Kumar, et. al. 2018).
Autoantibodies
The number one hallmark, and the number one concern, 
of lupus is the production of autoantibodies.  These an-
tibodies attack the patient’s own molecules found in the 
cytoplasm, nucleus, cell surface, and soluble molecules like 
coagulation factors and IgG.  Antinuclear antibodies are 
found in more than ninety five percent of SLE patients; an-
ti-double stranded DNA (ds-DNA) and anti-Sm antibodies 
are specific for SLE and not found in patients with other 
autoimmune diseases, making them very important in the 
diagnosis (Tan, et. al. 1982).  ANAs can be divided into 4 
groups: antibodies to DNA, antibodies to nucleolar anti-
gens, antibodies to nonhistone proteins bound to RNA, 
and antibodies to histones.  Additionally, many other auto-
antibodies are found in patients with SLE.  These autoan-
tibodies attack lymphocytes, platelets, and red blood cells. 
Thirty to forty percent of SLE patients have anti-phospho-
lipid antibodies.  These patients have complications sec-
ondary to excessive clotting (Kumar, et. al. 2018). 
Symptoms of SLE
SLE is a chronic disease, meaning that the disease is long 
lasting, in this case specifically, the disease waxes and 
wanes.  The symptoms and the effects on daily life of SLE 
vary, however, there are some that were seen in near-
ly all patients.  A group of patients were selected from 
6 rheumatology practices that were spread across the 
United States between May and July 2014.  These patients 
were between the ages of eighteen and seventy-five and 
had a clinical diagnosis of lupus.  Ninety eight percent 
of patients reported they felt fatigue, ninety three per-
cent reported joint pain, eighty eight percent reported a 
rash, eighty percent reported swelling of feet, legs, fingers, 
or hands and joint stiffness.  Because SLE is chronic it 
has major effects on a patient’s daily life and activities. 
Sixty one percent of those interviewed had difficulty 
with housework, thirty nine percent had difficulty driving 
and sleeping, and twenty two percent had difficulty car-
ing for children.  Sixty two percent of the patients who 
participated in this study were not working outside the 
home; ninety one percent said that this was caused by 
SLE (Mathias, et. al. 2018).
Hormonal Effects on SLE
Lupus is primarily a female disease; it is “characterized by a 
9:1 female to male ratio of disease incidence” (Weckerle, 
Niewold, 2011).  Generally, SLE occurs between puberty 
and menopause, the reproductive age range (15:1 ratio). 
Occurrence of SLE before puberty and after menopause 
is uncommon.  Furthermore, patients with a hypergo-
nadotrophic disorder, namely Klinefelter’s Syndrome, are 
prone to lupus as well.  From these observations, it is as-
sumed that endogenous sex hormones play a major role 
in lupus (Mok, Lau, 2003).  
Epidemiological studies show a connection between 
the use of exogenous estrogens and the emergence of 
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lupus.  The Nurses’ Health Study revealed that hormonal 
replacement therapy and the use of oral contraceptive 
pills have an association with an increased chance of 
developing SLE (Sanchez-Guerrero, et. al. 1997).  Lupus 
improvement was observed in patients who had gone 
through menopause or an oophorectomy.  Conversely, 
lupus flares mainly occur during hormonal changes, such 
as pregnancy, exogenous estrogen administration, puerpe-
rium, and ovulation during IVF (Mok, Wong, 2001).  Many 
patients exhibit disease flares during the second half of 
their menstrual cycle, this has been attributed to the mid-
cycle estrogen surge.  Additionally, patients who develop 
lupus after the age of fifty were reported to have a milder 
disease and less significant organ involvement.  All these 
observations are helpful in explaining and understanding 
why pregnancy for SLE patients is extremely difficult. 
Pregnancy and SLE Pregnancy
Healthy, normal pregnancy causes the body to go through 
many physiological changes; these changes may influence 
rheumatic disease expression.  Most organ systems go 
through some level of change during pregnancy.  The glo-
merular filtration rate goes up by fifty percent during a 
normal pregnancy.  Subsequently, women with preceding 
proteinuria might be expected to have a noticeable rise in 
urinary protein excretion in the 2nd and 3rd trimesters. 
There is also an expected thirty-fifty percent elevation in 
intravascular volume; women who have cardiac or renal 
compromise might not endure this well. Additionally, 
blood counts are usually different during pregnancy. 
Anemia is usual due to hemodilution, and in eight percent 
of uncomplicated pregnancies there is an occurrence of 
thrombocytopenia.  The chance of venous thromboem-
bolism increases by fivefold during normal pregnancy, 
because of the prothrombotic state that pregnancy cre-
ates along with compression by the expecting uterus and 
venous stasis (Sammaritano, 2016). 
 In normal pregnancy, the mother’s immune system is 
altered in order to ensure fetal health and survival: im-
munoglobulin secretion rises, cell mediated immunity 
decreases, and pregnancy-specific proteins work to in-
hibit lymphocyte function (Branch, Wong, 2014). General 
immunosuppression would reduce maternal resistance 
against infection, so instead, there is an activation in 
the maternal immune system during pregnancy of im-
mune-modulatory molecules and immunocompetent 
cells (Ostensen, Clowse, 2013).  Cytokines and chemok-
ines manage these immunocompetent cells with T helper 
cells; cytokines are an important factor in supporting suc-
cessful pregnancy.  The Th1/Th2 cytokine shift is a crucial 
immunological change that occurs during pregnancy.  Th2 
includes numerous interleukins which trigger antibody 
synthesis and humoral immunity.  In pregnancy a preva-
lence of the Th2 response might be anticipated, and since 
lupus is predominantly a Th2-mediated disorder, aggrava-
tion of the disorder is more likely (de Jesus, et. al. 2015).  
Pregnancy is high-risk for women with SLE, because 
disease flares during pregnancy have been linked to 
organ damage.  Therefore, it is recommended that every 
woman with lupus should receive a preconception evalu-
ation which should assess organ damage related to lupus, 
medications, and disease activity.  If a patient is taking 
medications for lupus that have adverse effects on preg-
nancy, it is suitable for the patient to change to a lower 
risk medication (Flint, et. al. 2016).    Additionally, for the 
best pregnancy outcome and for the mother’s safety, it is 
advised that women with SLE should conceive during a 
time of inactive disease.  Disease flares during pregnancy 
have been linked to disease activity six to twelve months 
before conception.  Lupus flare within 6 months prior 
to conception has been linked to a significant rise in the 
chance of flare during pregnancy and a fourfold increase 
in pregnancy loss (Clowse, 2007). 
Pregnancy for women with lupus has been linked 
to: risk of flare, preeclampsia, hypothyroidism, stroke, 
preterm birth, hypertension, pre-gestational diabetes, 
caesarean section, placental deficiencies leading to intra-
uterine growth restriction (IUGR), pregnancy loss, and 
even death.  The Danish National Registry stated that ma-
ternal complications were found in fifty percent of lupus 
pregnancies (Jakobsen, et. al. 2015).  A recent study ob-
served thirteen thousand five hundred and fifty-five SLE 
pregnancy deliveries.  Twenty five percent of SLE pregnan-
cies were delivered preterm, meaning the pregnancy was 
shorter than thirty-seven weeks (Yan Yuen, et. al. 2008). 
Six to thirty five percent of babies were born small for 
gestational age.  One in five lupus pregnancies ended in 
pregnancy loss (compared with one in ten from controls), 
with a four to six-fold increased likelihood of stillbirths 
compared with controls (Clark, et. al. 2003).  Disease 
activity within six months before conception has been 
linked to an increased rate of fetal loss.  Patients with 
anti-dsDNA antibodies have the highest risk for preterm 
birth and pregnancy loss.  Patients with lupus have a three 
to four-fold increased chance of developing preeclamp-
sia.  Antiphospholipid antibodies are found in thirty-forty 
percent of SLE patients and have been linked to negative 
obstetric outcomes.  Women with aPL antibodies have 
an increased chance of developing IUGR, preeclampsia, 
preterm birth, and fetal loss (Smyth, et. al. 2010).  
The PROMISSE study observed three hundred and eighty 
five women with lupus and found that fifteen percent of 
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them experienced a mild flare, whereas five percent ex-
perienced an extreme flare.  Sixty percent of women with 
active SLE prior to conception experienced flares during 
pregnancy, however, only ten percent of women with in-
active SLE prior to conception experienced flares during 
pregnancy (Buyon, et. al. 2015).   A study conducted in 
Sweden observed five hundred and fifty one first singleton 
births to patients with lupus and assessed their outcomes 
in comparison to the general population.  This study includ-
ed twelve thousand eight hundred and forty seven nor-
mal pregnancies, one hundred and ninety eight pre-lupus 
women, sixty five women who were first diagnosed with 
lupus zero-two years after giving birth, and one hundred 
and thirty three women who were diagnosed two-five 
years postpartum.  Compared to those who were diag-
nosed with lupus two-five years after their first pregnancy, 
those with lupus during their first pregnancy, or diagnosed 
soon after, had the highest risk of poor clinical outcomes. 
Twenty six percent of women who were diagnosed with 
lupus zero-two years after giving birth had preeclampsia 
during pregnancy, thirteen percent of women who were 
diagnosed two-five years after giving birth had preeclamp-
sia during pregnancy, and sixteen percent of women who 
had lupus while pregnant had preeclampsia; while only 
approximately five percent of women without lupus had 
preeclampsia (Arkema, et. al. 2016).  
Over the last forty years some of the adverse preg-
nancy outcomes have improved.  A study compared lupus 
pregnancies from forty years earlier to their current preg-
nancy group, which consisted of eighty three pregnant 
women.  The rate of pregnancy loss decreased dramati-
cally from forty percent to seventeen percent, compared 
with the general population rate of sixteen percent.  On 
the other hand, the preterm delivery rate did not change 
dramatically. It only dropped from thirty seven percent to 
thirty two percent versus nine to twelve percent preterm 
delivery rate of the general population (Clark, et. al. 2005). 
A Norwegian study analyzed pregnant women with con-
nective tissue diseases, including lupus, over the last four 
decades. Although maternal and fetal complications were 
more prevalent in lupus patients compared to the gener-
al population, the number of births did increase and the 
rate of C-sections, low birth weight infants, and preterm 
births decreased (Wallenius, et. al. 2015).  
Effects of SLE on the Baby
Complications during pregnancy can impact fetal and neo-
natal outcomes.  There is an increased chance of preterm 
delivery, preeclampsia, fetal loss, and low birth weight ba-
bies in women with lupus.  When maternal autoantibodies, 
aPL antibodies, anti-Ro/SS-A and anti-La/SS-B antibodies 
are present there are more precise risks.  The presence of 
aPL antibodies has been commonly linked to prematurity 
and intrauterine growth restriction.          Anti-Ro or an-
ti-La antibodies are found in around thirty percent of SLE 
patients.  These autoantibodies can cross the placenta by 
active transport between the sixteenth and thirtieth weeks 
of pregnancy.  Babies who are born to women with anti-Ro/
SS-A and anti-La/SS-B antibodies have an increased risk of 
having neonatal lupus erythematosus (Sammaritano, 2016). 
These autoantibodies have been linked to the development 
of congenital complete heart block and noncardiac neona-
tal lupus erythematosus expressions such as: transamini-
tis, reversible thrombocytopenia, and photosensitive rash 
(Brito-Zero’n, et. al. 2014).  
Congenital complete heart block is the most seri-
ous condition linked to anti-Ro/SS-A and anti-La/SS-B 
antibodies and occurs in approximately two percent of 
babies born to mothers with these antibodies.  If the 
mother previously had a child with congenital heart block, 
then the risk for the second child having it increases to 
eighteen percent; if the mother previously had two chil-
dren with congenital heart block then the risk increases 
to fifty percent (Brucato, et. al. 2001).  In more than eighty 
percent of children with congenital heart block the moth-
er had anti-Ro or anti-La antibodies.  Typically, congenital 
heart block develops between sixteen and twenty four 
weeks of pregnancy, and it can be recognized by low fetal 
heart rate which is less than sixty beats per minute.  Anti-
Ro and anti-La antibodies attack the myocardium and 
fetal atrioventricular node.  This causes immune mediated 
inflammation and fibrosis in tissues that are affected, re-
sulting in various levels of heart block or cardiomyopathy 
(Llanos, et. al. 2012).  The risk of death for babies affected 
is around ten-twenty percent and most of those who sur-
vive require a permanent pacemaker.  
Various treatments for congenital heart block have 
been tried.  Because of their capability to diffuse across 
the placenta, fluorinated steroids are used for cases that 
involve myocarditis, hydrops, or incomplete heart block 
due to its potential to reverse the affects (Friedman, et. 
al. 2009).  Exposure to hydroxychloroquine throughout 
pregnancy might lower the chances of development of 
congenital heart block (Izmirly, et. al. 2012). 
Treatments/Management of SLE Pregnancy
Firstly, patients with lupus who are considering pregnancy 
should be closely followed by their rheumatologist and 
obstetrician.  Lupus should be quiescent, and the patient 
should be on medications that are low risk for approx-
imately 6 months before conception.  Recent studies 
show that antimalarial medications are beneficial for the 
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mother and baby and have few side effects, and there-
fore should be taken throughout pregnancy.  In one study 
of one hundred and eighteen lupus pregnancies, poor 
pregnancy outcomes were dramatically reduced in the 
women who were taking hydroxychloroquine.  “Preterm 
delivery rates were 15.8% in that group versus 44.2% in 
untreated patients, and rates of IUGR were 10.5% ver-
sus 28.6%” (Leroux, et. al. 2015).  In a different study, 
women who stopped taking hydroxychloroquine suffered 
remarkably more lupus activity than women who con-
tinued hydroxychloroquine (Clowse, et. al. 2006).  The 
use of hydroxychloroquine throughout pregnancy in 
patients with lupus minimizes the number of flares and 
hypertensive disorders.  Hydroxychloroquine is safe to 
use during pregnancy, and there have been no “reported 
malformations, growth restriction and ocular, auditory, or 
neurological toxicity in exposed fetus” (Ruiz-Irastorza, 
Khamashta, 2011).  Hydroxychloroquine is secreted in 
breast milk; however, there were no reports of negative 
effects in children who were breastfed.  
In the case of disease reactivation during pregnancy, cor-
ticosteroids are usually used.  Since fluorinated corticoste-
roids diffuse across the placenta, they should not be taken 
during pregnancy.  On the other hand, non-fluorinated 
corticosteroids, (prednisone, prednisolone, methylprednis-
olone, hydrocortisone) are broken down by placental 11 
beta-hydroxysteroid dehydrogenase, and only ten percent 
of drug dosage crosses the placenta.  That said, non-fluo-
rinated corticosteroids are connected to various compli-
cations such as diabetes, preeclampsia, and hypertension; 
therefore, low doses are recommended (prednisone<7.5 
mg/day) (Ruiz-Irastorza, et. al. 2012).  A dose of above ten 
mg/day of prednisone has been linked to a higher chance 
of developing dyslipidemia, arterial hypertension, maternal 
hyperglycemia, and fluid retention.  Non-fluorinated cor-
ticosteroids are only slightly passed into breast milk and 
is permitted during breastfeeding.  However, if the dose is 
high then women should wait four hours after taking the 
corticosteroid to breastfeed.  
Most immunosuppressive medications are stopped during 
pregnancy and breastfeeding, except azathioprine in doses 
up to two and a half mg/kg/day, cyclosporin, and tacrolimus. 
Although cyclosporin has been deemed safe to use during 
pregnancy, it has been linked to an increased chance of pre-
eclampsia, hypertension, and gestational diabetes (Ateka-
Barrutia, Khamashta, 2013).  Mycophenolate mofetil, meth-
otrexate, and cyclophosphamide are not safe to use during 
pregnancy and should be switched to safer drugs.  
NSAIDs are overall safe to use throughout pregnan-
cy if they are limited to short term usage.  However, 
long term use of NSAIDs have been linked to cardiac 
and renal failure, fluid overload, and hypertension in the 
mother, and renal disorders and oligohydramnios in the 
fetus.  The use of these medications should only take 
place at the end of pregnancy, after thirty weeks of ges-
tation (Ostensen, et. al. 2006).  
Antiplatelets and anticoagulants are also used to treat 
lupus.  The use of low-dose aspirin (75-100 mg/day) and 
dipyridamole is safe to use during pregnancy.  Aspirin can 
be used even throughout labor or epidural anesthesia to 
decrease the chance of hemorrhagic issues.  Since hepa-
rins do not diffuse across the placenta, they are safe to 
use throughout pregnancy and breastfeeding.  However, 
warfarin is damaging to the fetus during organogenesis 
(the first six-ten weeks of pregnancy) and therefore 
should not be taken during this timeframe (Ostensen, et. 
al. 2006).  Patients taking these medications should be 
switched to heparin when pregnancy is confirmed.  
Conclusion
Systemic Lupus Erythematosus is a disease with varying 
severity in the population, but one that can have devas-
tating effects on mother and baby. Advances in the under-
standing of the disease as well as treatment and preven-
tion of flare ups have allowed women with lupus to have 
successful and healthy pregnancies with favorable out-
comes. It is imperative however, that women with lupus 
seek guidance from their rheumatologist and obstetrician 
and focus on prenatal care for the best possible outcome 
for mother and baby.
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Abstract
Hashimoto’s Thyroiditis (HT) is one of the most common autoimmune diseases (Hiromatsu et al. 2013 p.13). It primarily affects 
the thyroid gland. The thyroid gland influences growth and regulates the body’s metabolism by manipulating hormonal levels. 
Hashimoto’s thyroiditis affects thyroid function through mechanisms that cause the hormone levels to become dysregulated. 
The standard therapy for Hashimoto’s thyroiditis is hormone replacement. This approach helps most patients by regulating their 
thyroid hormones, though there are some individuals who fail treatment. Untreatable patients are plagued with weight gain, sleep 
disturbances, and other symptoms .  Certain factors in thyroid disease may cause various secondary complications including psychi-
atric manifestations . Research into these patients has shown that the removal of the thyroid gland seems to improve their clinical 
condition. Therefore, in the situation when significant symptoms remain after what appears to be adequate medicinal treatment, 
the possibility of surgery should be entertained. This review discusses the pathological underpinnings of Hashimoto’s disease and 
reviews some of the published literature from the past ten years in relation to the treatment of HT .
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Introduction
The thyroid gland is a butterfly-shaped endocrine gland 
found in the lower front portion of the neck. The thy-
roid primarily controls metabolic function. This includes 
hormone production, growth, and bodily maturation. 
Thermoregulation, as well as brain maturation and other 
cognitive functions, are also controlled by the thyroid 
(Drake 2018). Thyroid dysfunction can be due to hyper-
thyroidism, the overproduction of thyroid hormone, or 
hypothyroidism, which is the underproduction of hor-
mones. The most common symptoms of hyperthyroidism 
are weight loss and palpitations, while the most common 
symptoms of hypothyroidism are weight gain and lethargy 
(Guyton, Hall 2006 Pp. 938-940). 
According to the American Thyroid Association (ATA), 
there are approximately twenty-million people in the 
United States who suffer from thyroid disease. Of this 
twenty-million, about fourteen million of them suffer from 
an autoimmune condition known as Hashimoto’s thyroid-
itis (American Thyroid Association, General Information). 
An autoimmune disease develops when the body’s immune 
system begins attacking its own organs or particular pro-
teins. Autoimmune diseases are caused by autoantibod-
ies, which respond to normal organs as foreign invaders. 
Hashimoto’s Thyroiditis occurs when the body attacks 
either the thyroid cells or their product thyroxine.
Hashimoto’s Thyroiditis can develop in patients with 
either a genetic or environmental susceptibility (Pyzik 
et al. 2015). Hiromatsu et al. studied some of the cur-
rent concepts of genetic susceptibility to Hashimoto’s 
Thyroiditis. They noted that, specifically, the concordance 
rate for HT in identical twins (monozygotic) is 55%, while 
in non-identical twins (dizygotic) it is 0%. Moreover, they 
also observed that there is a higher rate of concordance of 
thyroid autoantibodies not associated with Hashimoto’s 
Thyroiditis in monozygotic twins than in dizygotic twins. 
In these siblings, 80% of monozygotic twins had autoanti-
bodies versus 40% in nonidentical twins (Hiromatsu et al. 
2013). This study concluded that genetics is a significant 
factor in HT.
Several genetic loci have also been identified as associ-
ated with Hashimoto’s thyroiditis, most notably multiple 
human leukocyte antigen-DR (HLA-DR) isotopes. HLA-
DR is a lymphocyte surface receptor.  When genetically 
altered it affects what is presented to the T-cells which 
elicits an immunologic response. This response can influ-
ence the selectivity and binding of peptides, which ap-
pears to predispose individuals to the development of 
HT (Hiromatsu et al. 2013). Other immune modulators 
released from the lymphocytes, such as interferon-gamma 
can also instigate the development of HT.
Environmental triggers that affect individuals suscepti-
ble to Hashimoto’s thyroiditis include infections, dietary 
factors, and pregnancy. Although iodine deficiency can 
cause thyroid diseases, excess iodine can induce autoim-
munity by increasing the body’s sensitivity to abnormal 
thyroglobulin. Thyroglobulin is the protein produced by 
the thyroid and is the precursor to the thyroid hormones 
triiodothyronine (T3) and thyroxine (T4).  In the pres-
ence of excess iodine, thyroglobulin can be abnormally 
iodinated.  This can lead to the production of autoanti-
bodies as well as to the toxicity of the thyroid cells and 
hypothyroidism (Hiromatsu et al. 2013).
With all this in mind, the two main autoantibodies 
linked to Hashimoto’s Thyroiditis are anti-thyroglobulin 
and antithyroid peroxidase.  An anti-thyroglobulin anti-
body binds to thyroglobulin which limits availability and 
subsequent release of T3 and T4 thyroid hormones. The 
thyroglobulin directly affects the functional aspect of the 
thyroid and its reduction, or absence contributes to a 
patient’s hypothyroid symptoms. Antithyroid peroxidase, 
on the other hand, targets thyroid follicular cells or thy-
rocytes. The way it does this is by tagging the thyroid 
cells for destruction which can in turn lead to hypothy-
roidism. HT is an insidious disease that can take years 
before becoming clinically significant (Guyon, Hall 2006, 
Pp. 940-943).
Many patients eventually require treatment with thy-
roid hormone replacement. This therapy involves being 
prescribed a bio-identical thyroid hormone medication, 
65
Do People with Hashimoto’s Disease Need a Thyroidectomy?
such as Levothyroxine also known as Synthroid or Armor 
Thyroid. For most patients, the treatment works well, 
and the symptoms are resolved. There are circumstances 
though where hormone replacement fails and in cases 
like these clinical research has shown that the surgical 
excision of the thyroid or thyroidectomy should be con-
sidered. This potentially works because it reduces the an-
tibody load and the antibody’s potential effects on other 
targets (Goldvog et al. 2019, p. 462). The main objective 
of this paper is to review the possible solutions to treat-
ment-resistant Hashimoto’s thyroiditis disease.
Methods
Data was collected through Touro College’s online li-
brary using several scientific scholarly databases such 
as ProQuest and PubMed databases. The key-phrases 
used were Hashimoto’s Disease, Hashimoto’s thyroid-
itis, thyroidectomy, and autoimmune thyroiditis. Only 
peer-reviewed journals and English language articles were 
analyzed.
Discussion
Autoimmune thyroid disease was first described in 1912 
by the Japanese surgeon Hakaru Hashimoto (Pyzik et al. 
2015). He identified a cohort of patients with lymphoid 
infiltration of the thyroid with associated destruction of 
the thyroid glands which he called “struma lymphomato-
sa” (Hiromatsu et al. 2013). The concept of autoimmune 
diseases was not recognized until the 1950s and even 
currently many of these diseases are not fully understood. 
Hypothyroidism is diagnosed by a thyroid function blood 
test that shows elevated thyroid stimulating hormone 
(TSH) which reflects a reduction in the thyroid’s function 
(Drake 2018). Unlike many other diseases, patients who 
suffer from hypothyroidism do not exhibit symptoms 
over a set timeline. Some patients develop their symp-
toms over days to months, while for others, symptoms 
evolve over years to decades (Lee 2020). In other words, 
hypothyroidism can exist in many states which can range 
from a subclinical harmless state to a significant clinical 
presentation (Chaker et al. 2017). Table 1 shows a flow 
chart on the process of diagnosing the disease.
There is controversy as to when medical professionals 
should start treating patients with clinical hypothyroid-
ism. According to the American Association of Clinical 
Endocrinology (AACE) guidelines, there are a few opin-
ions as to when treatment commences. Treatment gen-
erally relies on the Thyroid Stimulating Hormone (TSH) 
level. TSH responds to feedback inhibition of the pituitary 
gland, the organ which produces TSH. As the levels of thy-
roid hormone increase, the TSH decreases, and as the 
levels of thyroid hormone decrease the TSH increases. 
This is an example of a negative feedback loop (Guyon, 
Hall 2006, p. 939). The American Thyroid Association’s 
guidelines suggest that when the TSH levels approach 10 
mIU/L patients are clinically hypothyroid and need treat-
ment. Others claim that there are therapeutic reasons 
to start treating at lower levels. Regardless, treatment 
is always dependent on the clinical symptoms being ad-
dressed (Garber et al. 2012, p. 1112).
The most common symptoms of hypothyroidism in 
adults are weight gain, fatigue, hot/cold intolerance, and 
memory loss (brain fog). Table 2 lists the signs and symp-
toms related to hypothyroidism. The symptoms for the 
diagnosis of hypothyroidism are reflective of the hormon-
al insufficiency in different organs (Carle et al. 2014, p. 
593). Symptoms vary by age and health status. An increase 
in the severity of symptoms may predict a harsher course 
of hypothyroidism. Clinical symptoms were originally 
used to diagnose hypothyroidism. A variety of outdated 
scoring systems such as the Billewicz score system and 
the Zulewski score system were utilized. With the advent 
of a sensitive blood test for TSH, these systems have been 
phased out and the fluctuation in TSH levels is what is 
used to guide the treatment of the disease.
Thyroid function has also been proven to play a cru-
cial role in the cognitive development of youth and 
many other facets regulating nervous system activity. 
Neuropsychiatric symptoms refer to a gamut of emo-
tional and cognitive complications that are directly re-
lated to alterations in the brain (Dickerman, Barnhill 
2012). Due to the close association between thyroid and 
the nervous system function, disturbances in the body’s Table1: Diagnostic scheme (Chaker et al . 2017)
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metabolic state can be related to a range of neurologi-
cal signs and symptoms. These signs include headaches, 
mood, and cognitive disorders, ophthalmoplegia (eye 
movement disorder), tremors, and muscle weakness. 
Hypothyroidism can cause psychiatric symptoms such as 
depression, anxiety, memory deficits, and even psychosis. 
According to medical guidelines, testing for thyroid dis-
ease is a case-by-case decision, but patients who present 
with psychiatric issues should all be screened for thyroid 
dysfunction (Dickerman, Barnhill 2012, p.130).
In the neuropsychiatric realm, a sudden worsening in a 
patient’s hypothyroidism may result in myxoedema coma, 
a life-threatening condition that is also associated with a 
rapid decline in mental health.  The degree to which sub-
clinical hypothyroidism and mild hypothyroidism impacts 
moods and cognitive functions, as well as whether these 
symptoms respond to treatment, remains controversial 
(Stasiolek 2015).  A case study reported a 61-year-old 
woman who first presented to the emergency room 
complaining of severe chronic daily headaches. According 
to the patient, the headaches started 9 months prior and 
were described as, “bi-lateral with pressing-type quality, 
without associated symptoms such as nausea, photopho-
bia, and did not worsen with exercise,”. The patient also 
presented with depressive symptoms which were evalu-
ated by a psychiatrist. The woman was subsequently diag-
nosed as having depressive syndrome. She was prescribed 
antidepressants but the medication failed to correct the 
problem. The patient later had a full medical evaluation 
which included blood work. The blood work revealed 
an increased anti-TPO antibody titer. This patient was 
diagnosed with encephalopathy related to autoimmune 
thyroid disease, which is also known as Hashimoto’s en-
cephalopathy (Correia et al. 2019).
Another physical ailment associated with hypothyroid-
ism is reduced cardiac output.  This is a result of the re-
laxation of vascular smooth muscle tissue. This relaxation 
occurs because the thyroid hormones which control 
the pacemaker-related genes reduce the heart rate and 
cardiac output which subsequently increases arterial stiff-
ness leading to hypertension. (Udovcic et al. 2017,  p. 55). 
Because of this process, a person’s heart rate will elevate 
in the presence of excess thyroid hormone (hyperthy-
roidism) or reduce if the person has less thyroid hormone 
present (hypothyroidism). The change from normal levels 
to abnormal levels produces a domino effect of increased 
arterial stiffness, which then causes increased systemic 
vascular resistance. A variety of medicinal conditions can 
arise due to these changes which include atrial fibrillation 
and heart failure (Udovcic et al. 2017).
Thyroid dysfunction can also be associated with 
changes in body temperature and body weight. The thy-
roid-stimulating hormone regulates the basal metabolism, 
thermogenesis, and lipid glucose metabolism (Sanyal, 
Raychaudhuri 2016). “According to the National Health 
and Nutrition Examination Survey, obesity affected 32.2% 
of adults in 2003–2004.” (Biondi 2010, p. 3614). A study 
performed in India at the Medwin Hospital’s department 
of Endocrinology and Obesity Clinic found that thyroid 
dysfunction was realized more in individuals that were 
obese. All the patients included in the study underwent 
a physical examination which included, “Height, weight, 
waist circumference, presence of goiter, acanthosis nig-
ricans or peripheral stigmata of dyslipidemia and blood 
pressure measurement,” (Verma et al. 2008). Their study 
consisted of a total of 1075 patients. The study was divid-
ed into two subgroups. One group was made up of 625 
patients who were enrolled in the hypothyroidism clinic, 
and the other group was 450 patients who were enrolled 
in the obesity clinic. Of the patients from the hypothy-
roidism clinic, 44% of them found that their body mass 
index (BMI) was greater than 25 kg/m2 with the typical 
BMI for a healthy person being anywhere between 18.5 
and 24.9 kg/m2. Of the patients from the obesity clinic, 
only 33% had hypothyroidism (Verma et al. 2008). They 
concluded that most people who suffer from hypothy-
roidism have the likelihood of being obese.
Thyroid glands are also prone to develop nodules 
known as goiters.  A goiter refers to an abnormal enlarge-
ment within the thyroid gland. It is important to stress 
that the majority of people that have goiters do not have 
any thyroid gland dysfunction.  People with Hashimoto’s 
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thyroiditis, however, seem to have more nodules than the 
average person. This leads to patients with Hashimoto 
thyroiditis having a slightly higher risk of developing thy-
roid cancer (Fish 2019 p.334). Some researchers say that 
the higher rate for papillary thyroid carcinoma is due to 
the presence of an autoimmune-response, or possibly 
anti-tumor immune response to the immune mediators 
(Graceffa et al. 2019, p.5).
As mentioned previously in this paper, the primary 
treatment for Hashimoto’s disease consists of hormone 
replacement. Hormone replacement aims to balance the 
patient’s biochemical system. While taking out the thyroid 
might prevent an antibody response, if a patient does not 
have a significant quality of life issue, doctors would not 
suggest having a total thyroidectomy (Promberger et al. 
2014, p. 979). There are cases in which a patient is still 
affected by the symptoms of hypothyroidism, even after 
taking the correct dosage of medication and correcting 
the abnormal TSH level.  In that instance, doctors might 
suggest that the patient undergo a total thyroidectomy 
(Pollock et al. 2001, p.894).
There are some standard indications as to when it is 
appropriate to have a thyroidectomy beyond having thy-
roid cancer. When a patient starts to exhibit compressive 
symptoms such as discomfort while swallowing, the feeling 
of strangulation, or tightness in the neck, it is appropriate 
to surgically remove the thyroid gland (Pradeep et al. 2011). 
Greater than 63% of patients with HT identified with the 
symptom of compression (McManus et al. 2011, p. 336). 
Another symptom that hormone replacement cannot cure 
is painful Hashimoto thyroiditis.  Painful HT is also known 
as acute exacerbation of HT.  This condition is not very 
common and in most instances is treated adequately with 
painkillers. Having a total thyroidectomy is thought to be 
the best treatment for this condition especially when pain-
killers do not provide relief (Peng et al. 2020, p.12).
In certain instances, patients with Hashimoto’s disease 
may not necessarily experience a resolution of their com-
plaints with medication. A study of 426 women who were 
all planning on having their thyroids removed for various 
reasons including HT. Before surgery, they all answered 
the SF-36 questionnaire, which is a set of generic, and eas-
ily administered quality-of-life measurements. The results 
established that patients who had high anti-TPO levels 
had lower quality of life measures even though they were 
taking the correct dosage of medication based on their 
TSH levels (Ott et al. 2011, p.165).
In the Annals of Internal Medicine, Guldvog et al., who 
performed the first randomized controlled trial, demon-
strated that the removal of the thyroid gland in patients 
with histologically verified Hashimoto’s disease can 
improve their quality of life by normalizing their anti-TPO 
antibody titer levels. This study was performed on patients 
between the ages of 18 to 79 years. They all had anti-TPO 
titers above 1000 IU/ml (normally less than 35 IU/ml). In 
total there were 150 test subjects all of whom had per-
sistent Hashimoto-related symptoms. Before the data was 
collected and the surgery was performed, all the patients 
were monitored for thyroid function until they achieved 
euthyroid status or normal thyroid function. Participants 
were either assigned to undergo total thyroidectomy with 
continued hormone replacement or to only receive hor-
mone replacement therapy. After 18 months, the anti-TPO 
levels of the surgical group had fallen from a mean of 2232 
IU/ml to 152 IU/ml, and the general health score of the 
surgical group improved from 38 to 64 points. The chronic 
fatigue frequency in the surgical group decreased from 82% 
to 35% of the individuals.  The overall score was improved 
compared to the original SF-36 questionnaire. The control 
group showed no significant changes. The researchers hy-
pothesized that the improvement in symptoms could be 
related to the normalization of serum anti-TPO antibody 
titers. (Goldvog et al. 2019).
Dr. Trevor Angell interpreted and reviewed the study 
done by Guldvog et al. and concluded that the results 
were compelling. Guldvog et al. indicates that patients 
with Hashimoto’s thyroiditis might have persistent symp-
toms due to more than just the thyroid dysfunction. They 
found that a thyroidectomy may modulate the immune 
response by removing the antigen and thereby reducing 
the inflammation and the inflammatory mediators. With 
the removal, the symptoms caused by HT would subse-
quently be alleviated (Angell 2019, p.180).
Nevertheless, the initial plan of treatment for patients 
who have the symptoms of hypothyroidism should be 
supplemental hormone replacement. In the case when 
patients do not respond positively to hormone replace-
ment, a total thyroidectomy has proven to be effective 
as well. For a patient that chooses to have surgery, a 
risk analysis of surgical complications must be evaluated. 
One study predicted that if more people start removing 
their thyroids then complications will increase 12-fold. 
This rate, according to the literature, would change from 
3.05% to 36.6% (Memeh et al. 2020).
Conclusion
In conclusion, not every person who has Hashimoto’s 
thyroiditis should have thyroid surgery. According to the 
research reviewed, having a thyroidectomy might only 
be recommended to patients who have Hashimoto’s 
Thyroiditis and who are experiencing neuropsychiatric 
symptoms after their TSH levels are stabilized. There 
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needs to be more research evaluating and specifying the 
benefits of having a thyroidectomy. Larger test groups 
need to be observed, and the follow-up period should be 
extended. Though they are not frequent, complications of 
total thyroidectomy are real, and the risk-benefit ratio 
must be assessed on a case by case basis.
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